Cell delivery vector

By combining stimulus-responsive polymers and vitamin derivatives in cell delivery vectors, autophagy and lysosomes are activated, and the problem of low oxidative decomposition and absorption capacity is solved, efficient and stable drug delivery and decomposition are achieved, and delivery is improved Efficiency and safety.

CN115135307BActive Publication Date: 2024-11-22KK ITO
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202080096688.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-12-23
Filing Date
2020-07-16
Publication Date
2024-11-22
Estimated Expiration
2040-07-16

AI Technical Summary

Technical Problem

The oxidative decomposition of existing carriers for cell delivery in the preparation and between target cells is accelerated, resulting in the inability to fully reach the target tissue, and the cell absorption capacity is low, and the inability to effectively decompose, resulting in low drug delivery efficiency.

Method used

Using a cell delivery vector containing stimulus-responsive polymers and specific vitamin derivatives, activates autophagy and lysosomes through endocytosis, improves intracellular disintegration and absorption capacity, and enhances antioxidant activity through the liquid crystal layer structure to ensure The vector is stable outside the cell and easy to decompose internally.

Benefits of technology

It significantly improves the delivery efficiency and stability of drugs in cells, enhances antioxidant activity and intracellular decomposition capabilities, and ensures the safety and effectiveness of drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115135307B_ABST
    Figure CN115135307B_ABST
Patent Text Reader

Abstract

[Problem] Provide a cell delivery carrier that has antioxidant activity, intracellular absorption, intracellular disintegration, stability and safety, and has high delivery of active ingredients to cells and biological tissues. [Solution] Provide a cell delivery carrier that contains an active ingredient, the cell delivery carrier is composed of a vitamin derivative that has the ability to simultaneously activate autophagy-related genes and cathepsin synthesis genes, a molecule containing a stimulus-responsive polymer, an emulsifier stabilizer, an active ingredient, and a lipid, so that the active ingredient has high delivery to cells and biological tissues.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a stable and safe cell delivery carrier for a drug delivery system (DDS), which comprises a stimulus-responsive polymer and a substance that promotes cell uptake and intracellular degradation mechanism. Background Art

[0002] Drug delivery systems (DDS) are used for the following purposes: 1) Separation of drug effects: extract or inhibit only specific effects. 2) Enhancement and expression of effects: the effects are more accurate and the reproducibility is improved. It can be expected to reduce the amount of input and expand the application (discovery of new effects, etc.). 3) Reduction of side effects: by expanding the safety margin, improving the quality of life (QOL), and reducing the burden on patients. In addition, compounds that have failed due to side effects can be revived as drugs. 4) Improvement of usability: reduce the burden on patients and medical workers, and solve the problem of illegal medication. 5) Economy: achieve extension and differentiation of product life cycle. In addition, medical expenses and related expenses can be reduced. Improved efficiency of research and development can be expected.

[0003] The composition used for DDS is generally a cell delivery carrier, and the present invention discloses a novel cell delivery carrier. The unit of the particle size of the cell delivery carrier used in general medicines and cosmetics is in the range of submicron to micron, but when used for cell delivery carrier, the particle size is much smaller. For example, when the diameter is less than 300nm, it can be made to penetrate into the skin tissue from the hair follicle gap of the skin, especially, from the hair follicle through the epidermis and dermis to the fat layer, and further, the hair follicle skin stratum corneum is thinner, and the fat-soluble components can diffuse from the sebaceous glands to the dermis, almost without passing through the skin barrier. When the smaller particles of 150nm or less are administered subcutaneously, they cannot pass through the capillary wall, but can invade the capillary lymphatic vessels, so that the active ingredient can be retained in tissues such as skin tissue in particular. Further, when the particle diameter is 50nm or less, the drug will also pass through the general healthy blood vessel wall and diffuse into the body. Therefore, in order to make the drug stay in the target organ, a particle diameter of 50nm to 300nm is suitable.

[0004] In the existing cell delivery carrier, there is a problem that the oxidative decomposition between the preparation and the target cells is accelerated, and the effective ingredients cannot fully reach the target tissue. Further, in the target tissue, the cell absorption capacity of the cell delivery carrier is low, and the effective ingredients cannot be fully absorbed by the cells. In addition, there is also a problem that even if the cell delivery carrier is absorbed, it cannot be decomposed in the cell absorption, and thus the effective ingredients cannot be fully released. Therefore, the problem to be solved by the present invention is to solve the following three problems in the cell delivery carrier at the same time: 1) more effectively inhibit the oxidative decomposition of the carrier between the preparation and the target cells, and increase its arrival rate to the target tissue; 2) further improve the cell absorption capacity of the target tissue; 3) the carrier is more effectively decomposed in the cell absorption. In other words, the following three elements need to be enhanced simultaneously in the cell delivery carrier: 1) antioxidant activity; 2) intracellular absorption capacity; and 3) intracellular disintegration. Further, 4) ensuring stability and safety is essential for the circulation of the product. In the present invention, it is referred to as the four necessary elements of the cell delivery carrier.

[0005] Stimuli-responsive polymers refer to polymers containing stimuli-responsive molecules whose microstructures undergo reversible or non-chemical changes according to surrounding external stimuli, i.e., temperature, pH, ionic strength, magnetic field, electric field, light, sound waves, pressure, solvents, acceleration, and chemical species. Stimuli-responsive polymers are used for efficient drug delivery.

[0006] Patent documents 1 to 6 disclose a nanoparticle system containing a temperature-sensitive polymer, a pH-responsive polymer, a liquid crystal polymer and a polymer gel. However, these stimulus-responsive polymers are effective in destroying liposomes in cells alone or in combination, but are not sufficient to achieve the purpose of improving cell absorption capacity. In addition, when the stimulus-responsive polymer is stimulated and destroyed outside the cell, the inclusions diffuse outside the cell and are difficult to be effectively transported to the target cell, and the significance of making liposome capsules is weakened. That is, the use of these stimulus-responsive polymers can enhance the 3) intracellular disintegration of the cell delivery carrier, but cannot improve 1) antioxidant activity and 2) intracellular absorption capacity. Therefore, a carrier is needed, which adds a system that makes other cell delivery more effective on the cell delivery carrier using the stimulus-responsive polymer.

[0007] Vitamins are essential nutrients for the human body. The cells of various organs and tissues have a system that can capture vitamins in the blood as needed and actively bring them into the cells. Known transport channels include blood transport proteins, receptors on the cell membrane, and transporters.

[0008] The retention rate of ascorbic acid in skin cells is higher than that in the liver, and the concentration is second only to that in the brain, where the ascorbic acid concentration is high. In skin tissue, since it is concentrated at a concentration more than 20 times that of plasma, the existence of ascorbic acid transporters is implied, and in fact, the expression of SVCT1 and SVCT2 (Na-dependent vitamin C transporters) has been confirmed in skin cells, etc. Non-patent document 1, non-patent document 2. It is known that SVCT1 is mainly present in keratinocytes, and SVCT2 is present in keratinocytes, fibroblasts, and endothelial cells.

[0009] However, it has been reported that water-soluble derivatives without lipids such as ascorbyl glyceride and APPS (ascorbic acid-2-phospho-6-palmitic acid) are absorbed by skin cells at a higher concentration than general ascorbic acid. In Non-Patent Document 3, it is shown that APPS is amphiphilic and therefore may directly pass through the cell membrane, i.e., the phospholipid membrane, but this theory cannot explain the high concentration of water-soluble ascorbyl glyceride and ascorbic acid phosphate in cells.

[0010] α-Tocopherol is present at a high concentration in the liver. As for tocopherol binding protein, its transporter is mainly known (Non-Patent Document 4), and further, α-tocopherol transfer protein gene has been screened and reported in detail (Non-Patent Document 5).

[0011] Regarding retinol, retinol binding protein (transporter) is known, which is a protein with a molecular weight of 21 kDa synthesized in the liver and has a function of binding to and secreting vitamin A (retinol) accumulated in the liver and transporting it to target organs (cells).

[0012] Vitamin D binding protein circulates in high concentrations in serum as a vitamin D transporter, is produced primarily in hepatocytes, and brings vitamin D into cells via endocytosis mediated by megalin receptors.

[0013] Folic acid is present in high concentrations in the liver, which stores about half of the body's folate. Two-thirds of the folate in plasma is bound to proteins and transported.

[0014] The uptake of riboflavin into tissues such as the liver is mediated by special protein cell delivery carriers at physiological concentrations, but otherwise it is taken up by endocytosis.

[0015] Cobalamin (vitamin B12) binds to transcobalamin and is transported in the blood. Retinol-binding protein (RBP) is a 21 kDa protein synthesized in the liver and has the function of binding to and secreting vitamin A (retinol) accumulated in the liver and transporting it to target organs (cells)1.

[0016] It is known that the specific vitamins shown above bind to transport proteins and circulate in the blood, and bind to specific receptors on the cell membrane of the target tissue to be brought into the target cell at a high concentration through specific absorption channel proteins or endocytosis. Therefore, it is believed that the artificially synthesized derivatives of the specific vitamins shown above, if they can maintain sufficient stability in the blood, are likely to bind to specific receptors on the cell membrane in the form of derivatives. However, since the specific absorption channel can accurately identify the molecular structure of each vitamin, these artificially synthesized vitamin derivatives cannot be absorbed, but in endocytosis, since a large amount of surrounding water is also brought in, it is believed that the vitamin derivatives on the cell surface that bind to these receptors are also brought in together.

[0017] The object of the present invention is to find a special substance that can enhance endocytosis, and apply it to a cell delivery carrier using a stimulus-responsive polymer to improve the cellular uptake rate of the cell delivery carrier. It is believed that, based on the characteristics of the above-mentioned vitamins, by narrowing the screening objects to vitamin derivatives, it is possible to achieve a cell delivery carrier with a high absorption rate in a shorter time. Vitamins themselves are difficult to exist on the surface of the carrier due to physical properties and stability issues. Furthermore, in order to stably exist stimulus-responsive polymers and special vitamin derivatives in the same cell delivery carrier, the screening of specific lipids and stabilizers is indispensable. In particular, it is believed that if vitamin derivatives are not present on the surface of the carrier, endocytosis cannot be improved, so it is difficult to screen specific lipids and stabilizers to achieve it.

[0018] Therefore, if endocytosis can be measured in the presence of various vitamin derivatives by some method, it will be possible to find out which vitamin derivatives are likely to enhance endocytosis, and if the surface of a cell delivery carrier can be modified, intracellular transport based on endocytosis of the cell delivery carrier can be activated. That is, one of the purposes of the present invention is to find the substance that can best activate endocytosis among vitamin derivatives.

[0019] In addition, it has been reported in recent years that ascorbyl glyceride derivatives are taken into pigment cells at high concentrations to enhance autophagic activity. In the research of the present inventors, the enhancement of the autophagic activity of ascorbyl glyceride derivatives was observed not only in pigment cells but also in normal skin cells in general. Since autophagy is a recycling system for substances taken into cells, the enhancement of autophagy can explain the acceleration of the decomposition of melanin accumulated in pigment cells due to transport inhibition, but cannot explain the enhancement of autophagic activity in general cells without melanin.

[0020] Obviously, the high intracellular concentration of the intracellular delivery carrier cannot be explained simply by the fact that the vitamin increases the cell permeability to phospholipids. This is because the size of the cell delivery carrier is much larger than the size of the modified ascorbic acid derivative molecule, and unless a special system works, it is difficult to transport the huge cell delivery carrier into the cell.

[0021] The problem in 1) can be solved by adding an amphiphilic vitamin derivative having an antioxidant effect to the film on the surface of the cell delivery carrier. In the previous invention, the present inventors successfully used an amphiphilic ascorbic acid derivative as a surfactant, thereby constituting a part or the whole of the film of the cell delivery carrier with the amphiphilic ascorbic acid derivative. However, only by this, the cell delivery carrier cannot be efficiently absorbed into the cell.

[0022] The present inventors studied the intracellular uptake mechanism of various substances in order to improve the intracellular uptake effect of DDS, and as a result, found that utilizing endocytosis and modifying substances that induce endocytosis would increase the uptake rate of the carrier for cell delivery.

[0023] Further, it has been found that if endocytosis is utilized, the last problem, that is, the problem of being able to effectively decompose carriers and vitamin derivatives in cells can be solved. That is, if endocytosis is utilized, substances around the cell membrane can be taken up together with the extracellular fluid through its pinocytosis, thereby forming a vesicle (endosome) filled with extracellular fluid. This is a common uptake mechanism that occurs in all cells, and the ingested endosomes are decomposed by lysosomes. That is, it is effectively decomposed within the cell absorption.

[0024] We have realized that if we can screen out substances with endocytosis function from amphiphilic vitamin derivatives and apply them to cell delivery carriers, we can also solve the problem of effective decomposition of DDS particles in cell absorption.

[0025] First, cells continuously take in substances from outside the cell through endocytosis, but even in fibroblasts with standard endocytic activity, about 1% of the cell membrane is taken into the cell through endocytosis every minute. In each standard mammalian cell, there are about 200 endosomes, and their total volume is about 1% of the total volume of the cell. If converted by surface area, about 3% of the cell membrane's boundary membrane surrounds the endosome. That is, within one hour, 60% of the cell membrane flows into the endosome with only about 3% of the surface area. The purpose of the present invention is to specifically improve the intracellular uptake rate of the cell delivery carrier by utilizing the endosome to improve the absorption of the substance inside the cell, and modify it to the surface of the cell delivery carrier using a stimulus-responsive polymer. Furthermore, the carrier is required to be stable outside the cell and easy to decompose inside the cell. High safety is also one of the conditions. In the past, it was intended to activate the endosomal utilization of DDS by modifying various substances, but in the prior art, the stability outside the cell was poor, and in addition, sufficiently high endosomal activity could not be obtained, resulting in a high intracellular uptake rate. Furthermore, there is a problem that although the stability outside the cells is high, the active ingredient cannot be fully released because the drug is not decomposed inside the cells.

[0026] In cells, endosomes fuse with lysosomes. Lysosomes are structures surrounded by the biological membrane of eukaryotic organisms and have hydrolytic enzymes inside. Biopolymers taken into the membrane are hydrolyzed by these enzymes. The substance that fuses with the endosome containing the object to be decomposed is called a secondary lysosome or phagolysosome. One of the secondary lysosomes is derived from this endocytosis. The phagosome, which is a structure composed of a layer of biological membrane containing more microscopic molecules near the cell membrane, which has taken in huge foreign bodies such as bacteria, is called a phagosome and fuses with the primary lysosome to become a phagolysosome, which decomposes the taken-in substance. The hydrolytic enzyme group contained in the lysosome has the characteristic of working efficiently under acidic conditions, and the hydrogen ion index inside the lysosome is kept acidic at about pH 5 by the action of the proton pump. In other words, the method of taking in a carrier for cell delivery that activates endocytosis can also accelerate the decomposition of the carrier in the cell and increase the activity of the effective ingredient in the cell.

[0027] The cell delivery carrier molecules taken into the endosome are decomposed by lysosomes, and a part of them is accumulated in the cell, but at this time, the cell also contains a large amount of undigested cell delivery carrier constituent materials accumulated. Therefore, it is believed that autophagy is activated. In other words, when the endosome is activated by endocytosis, not only the endosomal system is activated, but also autophagy is activated, and the biosynthesis of related proteins of the autophagosome system is also activated. In other words, one of the purposes of the present invention is to detect markers responsible for the activity of endosomes and autophagosomes, use these markers to find substances that activate endosomes and autophagosomes, and finally modify them to the surface of the cell delivery carrier.

[0028] This also means that, among the four issues to be solved by the present invention, namely, the four necessary elements of a cell delivery carrier: 1) antioxidant activity, 2) intracellular absorption ability, 3) intracellular disintegration, and 4) stability and safety, endocytosis associated with endosomes is related to 2) intracellular absorption ability, and autophagy responsible for autophagosomes is related to 3) intracellular disintegration.

[0029] Lysosomes contain digestive enzymes inside, which decompose proteins and other substances in the cell. Autophagy is a mechanism for decomposing proteins and other substances in the cytoplasm, which is comparable to endocytosis. The lipid membrane stretches and surrounds part of the cytoplasm containing the decomposition substances. Next, the lipid membrane separates into an inner membrane and an outer membrane, thereby forming an autophagosome composed of a lipid bilayer membrane. The lysosome containing digestive enzymes fuses with the outer membrane of the autophagosome, and the digestive enzymes of the lysosome flow between the outer membrane and the inner membrane, and then only the inner membrane is decomposed, and the decomposition substances are mixed with the digestive enzymes, and the decomposition process begins.

[0030] There are many factors required for the formation of autophagosomes, but they can be roughly classified into the following five functional protein groups. 1) The binding reaction system of the ubiquitin-like factor Atg8 (Atg8 system): Atg8, Atg4, Atg7, Atg3. 2) The binding reaction system of the ubiquitin-like factor Atg12 (Atg12 system): Atg12, Atg7, Atg10, Atg5, Atg16. 3) Atg1 protein kinase complex: Atg1, Atg13, Atg17, Atg29. 4) Vps34 PI3 kinase complex: Vps34, Vps15, Atg14, Atg6. 5) Atg9 and Atg2-Atg18 complex: Atg2, Atg18, Atg9.

[0031] The present inventors focused on Atg5 as an activation marker for such endosomes and autophagosomes, because it has been clarified that Atg5 is required not only for the formation of autophagosomes but also for the biogenesis of endosomes and lysosomes (Non-Patent Document 6).

[0032] That is, in the present invention, substances that have the effect of accelerating the synthesis of any one or more proteins required for the biosynthesis of autophagosomes, endosomes and lysosomes are screened from vitamin derivatives. The reasons for selecting vitamin derivatives are as follows: 1) their stability is better than that of vitamins, and their physical properties can be made amphiphilic; 2) their safety is very high; 3) vitamin derivatives are decomposed and converted into vitamins in cells, and can play an effective physiological role in cells.

[0033] Among Atg proteins, Atg5 in particular is related to the production of endosomes, lysosomes and autophagosomes. Therefore, the present inventors detected the m-RNA responsible for the synthesis of the ATG5 protein by microarray, and studied the relationship between the type of vitamin derivative modified in the emulsified composition and cellular uptake by comparing it with a non-added control.

[0034] As a result, when a specific vitamin derivative was mixed with an emulsified composition, the cellular uptake of the cell delivery carrier increased, and the value of ATG5 significantly increased compared to the control. Furthermore, it was found that in addition to ATG5, the mRNA levels of ATG2, 3, 4, 7, 10, 101, 12, 13, 14, and 15 also increased at the same time.

[0035] Therefore, it is reported that, as an index of endocytosis and autophagy activity, it is also related to endosomes, but mainly related to autophagosome formation. The present inventors set ATG2, 3, 4, 5, 7, 10, 101, 12, 13, 14 and 15 as markers, modified various vitamin derivatives on the cell delivery carrier, and quantified the synthesis activity of the protein by detecting m-RNA by microarray, and completed the cell delivery carrier of the present invention. Furthermore, it was found that by modifying these substances on the cell delivery carrier, a cell delivery carrier with good cell absorption ability can be provided.

[0036] Water-soluble derivatives such as ascorbyl glyceryl esters show high ATG activity, which cannot be explained only by the permeability of cell phospholipid membranes, so endocytosis is activated, and as a result, it can be explained that they have high intracellular transport capacity. Furthermore, it is known that endocytosed substances enhance autophagic activity, so ascorbyl glyceryl esters can also be explained to enhance autophagic activity in non-melanin-producing cells.

[0037] For example, ATG2 is required for the expansion of the autophagosome precursor membrane phagosome (Non-Patent Document 7). The Atg2 protein plays a role in the formation of autophagosomes and in the regulation of the morphology and dispersion of lipid droplets such as lysosomes (Non-Patent Document 8).

[0038] Autophagy begins with the formation of a double-membrane autophagosome and ends with the fusion of the autophagosome with the lysosome. Oligomeric ATG14 on the autophagosome binds to a specific complex and accelerates the fusion of the autophagosome and endolysosome (Non-Patent Document 9).

[0039] As a result, the inventors have found that the following cell delivery carrier of the present invention can solve all the problems of the four necessary elements, and have completed the present invention.

[0040] When the endocytosis accelerating substance in the cell delivery carrier of the present invention is an amphiphilic antioxidant vitamin derivative, it can stabilize the oxidatively unstable substances in the cell delivery carrier and achieve a higher cellular absorption capacity. Furthermore, it enhances the affinity with the vitamin-binding protein of the cell, so it is easy to be taken up into the cell, which is more preferred.

[0041] Furthermore, when the endocytosis accelerating substance is an amphiphilic antioxidant vitamin derivative, it is more preferable because it is easily fixed to the surface of the emulsion membrane due to its surface activity.

[0042] The amphiphilic antioxidant vitamin derivative exists in the emulsion membrane itself or between the emulsion membranes, forming an antioxidant barrier, thereby effectively preventing the external active oxygen from invading the core part where the active ingredient is located. Therefore, it is significantly different from the situation where the antioxidant exists in the core part where the active ingredient is located and the DDS particles are suspended in the solvent, as in general DDS capsules.

[0043] The present inventors have discovered and published the following in 2007: by selecting specific amphiphilic antioxidant vitamin derivatives in the present invention and using them alone or in combination, a carrier for cell delivery having a useful liquid crystal layer structure can be formed; and substances contained in these antioxidant films can be isolated from active oxygen, and even effective ingredients that are easily oxidized can maintain their stability. However, this alone cannot achieve a sufficient cell delivery rate.

[0044] Amphiphilic antioxidants are derivatives that have amphiphilic properties by protecting the active centers of antioxidant ascorbic acid, tocopherol, etc. with modifying groups having opposite polarity, making water-soluble ascorbic acid closer to fat-soluble, and fat-soluble tocopherol closer to water-soluble. Due to the modification of the active center, the antioxidant activity is also reduced. On the contrary, the reaction rate with active oxygen is reduced. It is known that the reduction in the reaction rate of amphiphilic antioxidant vitamin derivatives with active oxygen also reduces the generation of pro-oxidants.

[0045] Simply adding amphiphilic antioxidant vitamins by conventional methods cannot effectively protect the active ingredients that are easily oxidized. The effect of the present invention can only be effectively exerted when the amphiphilic antioxidant vitamins are present in the emulsion membrane itself or between the emulsion membranes of the cell delivery carrier. This is because, compared with the presence of antioxidant vitamin derivatives in the central part where the active ingredient is located, the presence of a membrane-like barrier of antioxidant vitamin derivatives around the central part can more effectively remove active oxygen from the outside. Furthermore, if the membrane is multilayered by forming a liquid crystal layer structure, the antioxidant barrier will also be spread over multiple layers, thereby further strengthening the structure of the central part where the active ingredient is located. Therefore, in the emulsion membrane, a single lipid bilayer membrane (single-layer liquid crystal structure) or a multilayer structure of more than one membrane (multilayer liquid crystal structure) is more effective. In the present invention, a liquid crystal layer structure of three or more membranes is most suitable for exerting the effectiveness of the present invention.

[0046] Furthermore, the amphiphilic antioxidant vitamin derivative of the present invention is preferably present between the emulsion membranes of the liquid crystal layer structure of the present invention by 10% or more. This quantitative method can be easily measured by analyzing the concentration of amphiphilic antioxidant vitamins in the water content of the liposome part and the non-liposome part during gel filtration by HPLC.

[0047] In order to prevent the oxidation of the active ingredient contained in the cell delivery carrier, and isolated from active oxygen, in the past, what was carried out was the method of adding the strong antioxidants such as butylated hydroxyanisole (BHA), ascorbic acid, tocopherol and other antioxidant vitamins together with the active ingredient and the cell delivery carrier, but only adding these non-amphiphilic antioxidants can not bring into play enough antioxidant capacity, and it is very difficult to keep the active ingredient contained for a long time without inactivating it. This is because the reactiveness of the antioxidants such as ascorbic acid, tocopherol and the active oxygen that do not have amphiphilicity is high, and they will soon be oxidized to become pro-oxidants such as BHA free radicals, tocopherol free radicals, ascorbic acid free radicals, and antioxidant capacity will not be kept for a long time. In addition, the effect of these active ingredients is expected, and the antioxidant is retained in the central part of the cell delivery carrier so that it coexists with the active ingredient, therefore, not only can the inclusion film itself around the central part not be protected by these antioxidants from the influence of active oxygen, even this idea is impossible.

[0048] BHA, a synthetic strong antioxidant, has been proven to be carcinogenic, and in terms of safety, there is a problem of reduced product value when added to food, cosmetics, etc. (Minutes of the Food Sanitation Investigation Toxicity Department Meeting / Additive Department Meeting Contract Department Meeting on July 7, 1998). The carcinogenic mechanism of BHA is that it produces semiquinone free radicals and the like through oxidative metabolism in the body, which causes cancer. It has been clearly stated in the literature that many antioxidants, not limited to BHA, show toxicity, such as carcinogenicity, due to their pro-oxidative effects (Non-Patent Document 10).

[0049] Furthermore, it is pointed out that carotenoids, tocopherols or ascorbic acid also show characteristics as oxidation promoters based on the redox potential of each molecule and the inorganic chemical properties of cells. These antioxidant vitamins become pro-oxidants, and these active oxygen metabolites may damage DNA and cell membranes (Non-Patent Document 11).

[0050] Furthermore, in order to improve cell permeability, the size of the cell delivery carrier is reduced. However, if the size of the cell delivery carrier becomes smaller, the probability of binding between the cell membrane of the cell delivery carrier and the active oxygen per unit effective ingredient increases proportionally, thereby increasing the probability of producing pro-oxidants and facilitating decomposition.

[0051] In addition, the average diameter of a general cell delivery carrier is 30 μm or less, but if it is reduced to 300 nm or less, which is required in recent years, to improve skin permeability, its surface area increases 30 times, and thus becomes vulnerable to 30 times more active oxygen. In other words, the smaller the cell delivery carrier is, the easier it is to decompose the active ingredient, not only losing the effect, but also causing a major problem of increased pro-oxidant toxicity of the antioxidant.

[0052] That is, the object of the present invention is to provide a stable and safe nano-microcapsule with an antioxidant coating, while improving the oxidation stability of the effective ingredients in the emulsion membrane and the core part. It was found that when the conventional antioxidants were added to achieve this purpose, a completely opposite effect was achieved due to the effect of the pro-oxidant. It was found that only after using an amphiphilic antioxidant with lower antioxidant activity than the conventional antioxidants, both the emulsion coating and the effective ingredients in the core part of the nano-microcapsule can be protected from the influence of active oxygen in a long-term and stable manner. Furthermore, by forming the emulsion coating into a liquid crystal layer structure, that is, a multi-layer liquid crystal capsule, the mixing ratio of the amphiphilic antioxidant can be increased, and the passage of active oxygen can be more effectively blocked.

[0053] Prior art literature

[0054] Patent Literature

[0055] Patent Document 1: Japanese Patent Application No. 2011-522616

[0056] Patent Document 2: Japanese Patent Application Laid-Open No. 2015-107986

[0057] Patent Document 3: Table 2016 / 199895

[0058] Patent Document 4: Japanese Patent Application No. 2015 / 170506

[0059] Patent Document 5: Japanese Patent Application No. 2017-506681

[0060] Patent Document 6: Japanese Patent Application No. 2017-502997

[0061] Patent Document 7: Japanese Re-list 2016 / 199895

[0062] Non-patent literature

[0063] Non-patent document 1: Savinil, et al., Amino Acids 34, 347-355 (2008)

[0064] Non-patent document 2: Ishigami Akito et al., Vitarnin (Japan) 88 (11), 555-559 (2014)

[0065] Non-patent literature 3: Shibuya, S., et al., Nutrients 2017, 9, 645; doi: 10.3390 / nu9070645

[0066] Non-patent literature 4: Heublein S, et al., J Cancer Res Clin Oncol. 2017 / 5; 143(5): 773-781.

[0067] Non-patent literature 5: Qu YH, et al., Int J Mol Sci 2016Jun 27; 17(7): 1016.

[0068] Non-patent literature 6: Peng J, et al., Sci China Life Sci. 2014 Jan; 57(1): 59-68.

[0069] Non-patent literature 7: Chowdhury S, et al., Proc Natl Acad Sci USA, 2018, 16; 115(42): E9792-E9801.

[0070] Non-patent literature 8: Velikkakath AK, et al., Mol Biol Cell, 2012 Mar; 23(5): 896-909.

[0071] Non-patent literature 9: Diao J, et al., Nature. 2015Apr 23; 520(7548): 563-6.

[0072] Non-patent literature 10: Ito N, Hirose M. Adv Cancer Res. 1989; 53: 247-302.

[0073] Non-patent document 11: Schwartz JL. J Nutr. 1996 Apr; 126(4 Suppl): 1221S-7S

[0074] Non-patent document 12: JE Chong M. et al., Volume 9, Issues 1-2, 1997, 37-48

[0075] Non-patent literature 13: Galovie Renge lR, et al., Eur J Pharm Sci. 2002Jun; 15(5): 441-8.

[0076] Non-patent literature 14: Filipovie-Grcie J, et al., J Microencapsul. 2001 Jan-Feb; 18(1): 3-12.

[0077] Non-patent literature 15: Takeuchi H, et al., Pharm Res. 1996 Jun; 13(6): 896-901. Summary of the invention

[0078] Problems to be Solved by the Invention

[0079] In summary, the problem to be solved by the present invention is to provide a carrier for cell delivery that simultaneously enhances four essential elements, namely: 1) antioxidant activity, 2) intracellular absorption, 3) intracellular disintegration, and 4) stability and safety.

[0080] Means for solving problems

[0081] The means for solving the above-mentioned problems can be summarized as providing the following cell delivery carrier: 1) the antioxidant property required for the cell delivery carrier can be achieved by configuring an excellent antioxidant vitamin derivative on the surface of the cell delivery carrier, and 2) the intracellular absorption ability can be improved by mixing the vitamin derivative that induces endocytosis with the emulsifying component. Furthermore, the cell delivery carrier can be disintegrated in the target cell or near the target cell by configuring a stimulus-responsive polymer on the surface of the cell delivery carrier. Furthermore, 3) intracellular disintegration can be induced by limiting the mixed vitamin derivatives to vitamin derivatives that can enhance the autophagic activity and lysosomal activity in the cell, decomposing the amphiphilic vitamin derivative components that are stable inside the cell delivery carrier, and converting them into vitamins that can be used by the cells.

[0082] The present invention is as follows.

[0083] (1) A cell delivery carrier, which is composed of a mixture of one or more substances selected from the following three groups: a substance that simultaneously activates an autophagy-related gene and a cathepsin synthesis gene, a molecule containing a stimulus-responsive polymer, and a lipid.

[0084] (2) A cell delivery carrier, which is composed of a mixture of one or more substances selected from the following four groups: a substance that simultaneously activates autophagy-related genes and cathepsin synthesis genes, a molecule containing a stimulus-responsive polymer, an emulsion stabilizer, and a lipid.

[0085] (3) A cell delivery carrier, which is composed of a mixture of one or more substances selected from the following five groups: substances that simultaneously activate autophagy-related genes and tissue protease synthesis genes, molecules containing stimulus-responsive polymers, emulsifier stabilizers, active ingredients, and lipids, wherein the active ingredients are encapsulated in the cell delivery carrier.

[0086] (4) A cell delivery carrier, wherein part or all of the lipids are lipids having 8 or more continuous hydrocarbon chains.

[0087] (5) A cell delivery carrier, wherein part or all of the lipid is a surfactant.

[0088] (6) A cell delivery carrier, wherein a part or all of the lipids are liquid crystal layer-forming surfactants.

[0089] (7) A cell delivery carrier, wherein the cell delivery carrier has any one of a single-layer liquid crystal structure and a multi-layer liquid crystal structure.

[0090] (8) A cell delivery carrier, wherein part or all of the lipids are selected from cationic lipids or anionic lipids.

[0091] (9) A carrier for cell delivery, which exists in the form of microparticles dispersed in an aqueous solvent.

[0092] (10) A cell delivery carrier, wherein the particles dispersed in the aqueous solvent are nanoparticles having an average particle size in the range of 1 nm to 300 nm. (11) A cell delivery carrier, wherein the cell delivery carrier is a cell delivery carrier for a drug delivery system.

[0093] (12) A vector for cell delivery, wherein the autophagy-related gene and the cathepsin synthesis gene are selected from the following Table 1 and registered with the Human Genome Nomenclature Committee of the Human Genome Organization.

[0094] [Table 1]

[0095] (Autophagy-related genes)

[0096] ULK1, ULK2, ATG2A, ATG2B, ATG3, ATG4A, ATG4B, ATG4C, ATG4D, ATG5, BECN1, ATG7, GABARAP, GABARAPL1, GABARAPL2, MAP1LC3A, MAP1LC3B, MAP1LC3B2, MAP1LC3C, ATG9A, ATG9B, ATG10, ATG12, ATG13, ATG14, ATG16L1, ATG16L2, RB1CC1, WIPI1, WIPI2, SNX30, SNX4, ATG101, AMBRA1

[0097] (Cathepsin synthesis gene)

[0098] CTSA, CTSB, CTSC, CTSD, CTSD, CTSE, CTSF, CTSG, CTSH, CTSK, CTSL, CTSLP6, CTSO, CTSS, CTSV, CTSW, CTSZ

[0099] (13) A carrier for cell delivery, wherein any one or more of a substance that simultaneously activates an autophagy-related gene and a cathepsin synthesis gene and a molecule containing a stimulus-responsive polymer constitute a part of a membrane molecule mainly composed of lipids.

[0100] (14) A cell delivery carrier, wherein a molecule containing a stimuli-responsive polymer is ionically bonded to a lipid.

[0101] (15) A vector for cell delivery, wherein the molecule containing the stimulus-responsive polymer comprises any one or more of the following three stimulus-responsive molecules: temperature, pH value and light.

[0102] (16) A vector for cell delivery, wherein the substance that simultaneously activates autophagy-related genes and cathepsin synthesis genes is selected from vitamin derivatives. (17) A vector for cell delivery, wherein the substance that simultaneously activates autophagy-related genes and cathepsin synthesis genes is composed of one or more substances selected from the group of vitamin derivatives listed in Table 2 below.

[0103] [Table 2]

[0104] Sodium (ascorbyl / cholesteryl) phosphate, potassium ascorbyl tocopheryl phosphate, tocopheryl linoleate / oleate, 2,4-diethoxycarbonyl ethyl pantothenate, 3-O-ethyl ascorbic acid, 3-O-hexadecyl ascorbic acid, 3-ascorbyl carbonyl dipeptide-17, ethyl ascorbic acid, ascorbyl methylsilanol pectin, ascorbyl diglyceryl tocopherol, ascorbyl glucoside, ascorbyl diester tocopherol, tetrahexyldecyl ascorbate, ascorbic acid polypeptide, methylsilanol ascorbic acid, caprylyl 2-glyceryl ascorbic acid, caprylyl 3-glyceryl ascorbic acid, tocopheryl succinate, diethyl ascorbic acid, dioleyl tocopheryl methylsilanol, pyridoxine dioctanoate, diethoxycarbonyl ethyl pantothenate, pyridoxine dipalmitate, anti Ascorbyl stearate, lipoyl stearate, lipoyl palmitate, lipoyl margarate, tetrahexyldecyl ascorbyl ester, riboflavin tetrabutyrate, tocopheryl oxypropyl trisiloxane, tocopheryl glucoside, sodium tocopheryl phosphate, tocosolan, pyridoxine trihexyldecanoate, tocopheryl nicotinate, retinyl palmitate, vitamin C propylene glycol hyaluronic acid, hydroxydecyl ubiquinone, retinol propionate, ascorbyl tocopheryl maleate, disodium lauriiminodipropionate tocopheryl phosphate, tocopherol linoleate, retinol linoleate, disodium tocopherol phosphate, tocopherol retinoic acid ester, retinol retinoic acid ester, tocopherol acetate, retinyl acetate (18) a carrier for cell delivery, wherein the lipid is one or more substances selected from the group consisting of substances listed in Table 3 below.

[0105] [Table 3]

[0106] Alkanesulfonic acid, triethanolamine dodecanol sulfate, alkyl glucoside, aluminum isostearate, glyceryl isostearate, sorbitan isostearate, polyethylene glycol isostearate, polyoxyethylene (20) sorbitan isostearate, isostearyl lactylic acid, isopalmitoyl diglyceride, undecyl-N-carboxymethyl imidazolyl betaine, undecyl hydroxyethyl imidazolyl betaine, zinc undecylenate, ethylene glycol fatty acid ester, glyceryl erucate, oleyl dimethylamine oxide, oleyl sulfuric acid, triethanolamine oleyl sulfate, oleic acid, oleyl glyceryl, oleyl sarcosine, methyl oleoyl taurine, ganglioside, bile acid, surfactant protein and its salts, safflower oil fatty acid glyceride, saponin, glyceryl diarachidate, glyceryl diisostearate, polyglyceryl diisostearate Stearate-2-10, Tetradecyl Polyoxypropylene Polyoxyethylene Ether, Ethylene Glycol Dicaprylate, Dioctylamine, Ethylene Glycol Dioleate, Polyethylene Glycol Dioleate, Ethylene Glycol Distearate, Glyceryl Distearate, Ethylene Glycol Distearate, Sorbitan Distearate, Poly (6-10) Glyceryl Distearate, Polyethylene Glycol Distearate, Polyethylene Glycol Dipalmitate-150, Dodecyl Dimethylamine Oxide, Aluminum Dimyristate, Dimethyl Stearylamine, Sucrose Fatty Acid Ester, Diethylene Glycol Dilaurate, Polyethylene Glycol Dilaurate, Polyethylene Glycol Diricinoleate, Stearyl Dihydroxyethyl Betaine, Betaine Stearyl Dimethylaminoacetate, Stearyl Dimethylamine Oxide, Stearyl Dimethyl Betaine, Stearyl Trimethyl Ammonium Saccharin, Stearyl Fatty acid sulfate, stearic acid, stearamidoethyl diethylamine, stearic acid diglycol, stearic acid triethanolamine, stearoyl acyl glutamic acid, stearoyl methyl taurine, stearoyl lactic acid, acanthosporic acid, sphingomyelin, sphingomyelin, dioctyl sulfosuccinate, dilauryl sulfosuccinate, sorbitan sesquiisostearate, sesquiolein, sesquiolein diglyceryl, sesquioleic acid, sorbitan sesquistearate, hexadecyl trimethyl ammonium saccharin, hexadecyl phosphoric acid, hexadecyl phosphoric acid diethanolamine, hexadecyl sulfate, sophorolipids, deoxycholic acid, poly (10) glyceryl decaoleate, decaglycerol decasteate, poly (2) glyceryl tetraisostearate, tetradecane sulfonic acid, triisostearate diglyceryl, sorbitan trioleate, poly (10) glyceryl trioleate, polyoxyethylene (20) sorbitan trioleate, sorbitan tristearate, poly (10) glyceryl tristearate, polyoxyethylene (150) sorbitan tristearate, polyoxyethylene (20) sorbitan tristearate, polyoxyethylene sorbitan tristearate, trilaurylamine, trehalose lipids, palm oil fatty acid acyl-N-carboxyethyl ester-N-hydroxyethyldiamine, palm oil fatty acid amide propyl betaine, palmitic acid, isopropanolamine palmitate, polyethylene glycol palmitate, palmitoyl methyl taurine, castor oil fatty acid, poly (10) glyceryl pimelate, glyceryl behenate, poly (6-10) glyceryl pentaoleate, poly (6-10) glyceryl pentaoleate, pentastearate decaglycerol, polyoxygen agent,Polyoxyethylene (1) alkyl (11,13,15) ether sulfate, polyoxyethylene (1) alkyl (11,13,15) ether sulfate triethanolamine, polyoxyethylene (1) polyoxypropylene (1,2,4,8) hexadecyl ether, polyoxyethylene (10) alkyl (12,13) ​​ether, polyoxyethylene (10) alkyl (12,13) ​​ether phosphate, polyoxyethylene (10) polyoxypropylene (1,2,4,8) hexadecyl ether, polyoxyethylene (10) hydrogenated castor oil, polyoxyethylene (2) alkyl (12,13) ​​ether sulfate, polyoxyethylene (2) lauryl ether sulfate, polyoxyethylene (2,10,20) isostearyl ether, polyoxyethylene (20) aryl ether, polyoxyethylene (20) polyoxypropylene (1,2,4,8) ten Hexadecyl ether, polyoxyethylene (20) coconut fatty acid sorbitan, polyoxyethylene (20) hydrogenated castor oil, polyoxyethylene (3) alkyl (11-15) ether sulfate, polyoxyethylene (3) polyoxypropylene (34) stearyl ether, polyoxyethylene (3) myristic ether sulfate, polyoxyethylene (3,7,12) alkyl (12-14) ether, polyoxyethylene (34) polyoxypropylene (23) stearyl ether, polyoxyethylene (4) polyoxypropylene (30) stearyl ether, polyoxyethylene (40) hydrogenated castor oil, polyoxyethylene (5) polyoxypropylene (1,2,4,8) hexadecyl ether, polyoxyethylene (50) hydrogenated castor oil, polyoxyethylene (60) hydrogenated castor oil, polyoxyethylene secondary alkyl ether, polyoxyethylene alkyl ether phosphate, polyoxyethylene Alkylphenyl ether phosphate, polyoxyethylene alkylphenyl ether phosphate triethanolamine, polyoxyethylene isohexadecyl ether, polyoxyethylene octyl ether phosphate, polyoxyethylene octyldodecyl ether, polyoxyethylene octylphenyl ether, polyoxyethylene oleyl ether, polyoxyethylene oleyl ether phosphate, polyoxyethylene oleyl ether diethanolamine phosphate, etc., polyoxyethylene oleyl cetyl ether, polyoxyethylene dinonylphenyl ether, polyoxyethylene stearic acid ether, polyoxyethylene stearyl ether phosphate, polyoxyethylene cetyl ether, polyoxyethylene cetyl ether phosphate, polyoxyethylene cetyl stearyl ether, polyoxyethylene tridecyl ether, polyoxyethylene tridecyl ether acetate, polyoxyethylene nonylphenyl ether, polyoxyethylene castor oil, polyoxyethylene behenyl ether, polyoxyethylene polyoxypropylene cetyl ether, polyoxyethylene poly Oxypropylene lauryl ether, polyoxyethylene myristyl ether, polyoxyethylene coconut oil alkyl dimethylamine oxide, etc., polyoxyethylene lauryl ether phosphate, polyoxyethylene lauryl ether phosphate triethanolamine, polyoxyethylene lauryl ether acetate, polyoxyethylene lauryl ether sulfate, polyoxyethylene lauryl ether sulfate triethanolamine, mannosyl erythritol lipid, myristyl sulfate, myristic acid, myristic acid isopropanolamine, myristic acid glyceryl, polyethylene glycol myristate, myristoyl glutamic acid, myristoyl sarcosine, myristoyl methyl alanine, sorbitan monoisostearate, polyglyceryl monoisostearate, monomyristyl glyceryl monoisostearate, sorbitan monooleate, polyglyceryl monooleate, polyethylene glycol monooleate, ethylene glycol monostearate,Sorbitol monostearate, polyglycerol monostearate, polyethylene glycol monostearate, polyoxyethylene sorbitan monostearate, sorbitan monopalmitate, polyoxyethylene sorbitan monopalmitate, glyceryl monohydroxystearate, polyglycerol monomyristate, sorbitan monolaurate, polyethylene glycol monolaurate, polyoxyethylene sorbitan monolaurate, monolanolin fatty acid glyceride, monotallow fatty acid glyceride, coconut oil alkyl dimethylaminoacetic acid betaine, coconut oil alkyl dimethylamine oxide, coconut oil alkyl sulfate magnesium / triethanolamine, coconut oil fatty acid, coconut oil fatty acid / hydrogenated tallow fatty acid acyl glutamic acid, coconut oil fatty acid acyl-N-carboxyethyl-N-hydroxyethylethylenediamine, coconut oil fatty acid acyl-N -Carboxyethoxyethyl-N-carboxyethylethylenediamine, coconut oil isethionate, coconut oil fatty acid sarcosine triethanolamine, coconut oil fatty acid sucrose ester, coconut oil fatty acid anhydrous sorbitan, coconut oil fatty acid triethanolamine, lauryl iminodipropionic acid, lauryl iminopropionic acid, lauryl iminotriethanolamine, lauryl dimethylamine oxide, lauryl hydroxysulfobetaine, lauryl alcohol phosphate, dodecyl sulfate, ammonium dodecyl sulfate, diethanolamine lauryl sulfate, triethanolamine lauryl sulfate, magnesium dodecyl sulfate, monoethanolamine lauryl sulfate, lauric acid, lauramidopropyl betaine acetate, lauric acid glyceryl, diethylene glycol laurate, lauric acid triethanolamine, lauroyl glutamic acid, lauroyl glutamic acid triethanol, lauroyl Methylalanine triethanolamine, rhamnolipid, ricinoleic acid amide propyl betaine, ricinoleic acid glyceryl, linoleic acid glyceryl, alkyl (16, 18) trimethyl ammonium chloride, alkyl (20-22) trimethyl ammonium chloride, alkyl (28) trimethyl ammonium chloride, isostearyl lauryl dimethyl ammonium chloride, di (polyoxyethylene) oleyl methyl ammonium chloride (2EO), alkyl (12-15) dimethyl ammonium chloride, dialkyl (12-18) dimethyl ammonium chloride, alkyl (14-18) dimethyl ammonium chloride, dicocoyl dimethyl ammonium chloride, dioctadecyl dimethyl ammonium chloride, ammonium chloride hexadecyl dimethyl ammonium, dipolyoxyethylene stearyl methyl ammonium chloride, stearyl dimethyl benzyl ammonium chloride, stearyl trimethyl ammonium chloride, stearyl carbamoyl methyl Pyridinium chloride, hexadecyltrimethylammonium chloride, hexadecylpyridinium chloride, tri(polyoxyethylene) stearic acid ammonium chloride (5EO), benzalkonium chloride, benzethonium chloride, polyoxyethylene chloride (1) polyoxypropylene (25) diethylmethylammonium, myristyldimethylbenzyl ammonium chloride, methylbenzethonium chloride, lauryldimethyl (ethylbenzyl) ammonium chloride, lauryltrimethylammonium chloride, laurylpyridinium chloride, N-(lauroylaminoformylmethyl)-pyridinium chloride, alkyldiaminoethylglycine hydrochloride, hydrogenated tallow fatty acid acyl glutamic acid, self-emulsifying ethylene glycol monostearate, self-emulsifying monostearate glyceryl, self-emulsifying polyethylene glycol monostearate (2), alkyl isoquinoline bromide, stearyltrimethyl bromide, hexadecyltrimethylammonium bromide,Lauryl trimethyl ammonium bromide, poly (6) glycerol condensed ricinoleate, wheat germ oil fatty acid glyceride, lipophilic monoolein, lipophilic monostearic glyceride, hydrogenated soybean lysophospholipids, hydrogenated soybean lecithin, hydrogenated soybean fatty acid glyceride, hydrogenated egg yolk lysophosphatidylcholine, soybean lysophospholipids, soybean lecithin, saturated fatty acid glyceride, cottonseed fatty acid glyceride, egg yolk lecithin and their sodium, magnesium, potassium, aluminum, zinc, calcium and triethanolamine salts (19) Cell delivery carrier, wherein the lipid is a surface-active lipid.

[0107] (20) A carrier for cell delivery, wherein the surface-active lipid is one or more substances selected from Table 4 and forms a lamellar liquid crystal structure in an aqueous solution.

[0108] [Table 4]

[0109] 2-Alkyl-N-carboxymethyl-N-hydroxyethyl imidazoline betaine, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine, 14) aspartic acid triethanolamine, 2-alkyl-N-carboxymethyl-N-hydroxyethyl imidazoline betaine, N-acyl aspartic acid, N-acyl glutamic acid, N-acyl sarcosine, N-acyl methyl alanine, N-acyl methyl taurine, N-stearoyl dihydrosphingosine, N-stearoyl phytosphingosine, PEG-20 phytosterol, PEG-phytosterol, acyl C12-acyl-N-methyl amino acid, acyl amino acid, acyl lactic acid, acetylethyl carboxymethyl thiazolidinecarboxylic acid, aminoacetic acid betaine type amphoteric surfactant, alkyl (alkenyl) oligoglycoside, alkylphenol polyethylene glycol ether, alkoxylated triglyceride, phytosteryl isostearate, EmulgadeNLB, Emulgade PL68 / 50, Emulgade SEPF, Emulgade Sucro, Eumulgin B1, Eumulgin B2, Eumulgin B3, Eumulgin S21, Hexanoylproline, Glycerol phosphate, Glycerophospholipid, Glucuronic acid, Cremophor A25, Cremophor GS32, cocamide MEA, cocoyl alanine triethanolamine, cocoyl glutamic acid, cocoyl glutamic acid triethanolamine, cocoyl methyl taurine, succinate, surfactant protein, lysine distearoyl glutamate, bisphosphatidylglycerol (cardiolipin), lysine dimyristoyl glutamate, lysine dilauroyl glutamate, dilinoleoyl glutamate lysine, stearoyl glutamate, dioctyldodecyl stearoyl glutamate, sphingosine, ceramide, ceramide 1-phosphonic acid, ceramide 1-phosphate, ceramide aminoethyl phosphonic acid, cerebroside, sorbitol ester, soybean sterol, triethanolamine salt, palm kernel oil fatty acid amide propyl betaine liquid, palm fatty acid glutamic acid, palmitoyl aspartic acid ditriethanolamine, bis (Nε-lauroyl-L-lysine) sebacamide, hydroxystearyl phytosphingosine, polyoxyethylene glyceryl pyroglutamic acid isostearate, polyoxy Ethylene hydrogenated castor oil monoisostearate, glyceryl monoisostearate, phytosterol, phytosphingosine, hexaglycerol monostearate, phosphatidylinositol, phosphatidylinositol polyphosphate, phosphatidylethanolamine, phosphatidylglycerol, phosphatidylcholine, phosphatidylcholine (lecithin), phosphatidylserine, phosphatidic acid, polyol fatty acid ester, polyoxyethylene alkyl ether acetic acid, polyoxyethylene distearate, polyoxyethylene dehydrated sorbitan Sugar alcohol tristearate, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene methyl glucose distearate methyl ester, polyoxyethylene monostearate, polyoxyethylene lauryl ether, polyoxyethylene hydrogenated castor oil, polyoxyethylene fatty acid amine sulfate, polyquaternium-10, polyquaternium-51, polyquaternium-61, polyquaternium-64, polyquaternium-65, polyquaternium-7, myristoyl glutamate, sodium myristoyl glutamate,Myristoyl methylaminopropionate hexyldecyl ester, myristoyl methyl taurine, polyoxyethylene sorbitan monooleate, coconut oil alkyl betaine liquid, coconut oil fatty acid N-methylethanolamide, coconut fatty acid acyl glycine, coconut oil fatty acid acyl glutamic acid, coconut fatty acid acyl glutamic acid triethanolamine, coconut oil fatty acid amide propyl betaine, coconut oil fatty acid glyceride, coconut oil fatty acid glutamic acid, coconut oil fatty acid sarcosine, coconut fatty acid diethanolamide (cocamide DEA), coconut oil fatty acid methyl alanine, coconut fatty acid methyl ethanolamide (cocamide methyl MEA), coconut oil fatty acid methyl taurine, seed oil fatty acid monoethanolamide (cocamide MEA), lauryl amidopropyl betaine lauryl aminodiacetic acid liquid, lauryl diaminoethyl glycine, lauryl di Betaine methylaminoacetic acid, lauramidopropyl betaine, lauryl ether acetate, lauryl ether sulfate, lauroyl aspartic acid, lauroyl glutamic acid, lauroyl glutamic acid POE (2) octyldodecyl ether diester, lauroyl glutamic acid POE (2) stearyl ether diester, di (octyldodecyl / phytosteryl / behenyl) lauroyl glutamic acid, phytosteryl / octyldodecyl lauroyl glutamic acid, dihexyldecyl lauroyl glutamate, lauroyl glutamic acid triethanolamine, lauroyl glutamic acid polyoxyethylene octyldodecyl ether diester, lauroyl glutamic acid polyoxyethylene stearyl ether diester, methyl alanine lauroyl glutamic acid, lauroyl sarcosine, lauroyl sarcosine triethanolamine, lauroyl methyl alanine, lauroyl methyl glycine, lauroyl methyl taurine, lauroyl monoethanolamide succinic acid, Lanette WAXAO, lysophosphatidylinositol, lysophosphatidylethanolamine, lysophosphatidylglycerol, lysophosphatidylcholine, lysophosphatidylserine, lysophosphatidic acid, phospholipid glycerol, lecithin, secosporium penicillic acid, hydrogenated coconut fatty acid glycerol sulfate, fatty amine polyethylene glycol ether, fatty alcohol polyethylene glycol ether, fatty acid N-alkyl glucamide, fatty acid amide polyethylene glycol ether, fatty acid alkanolamide, fatty acid alkanolamide ether carboxylic acid, fatty acid alkanolamide sulfate, fatty acid glyceride sulfate, fatty acid polyethylene glycol ester, hydrogenated cyclic lysophosphatidic acid, hydrogenated soybean lecithin, hydrogenated egg yolk lecithin, branched fatty acid (C12-31) cholesterol, and their sodium, magnesium, potassium, aluminum, zinc, calcium, triethanolamine salts,

[0110] (21) A vector for cell delivery, wherein the molecule containing the stimulus-responsive polymer has a structure of a linear or branched polymer structure containing one or more monomers selected from the temperature stimulus responsive substance, pH stimulus responsive substance and light stimulus responsive substance in Table 5.

[0111] [Table 5]

[0112] (Temperature stimulus responsive substance)

[0113] (Polyoxyethylene octylphenyl ether) acrylate, (polyoxyethylene octylphenyl ether) methacrylate, (polyoxyethylene nonylphenyl ether) acrylate, (polyoxyethylene nonylphenyl ether) methacrylate, (polyoxyethylene lauryl ether) acrylate, (polyoxyethylene lauryl ether) methacrylate, 1,2,4,5-tetrakis(N,N-dithioaminomethyl)benzene, 1,3,5-tris(bromomethyl)benzene, 2-n-propyl-2-oxazoline, 2-N,N-dimethylaminoethyl acrylate, 2-N,N-dimethylaminoethyl methacrylate DMAEMA, 2-amino-2-hydroxymethyl-1,3-propanediol, 2-amino-2-hydroxymethyl-1,3-propanediol (T ris), 2-amino-2-hydroxymethyl-1,3-propanediol hydrochloride, 2-hydroxy-3-phenoxypropyl acrylate, 2-hydroxybutyl acrylate, 2-hydroxybutyl methacrylate, 2-hydroxypropyl acrylate, 2-hydroxypropyl methacrylate, 3,5-tris(N,N-dithiocarbamoylmethyl)benzene, 3-N,N-dimethylaminopropyl acrylamide, N-acryloyl asparagine, N-acryloyl glycinamide, N-acryloyl glutamine, N-methylacryloyl asparagine, N,N-dimethyl methacrylamide, N,N-dimethyl acrylamide, N,N-methylenebisacrylamide, N-ethyl methacrylamide, N,N-ethyl methyl amide, N,N-ethyl Methacrylamide, N,N-dialkyl-dithiocarbamoylmethyl, N,N-dialkyl-substituted acrylamide derivatives, N,N-dialkyl-substituted methacrylamide derivatives, N,N-diethylacrylamide, N,N-diethylamide, N,N-diethylmethacrylamide, N,N-dithiocarbamate ammonium (sodium N,N-dithiocarbamate), N,N-dimethylacrylamide, N,N-dimethylmethacrylamide, N,N-propylacrylamide, N,N-propylacrylamide, N,N-propylmethacrylamide, N-acryloylpiperidine, N-acryloylmorpholine, N-alkylacrylamide, N-alkylmethacrylamide, N-alkyl-substituted acrylamide acrylamide, N-alkyl substituted methacrylamide, N-allylphthalimide, N-isopropyl methacrylamide, N-ethylacrylamide, N-ethyl methacrylamide, N-ethoxyethylacrylamide, N-ethoxyethylamide, N-ethoxyethyl methacrylamide, N-cyclopropylacrylamide, N-cyclopropylamide, N-cyclopropyl methacrylamide, N-tetrahydrofurfurylacrylamide, N-tetrahydrofurfuryl methacrylamide, N-biotin-N′-methacryloyl trimethyleneamide, N-vinylacrylamide, N-vinylalkylacrylamide, N-vinylmethacrylamide, N-propylacrylamide, N-methacryloylpiperidine, N- or N,N-dialkyl-substituted methacrylamide derivatives, s-butylacrylamide, t-butylacrylamide, acryloyl glycinamide, acryloyl sarcosine amide, acryloyl piperidine carboxamide, acryloyl methyl uracil, acetylacrylamide, ethyl isopropyl acrylamide, ethylene glycol / propylene glycol copolymer, ethylene glycol allyl methyl ether, oxyethylene acrylate derivatives, oxyethylene sorbitan laurate, oxyethylene methacrylate derivatives, oxyethylene laurylamine, acrylates having oligoethylene glycol in the side chain, diisopropyl acrylamide, diethyl acrylamide, diethylamino acrylate, Diethylaminomethacrylate, diethylene glycol allyl methyl ether, dibutylacrylamide, dipropylacrylamide, dimethylacrylamide, dimethylaminoacrylamide, dimethylaminoacrylate, dimethylaminopropylacrylamide, dimethylaminopropylmethacrylamide, dimethylaminomethacrylamide, dimethylaminomethacrylamide, sodium N,N-dithiocarbamic acid, hexa(N,N-dithiocarbamoylmethyl)benzene, hexa(bromomethyl)benzene, methacrylamide / N-acetylacrylamide copolymer, and its sodium, magnesium, potassium, aluminum, zinc, calcium, triethanolamine salts and their derivatives,

[0114] (pH stimulus responsive substance)

[0115] Glucosamine, chitosan, 2-ethoxyethyl vinyl ether, N-alkyl acrylamide / polyacrylic acid, N-vinyl alkyl acrylamide, 4-(2-vinyloxyethoxy)benzoic acid, 6-(2-vinyloxyethoxy)hexanoic acid, 6-(vinyloxy)hexanoic acid, isobutyl vinyl ether and its alkali metal salts and derivatives, and salts of sodium, magnesium, potassium, aluminum, zinc, calcium, triethanolamine and their derivatives (photostimulation responsive substances)

[0116] N-alkyl acrylamide, n-(4-phenylazophenyl) acrylamide, 6-[4-(4-pyridylazo)phenoxy]hexamethylacrylate, N-vinyl alkyl acrylamide, 4-[2-(vinyloxy)ethoxy]azobenzene, 2-(2-ethoxy)ethoxyethyl vinyl ether, and salts of sodium, magnesium, potassium, aluminum, zinc, calcium, triethanolamine and their derivatives

[0117] (22) A cell delivery carrier, wherein the emulsion stabilizer is one or more components selected from the group consisting of polyols, synthetic antioxidants, ultraviolet absorbers, and preservatives listed in Table 6.

[0118] [Table 6]

[0119] (Polyol)

[0120] Ethylene glycol, diethylene glycol, polyethylene glycol, propylene glycol, polypropylene glycol, glycerol, diglycerol, polypropylene glycol, 1,3-butylene glycol, triethylene glycol, dipropylene glycol, 3-methyl-1,3-butylene glycol, 1,2-pentanediol, 1,4-pentanediol, 1,5-pentanediol, 2,4-pentanediol, 2-methyl-2,4-pentanediol, 3-methyl-1,5-pentanediol, 1,2-hexanediol, 1,6-hexanediol, glycerol, diglycerol, triglycerol, polypropylene glycol, methylbutylene glycol, butanediol, isoprene glycol, polyethylene glycol, pentanediol, hexanediol, propylene glycol, dipropylene glycol, poly Propylene glycol, ethylene glycol, diethylene glycol, neopentyl glycol, polyethylene glycol, sorbitol, xylitol, sodium pyrrolidone carboxylate, hyaluronic acid, carrageenan, alginic acid, agar, fucose, pectin, locust bean gum, xanthan gum, tragacanth gum, guar gum, carboxymethyl cellulose, hydroxyethyl cellulose, polyvinyl alcohol, polyvinyl pyrrolidone, carboxyvinyl polymer, acrylic acid / methacrylic acid copolymer, polyglutamic acid, sodium alginate, carrageenan, agar, furcellaran, guar gum, quince seeds, konjac mannan, tamarind gum, tara gum, dextrin, starch, locust bean gum, gum arabic, gum ghatti, karaya gum , tragacanth gum, arabinogalactan, pectin, quince pectin, chitosan, starch, curdlan, xanthan gum, gellan gum, cyclodextrin, dextran, pullulan, microcrystalline cellulose, methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose, carboxy starch, cationic cellulose, starch phosphate, cationic guar gum, carboxymethyl / hydroxypropyl guar gum, hydroxypropyl guar gum, albumin, casein, gelatin, sodium polyacrylate, polyacrylamide, carboxyethylene polymer, polyethyleneimine, high polymer polyethylene glycol, polyvinyl alcohol , polyvinyl pyrrolidone, polyvinyl ether, polyacrylamide, acrylic acid copolymer, methacrylic acid copolymer, maleic acid copolymer, vinyl pyridine copolymer, ethylene / acrylic acid copolymer, vinyl pyrrolidone polymer, vinyl alcohol / vinyl pyrrolidone copolymer, nitrogen-substituted acrylamide polymer, amino-modified silicone, cationic polymer, dimethyl acryloyl ammonium polymer, acrylic acid anion polymer, methacrylic acid anion polymer, modified silicone, acrylic acid methacrylate alkyl ester (C10-30) copolymer, polyoxyethylene / polyoxypropylene copolymer

[0121] (Synthetic Antioxidant)

[0122] Butylated Hydroxyanisole, Butylated Hydroxytoluene, Propyl Gallate, Erythorbate, Sodium Erythorbate, Para-Hydroxyanisole, Octyl Gallate

[0123] (Ultraviolet light absorber)

[0124] p-Aminobenzoic acid, ethyl p-aminobenzoate, glyceryl p-aminobenzoate, amyl p-dimethylaminobenzoate, 2-ethylhexyl p-dimethylaminobenzoate and other p-aminobenzoic acid derivatives, benzyl cinnamate, 2-ethylhexanoic acid dimethoxycinnamate, methyl 2,4-diisopropylcinnamate, 2,4-diisopropylcinnamate, potassium p-methoxycinnamate, sodium p-methoxycinnamate, isopropyl p-methoxycinnamate, 2-ethylethyl p-methoxycinnamate, 2-ethoxyethyl p-methoxycinnamate, ethyl p-ethoxycinnamate and other cinnamic acid derivatives, urocanic acid, ethyl urocanate and other urocanic acid derivatives, 2,4-dihydroxybenzophenone, 2,2',4,4'-tetra Benzophenone derivatives such as hydroxybenzophenone, 2-hydroxy-4-methoxy-5-sulfonic acid benzophenone, 2-hydroxy-4-methoxybenzophenone-5-sulfonic acid, 2-hydroxy-4-methoxybenzophenone, 2,2'-dihydroxy-4,4'-dimethoxybenzophenone, and 2,2'-dihydroxy-4,4'-dimethoxy-5-sulfonic acid benzophenone sodium, salicylic acid ethylene glycol, salicylic acid-2-ethylhexyl ester, phenyl salicylate, benzyl salicylate, tert-butylphenyl salicylate, homosalate, salicylic acid-3,3,5-trimethylcyclohexyl ester and other salicylic acid derivatives, 2-(2'-hydroxy-5'-methoxyphenyl)benzotriazole, 4-tert-butyl-4'-methoxybenzoylmethane

[0125] (preservative)

[0126] Preservatives: Benzoic acid, sodium benzoate, undecylenic acid, salicylic acid, sorbic acid, potassium sorbate, dehydroacetic acid, sodium dehydroacetate, isobutyl parahydroxybenzoate, isopropyl parahydroxybenzoate, ethyl parahydroxybenzoate, butyl parahydroxybenzoate, propyl parahydroxybenzoate, benzyl parahydroxybenzoate, methyl parahydroxybenzoate, sodium methyl parahydroxybenzoate, phenoxyethanol, photosensitizer 101, photosensitizer 201, photosensitizer 401, radish extract, grape seed extract

[0127] (23) A cell delivery carrier, comprising a stimulus-responsive polymer in which one or more chemical substances selected from the group of substances in Table 7 are chemically modified by covalent bonds.

[0128] [Table 7]

[0129] Acrylamide, acrylic resin, acrylic acid, metal salt of acrylic acid, amino, arginine, alkyl acrylate, uracil acrylate, ethylene glycol, ethyl acrylamide, ethanol, ethyl butyl acrylamide, ethylene oxide, ethylene glycol, ethylene glycol derivatives, oxyalkylene, oxyethylene, oxytetramethylene, oxybutylene, oxypropylene, oxyhexene, ornithine, curdlan, polyamino acid having a cationic group on the side chain, glycerol, styrene, cellulose, dextran sulfate, tetramethylene glycol, tryptophan, hyaluronic acid, biotin acrylate, histidine, hydroxyethyl acrylate, hydroxyethyl methacrylate, hydroxypropyl cellulose, hydroxy, vinyl alkyl ether, vinyl alcohol, partially acetylated vinyl alcohol, vinyl ether derivatives, vinyl pyrrolidone, vinyl methyl ether, butyl acrylamide, Butanediol, propanol, propylbutylacrylamide, propylene glycol, hexylacrylamide, hexyl glycol, heparin, amylacrylamide, polyacrylic acid, polyarginine, polyalginic acid, polyethyleneimine, polyoxyethylene, polyoxypropylene, polyornithine, polystyrenesulfonic acid, polytryptophan, polyhistidine, polymethacrylic acid, polylysine, polyphosphoric acid, methacrylamide, methacrylamide compounds, methacrylic acid sarcosine amide, methacrylic acid, methacrylic acid esters, metal salts of methacrylic acid, methyl glycol group, methyl, methacrylamide, methanol group, methylisopropylacrylamide, methylethylacrylamide, methylpropylacrylamide, ethylmethoxyacrylate, ethylmethoxyacrylate, methoxymethacrylate, lysine, riboadenylic acid, nucleic acids, sulfated polysaccharides

[0130] (24) A vector for cell delivery, wherein the active ingredient comprises one or more substances selected from Table 8.

[0131] [Table 8]

[0132] Acridine, ascorbic acid, calcium ascorbate, sodium ascorbate, ascorbyl glucoside, ascorbyl distearate, ascorbyl dipalmitate, ascorbyl stearate, ascorbyl palmitate, magnesium ascorbyl phosphate, magnesium zinc ascorbyl phosphate, sodium ascorbyl phosphate, sodium ascorbyl palmitate, astaxanthin, acetylcysteine, aminoalkylphenone, aminolevulinic acid, anther xanthin, anthocyanin, isoflavone, iridium, intein, uroporphyrinogen, uroporphyrin, eosin Y, ellagic acid, isoascorbic acid , isoascorbic acid, catechins, carotenoids, carotene, canthaxanthin, lutein, coumarin, curcumin, glutathione, glutamylcysteine, chlorogenic acid, chlorophyll, coproporphyrin, coproporphyrinogen, cyanidin, cyanocobalamin, cysteine, cytochrome C, dihydrolipoic acid, stilbene, zeaxanthin, semiquinone, thiol protein, sulfur chitosan, tetracycline, tetraphenylporphyrin, dehydroascorbic acid, delphinidin, tocotrienol, tocopherol, purpurin, hydroquinone, violaxanthin, vitamin A, hydroxymethylcholine Chromane, heme, fucoxanthin, phthalocyanine, fullerene, proanthocyanidin, procyanidin, protoporphyrinogen, protoporphyrin, provitamin A, peony pigment, petunia pigment, heme, heme, heme, hemoglobin, hemoglobin, pelargonium pigment, verteporfin, benzoquinone, benzophenone, porphyrin, porphobilinogen, porphobilinogen, protoporphyrin, porphyrin, magnesium, malva pigment, metallothionein, metalloproteinase, methylene blue, ubiquitin, ubiquinone, ubiquinone, ubiquitin semiquinone, lignans, lycopene, nuclear xanthophyll, rutin, lutein, rubrene, retinal, retinoic acid, retinol, rose bengal, zinc, iron, copper, α-hydroxyacetophenone, α-lipoic acid, α-carotene, α-tocotrienol, α-tocopherol, β-lipoic acid, β-carotene, β-tocotrienol, β-tocopherol, γ-carotene, γ-tocotrienol, γ-tocopherol, δ-tocotrienol, δ-tocopherol salts, δ-carotene, and their sodium, magnesium, potassium, aluminum, zinc, calcium, triethanolamine salts and their derivatives

[0133] (25) A cell delivery carrier, wherein the use of the cell delivery carrier is one selected from the group consisting of pharmaceuticals, quasi-drugs, cosmetics, supplements, veterinary drugs, and sundries.

[0134] (26) A cell delivery carrier, wherein the dosage form of the cell delivery carrier is one or more selected from the following: external preparation, oral preparation, suppository, oral preparation, health drink, poultice, facial mask, spray, injection, flavoring agent, liquid, ointment, aerosol, powder, compressed preparation, paste, external spray, powder, granule, tablet, soft capsule, pill, plate-shaped dosage form, lozenge, paste, solid preparation, wetting agent, adhesive.

[0135] (27) A cell delivery vector, wherein the efficacy or effect of the cell delivery vector is one or more selected from Table 9.

[0136] [Table 9]

[0137] Cleans the skin, inhibits prickly heat, frostbite, chapped skin, acne, rash, and prevents rough skin. It has the effect of fighting diapers, rashes, sores, and crotch sores. It has the effect of improving dry skin, trauma, stiff shoulders, wrinkles, neuralgia, eczema, frostbite, hemorrhoids, cold hands and feet, back pain, rheumatism, fatigue recovery, cracked skin, chapped skin, cold hands and feet before and after childbirth, and acne. Prevents itching. Prevents body odor (armpit odor), inhibits sweat odor, and stops sweating. It has the effect of promoting hair growth, preventing thinning hair, hair loss, promoting hair growth, inhibiting dandruff, hair loss after illness or after childbirth, and hair care. Inhibits bad breath and improves emotional anxiety. Whitens teeth, purifies the mouth, freshens breath, prevents periodontitis (alveolar abscess), prevents gingivitis, prevents tartar deposition, prevents caries, prevents the occurrence and development of caries, prevents bad breath, and removes tobacco tar. Hair removal effect. Effects of hair dyeing, bleaching, and dye removal. Improvement of sunburn / snow spots, blemishes, wrinkles, fine lines, nasolabial folds, freckles, rough skin, and dryness. Tightens skin. Cleanses skin. Conditions skin. Cleanses, sterilizes, and disinfects skin. Prevents body odor, sweat odor, and acne. Keeps skin healthy. Moisturizes skin. Cleanses skin. Improves oily skin. Protects skin and prevents dryness. Prevents hair and scalp sweat odor, cleans hair and scalp, keeps healthy, softens skin, and prevents hair splitting, breakage, and split ends. Replenishes and maintains moisture and oil content in hair

[0138] (28) A cell delivery carrier, which is a temperature-responsive polymer having an effect-exhibiting temperature of 45°C to 70°C.

[0139] The present invention is a cell delivery carrier, which is composed of a mixture of one or more substances selected from the following three groups: molecules containing stimulus-responsive polymers; substances that simultaneously activate autophagy-related genes and tissue protease synthesis genes; and lipids containing hydrocarbon chains composed of more than 8 carbons continuously bonded in addition to the two substances. Through this structure, the antioxidant activity, intracellular absorption capacity and intracellular disintegration of the cell delivery carrier are improved, the intracellular delivery efficiency of the substances in the cell delivery carrier is excellent, and stability and safety are ensured.

[0140] The reason why the cell delivery carrier of the present invention has the above-mentioned properties is as follows. That is, it is clearly known in the examples of the present invention that the stability and surface activity of substances having ATG-CTS activity, especially vitamin derivatives, are not necessarily related to the cell delivery rate; and the cell absorption rate and ATG-CTS are related to cleanliness.

[0141] Vitamins are important nutrients for human cells, and their intracellular concentration is higher than that of blood. Therefore, they adhere to vitamin-specific receptors on the surface of certain cells in the first stage, and are actively transported by specific channel proteins in the second stage. In stable vitamin derivatives, although they adhere to vitamin receptors, they cannot be actively transported by specific channel proteins in the second stage. That is, the vitamin receptors on the cell surface recognize part of the vitamin molecule and only adhere to this part of the vitamin molecule, but in the specific channel proteins in the second stage, most of the vitamin derivatives used to recognize all vitamin molecules and take them into the protein to make them pass through the gate for active transport adhere and stay on the cell surface in a state of not actively transporting. When this state is temporarily maintained, through frequent endocytosis of extracellular fluid, i.e., endocytosis (cell endocytosis), they are taken into the cell in a state bound to the receptor, forming a vesicle (endosome) filled with extracellular fluid. The vitamin receptors bound to the vitamin derivatives in the cell are recycled, decomposed, and used to regenerate new vitamin receptors. Therefore, the endosome activates CTS to form a lysosome, which merges with it to digest the vitamin derivatives in the vesicle, but a part of the derivatives is directly decomposed and released into the cell. The foreign body is recognized by the autophagy system through certain systems, the ATG gene is activated to form lysosomes, CTS is activated and formed, and the vitamin derivatives in the vesicles are fused with the lysosomes to decompose. In this way, the vitamin derivatives taken into the cells eventually become vitamins that can be used by the cells. Therefore, by adding the vitamin derivatives having the ATG-CTS activity to the cell delivery carrier of the present invention, the adhesion of the cells to the cell delivery carrier can be increased, and the intracellular uptake can be promoted.

[0142] Effects of the Invention

[0143] That is, the cell delivery carrier of the present invention can improve the adhesion of cells to the cell delivery carrier, promote the uptake of useful components in cells, and deliver the contents to the target tissue with high efficiency. Further, in the surface modification containing the molecule of the stimulus-responsive polymer, specifically, in the temperature stimulus-responsive polymer and the light stimulus-responsive polymer modification, the polymer is made hydrophobic by heating and light irradiation, so that the hydration layer formed is reduced, and thus the cell delivery carrier film is destroyed, and the cell delivery carrier contains substances released into the cell, which can further improve the delivery rate. Thus, it is possible to achieve a very high drug delivery efficiency to biological tissues, and improve the delivery efficiency of medicines, cosmetics, nutritional supplements, etc., therefore, it is possible to achieve a substantial cost reduction, becoming an extremely useful technology in the industry. DETAILED DESCRIPTION

[0144] The mechanism of action of the cell delivery carrier of the present invention is shown in Figure 1 .

[0145] Figure 1: is a diagram showing the effect of the cell delivery carrier of the present invention. Figure 1 In the figure, (5) represents the cell membrane, the upper side of (5) is outside the cell, and the lower side of (5) is inside the cell. (1) is a molecule containing a stimulus-responsive polymer that is bound to the cell delivery vector of the present invention. The active ingredient is represented by (2) and is contained in the cell delivery vector. There is a long tail structure in (1), which represents a stimulus-responsive polymer, which is bound to the membrane of the cell delivery vector through a lipid (ellipse) with surface activity that is bound to it. (3) is a substance that simultaneously activates autophagy-related genes and protease synthesis genes, for example, a vitamin derivative, which has amphipathic properties and is therefore also connected to the membrane of the cell delivery vector. A is a cell delivery vector that is bound to a vitamin receptor (represented by a square and a circle with a notch at the top) that passes through the cell membrane, namely (5). In this way, the vitamin derivative (3) binds to the vitamin receptor on the surface of the cell membrane, but its molecular shape is different from that of the original vitamin, so it cannot be transported through the vitamin transport channel, and a part of the cell membrane is sunken into a bag B), and is taken up from the cell membrane surface into the cell C) through endocytosis. C) The cell delivery carrier enclosed in the endosome, due to external stimuli such as temperature and light 4), the stimulus response polymer on the cell surface shrinks and becomes hydrophobic, thereby breaking the parallelism of the membrane, easily destroying the membrane of the cell delivery carrier, and releasing the active ingredients into the endosome. On the other hand, 6) is a lysosome with digestive enzymes (small quadrilaterals). D) The lysosome fuses with the endosome and moves the digestive enzymes to the endosome, decomposing (digesting) the molecules in the endosome in E). As a result, stable vitamin derivatives can be converted into vitamins that can be used by cells. F) Finally, the endosome is destroyed, and the active ingredients (black ▲), vitamins (ovals) and undigested vitamin derivatives (7) are released into the cell. The undigested vitamin derivatives further activate the autophagy system, are digested by the autophagosome, and are finally converted into vitamins for cell use.

[0146] In pH stimulus responsive polymers, it is believed that the role is played by the participation of the proton sponge effect in vesicles such as endosomes and lysosomes after being taken into cells. The proton sponge effect refers to that when a protonated compound is taken into a vesicle under a weakly acidic environment, protonation inhibits the decrease of pH in the vesicle, and a large number of protons and chloride ions flow into the vesicle, thereby increasing the osmotic pressure inside the vesicle, causing the vesicle to swell and rupture. That is, the effect of absorbing a large number of protons as the pH decreases, for example, cationic polymers with a large number of amino groups such as chitosan with a polyglucosamine structure show this effect. This hypothesis was proposed by Behr et al. as a method to help endosomal release in a nucleic acid delivery drug system in particular. There is a proton pump called V-ATPase in the endosomal membrane produced by endocytosis, which transports protons to the endosome until the pH in the endosome reaches about 5 to 6. The buffer range of cationic polymers with this proton sponge effect is pH 5 to 7, and a large number of protons are absorbed as the pH in the endosome decreases. Thus, the decrease in pH in the endosome is suppressed, and more protons are required to flow in to reduce the pH. In addition, anions also flow in to maintain the charge balance inside and outside the endosome, and the salt concentration and osmotic pressure increase. In order to eliminate this high osmotic pressure, a large amount of water flows into the endosome, and the membrane cannot bear the volume and collapses, thereby promoting the endosomal release of the inclusions of the carrier for cell delivery. The vitamin derivatives that can be used in the present invention and are recognized and bound by vitamin receptors on the cell surface can be selected from one or more substances selected from the group of vitamin derivatives shown in Table 2 of the above paragraph 0057. Through our screening, it has been confirmed that these derivatives are different from conventional vitamins and their derivatives, and are not transported through vitamin transport channels, but are bound to vitamin transport channels, remain on the cell membrane surface and are internalized.

[0147] A mixture of three different vitamin derivatives with ascorbic acid-2-phosphate in structure, i.e., trisodium ascorbyl phosphate (APS), trisodium ascorbyl palmitate phosphate (APPS) and potassium ascorbyl tocopherol phosphate (EPC), was cultured in human epidermal fibroblasts and then subjected to comprehensive analysis using DNA chips, and compared with the amount of RNA in the no-addition control, it was found that the mixture activated many autophagy-related genes (ATG) and lysosomal localized proteases, i.e., cathepsin (CTS) genes. Thus, 84 different vitamin derivatives were studied and evaluated in the same manner as above, and it was found that some derivatives had high activity and some derivatives had low activity. The inventors came up with the idea of ​​applying highly active vitamin derivatives to the cell delivery carriers of the present invention. The inventors conducted clinical trials on the effects of cell delivery carriers of vitamin derivatives with different ATG-CTS activities on cellular uptake and found that ATG-CTS activity was correlated with cell delivery rate. Furthermore, the combination of the constituent elements of the carrier, namely the stimulus-responsive substance, lipid, surfactant, and stabilizer, was studied, and further, stability tests and surface activity tests required for the stability of the carrier were conducted, thereby narrowing the range of substances that can be used in the cell delivery carrier for achieving the high cell delivery rate of the present invention.

[0148] It is known that polyethyleneimine (PEI) and polyamidoamine dendrimers have a proton sponge effect and are widely used to improve the efficiency of gene transfer. A high buffering capacity is required to exhibit the proton sponge effect, but in recent years, it has been reported that the buffering capacity of chitosan is better than PEI in the pH range (4.5 to 7) within the endosome. The cell delivery carrier of the present invention must be composed of a mixture of at least one or more substances selected from the following three groups: 1) a substance that simultaneously activates autophagy-related genes and cathepsin synthesis genes, 2) a molecule containing a stimulus-responsive polymer, and 3) a lipid containing more than 8 continuously bonded hydrocarbon chains. It can be used directly, but further, in addition to the above, in order to improve the stability of the cell delivery carrier, it is preferably selected from an existing emulsifier stabilizer.

[0149] As the emulsion stabilizer that can be used in the present invention, one or more components selected from the polyols, synthetic antioxidants, ultraviolet absorbers and preservatives listed in Table 6 above can be selected. Preferably, one or more substances are selected from polyols, synthetic antioxidants, ultraviolet absorbers and preservatives, respectively. These stabilizers can be added in a range of 0.01 to 10% by weight relative to the entire cell delivery carrier of the present invention. When added at a ratio higher than this, toxicity increases, and when added at a ratio lower than this, it is difficult to exert a stabilizing effect.

[0150] The autophagy-related gene and the cathepsin synthesis gene in the substance that simultaneously activates the autophagy-related gene and the cathepsin synthesis gene of the present invention are genes registered in the Human Genome Nomenclature Committee (HGNC) of the International Human Genome Organization, and the details are shown in Tables 10 and 11. Hereinafter, in the present invention, only the approval number of HGNC is used, but since there are multiple previous symbols and synonyms, they are organized in the following table. It has been confirmed that the genes with different names and symbols in the previous symbols and synonyms are also the same as the genes with the approval number of HGNC.

[0151] The cell delivery carrier of the present invention must use a substance that simultaneously activates the autophagy-related genes in Table 10 below and the cathepsin synthesis genes in Table 11 below, and the most preferred examples thereof are the specified vitamin derivatives.

[0152] Autophagy-related genes (ATG)

[0153] [Table 10]

[0154]

[0155] Cathepsin synthesis gene (cathepsin)

[0156] [Table 11]

[0157]

[0158] In the simultaneous activation substances of the present invention, among all the genes of the autophagy-related genes and cathepsin synthesis genes recorded in Tables 10 and 11 above, only substances that can activate one or more genes from each of Tables 10 and 11 can be used, and in particular, substances that simultaneously activate each of the autophagy-related genes and cathepsin synthesis genes recorded in the said tables are suitable. As the evaluation method of gene activation of the present invention, all commonly used DNA and corresponding RNA gene expression analysis methods can be used, and can be used but not limited to: real-time PCR, digital PCR, next generation sequencing, microarray analysis, Sanger sequencing, gene quantitative RNA determination, laser capture microdissection, etc. Table 1 of paragraph 0057 only records the HGNC approval symbols of the autophagy-related genes recorded in Tables 10 and 11 above, but the ID of the Human Genome Nomenclature Committee (HGNC) of the Human Genome Organization, the approved name of HGNC, the previous symbol, and the synonym can also be used.

[0159] As lipids that can be used in the present invention and contain more than 8 continuously bonded hydrocarbon chains, it is most ideal. Furthermore, any surfactant having a surfactant effect can be used. Lipids containing hydrocarbon chains with more than 8 carbon atoms continuously bonded further improve the stability of the cell delivery carrier. When the carbon number is less than 7, the stability of the cell delivery carrier will be reduced, and when the carbon number is more than 30, the stability of the cell delivery carrier will also be reduced. Furthermore, in order to improve the stability of the cell delivery carrier, it is preferred that both lipids and substances having a surfactant effect exist at the same time. That is, the main part of the cell delivery carrier of the present invention is composed of lipids and substances having a surfactant effect. Furthermore, it is most ideal that in the emulsified film, the lipids, substances having a surfactant effect, and molecules containing stimulus-responsive polymers are arranged as follows: Figure 2 or Figure 3 As shown, it binds to the constituent units of the membrane or surface ions. The cell delivery carrier of the present invention may be a cell delivery carrier in which one or more of the substances that simultaneously activate autophagy-related genes and cathepsin-binding genes and the molecules containing the stimulus-responsive polymer constitute a part of the membrane molecule mainly composed of lipids. As a typical structure, Figure 2 The structure in, but not limited to.

[0160] Figure 2 This is a typical structural example 1 of the lipid bilayer membrane (single-layer liquid crystal structure) of the cell delivery carrier of the present invention.

[0161] Figure 3 The typical structure example 2 of the cell delivery carrier of the present invention is shown. In this figure, a typical structure of a lipid bilayer membrane (monolayer liquid crystal structure) of the cell delivery carrier of the present invention is shown. The cell delivery carrier of the present invention may also be a lipid monolayer membrane, in which case the membrane structure at the top (outermost layer) in the figure can be used. The lipids constituting the molecules of the outermost membrane are in contact with the lipids of the inner membrane molecules to form a bilayer membrane structure (monolayer liquid crystal structure).

[0162] The lipid constituting the cell delivery carrier of the present invention may be a lipid containing a hydrocarbon chain with 8 or more carbon atoms continuously bonded, preferably a lipid or a lipid having surface activity. Furthermore, it is more preferred if it is a substance having membrane fusogenicity and having a cationic, anionic or zwitterionic lipid as a membrane constituent.

[0163] The lipids that can be used as the carrier of the present invention can be used if they are liquid at 35°C and, when used in combination with the vitamin derivatives in Table 2 above, can suppress the decay rate of the vitamin derivatives to below 20% in an accelerated test at 40°C, 80% humidity, and for 6 months, and can keep the vitamin derivatives stable. Among the lipids that meet these conditions, those that can suppress the decay rate of the vitamin derivatives to below 10% are particularly shown in Table 3 in paragraph 0057. Furthermore, the lipids with surface activity that can be used in the lipids of the present invention can be used if they are liquid at 35°C and, when used in combination with the vitamin derivatives in Table 2, suppress the decay rate of the vitamin derivative to 20% or less in an accelerated test at 40°C, 80% humidity, and for 6 months and remain stable. Among the lipids that satisfy these conditions, the lipids with surface activity that are particularly suitable for the present invention contain inclusions under an optical microscope, and the presence of a liquid crystal layer structure can be confirmed. Therefore, further, as long as the decay rate of the vitamin derivative is suppressed to 10% or less and the vitamin derivative is kept stable, the presence of the liquid crystal layer structure can be confirmed by direct observation of a multilayer film (multilayer liquid crystal structure) by a staining electron microscope as a known method or by cross polarization of maltase under a polarizing microscope. Among them, the lipids with surface activity shown in Table 4 of paragraph 0057 have high stability, and the inventors have confirmed that they can confirm a good liquid crystal layer formation effect of a large number of liquid crystal layer structures, and are very suitable for the present invention.

[0164] For example, the lipids that can be used in the present invention can be lipids formed by lipids and polymers having membrane fusion properties of the cell delivery carrier, and cationic lipids or anionic lipids themselves can also be lipids having membrane fusion properties. In the cell delivery carrier of the present invention, the lipids contained as membrane constituents and the lipids having surface activity can be one or a combination of two or more. In addition, the membrane fusion properties in the present invention refer to the fusion properties of the endosomal, autophagosome, lysosomal membrane or cell membrane.

[0165] Examples of cationic lipids include non-phospholipid lipids: 1,2-dioleoyl-3-trimethylammonium propane (DOTAP), N-[1-(2,3-dioleoylpropyl)]-N,N-dimethylamine (DODAP), N,N-dioleoyl-N,N-dimethylammonium chloride (DODAC), N,N-distearyl-N,N-dimethylammonium bromide (DDAB), N-(1-(2,3-dioleyloxy)propyl)-N,N,N-trimethylammonium chloride (DODAC), N,N-distearyl-N,N-dimethylammonium bromide (DDAB), N-(1-(2,3-dioleyloxy)propyl)-N,N,N-trimethylammonium chloride (DODAP), N,N-dioleoyl-N,N-di ... TMA), N,N-dimethyl-2,3-dioleyloxypropylamine (DODMA), 2,3-dioleyloxy-N-[2-(sperminecarboxamide)ethyl]-N,N-dimethyl-1-trifluoroacetic acid propylammonium (DOSPA), N-[1-(2,3-tetradecanoyloxypropyl)]-N,N-dimethyl-N-hydroxyethylammonium bromide (DMRIE), N-[1-(2,3-dioleyloxypropyl)]-N,N-dimethyl-N-hydroxyethylammonium bromide (DORIE), etc. Alternatively, phospholipids, etc. can be listed. These can be used alone or in combination of two or more.

[0166] As the phospholipids that can be used in the present invention, for example, natural phospholipids such as phosphatidylethanolamine, phosphatidylcholine, lysophosphatidylcholine, phosphatidylglycerol, phosphatidic acid, phosphatidylserine, phosphatidylinositol, cardiolipin, sphingomyelin, soybean lecithin, egg yolk lecithin, and lysophosphatidylcholine, and high-molecular-weight succinylated polyglycidol (SucPG) having membrane fusion ability can be listed. As phosphatidylethanolamine, there can be mentioned: 1,2-dioleoyl-sn-glycerol-3-phosphatidylethanolamine (DOPE), 1,2-dilinoleoyl-sn-glycerol-3-phosphatidylethanolamine (DLoPE), 1,2-dierucyl-sn-glycerol-3-phosphatidylethanolamine (DEPE), 1,2-dimyristoyl-sn-glycerol-3-phosphatidylethanolamine (DMPE), 1,2-dipalmitoyl-sn-glycerol-3-phosphatidylethanolamine (DPPE), 1,2-distearoyl-sn-glycerol-3-phosphatidylethanolamine (DSPE), etc. In addition, cell death can be further inhibited, so the lipid in the present invention preferably contains phospholipids as a membrane constituent.

[0167] Examples of the anionic lipids that can be used in the present invention include phosphatidylserine, phosphatidylglycerol, phosphatidic acid, phosphatidylinositol or phosphatidylinositol phosphate, or lysolipids, lipid peroxides, oxides, plasmalogens or diether lipids thereof.

[0168] When ionically bonding molecules containing ionic stimulus-responsive polymers, the lipids of the present invention preferably use lipids having ionicity opposite to that of the stimulus-responsive polymers. For example, lipids used to ionically bond polymers having a large number of cationic amines such as polyglucosamine and chitosan to the surface of the cell delivery carrier of the present invention are suitable for using anionic, non-cationic or amphoteric lipids in a large proportion of the total lipids or in their entirety. Among them, anionic lipids are more preferably used.

[0169] From the viewpoint of having a better effect of inhibiting cell death after cell delivery and excellent efficiency of delivery into cells, the cell delivery carrier of the present invention preferably contains non-phospholipid lipids and membrane fusogenic lipids as membrane constituents at a molar ratio of 3:0.5 to 3:20, more preferably contains non-phospholipid lipids and membrane fusogenic lipids as membrane constituents at a molar ratio of 3:2 to 3:15, and further preferably contains non-phospholipid lipids and membrane fusogenic lipids as membrane constituents at a molar ratio of 3:5 to 3:10. In addition, it is preferred to contain 1,2-dioleoyl-3-trimethylammonium propane (DOTAP) as a lipid, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) as a membrane fusogenic lipid, and contain the membrane constituents of the cell delivery carrier at the molar ratio.

[0170] The molecule containing the stimulus-responsive polymer in the present invention can be the stimulus-responsive polymer itself or a derivative after chemical modification of the stimulus-responsive polymer by other substances according to different purposes. Here, the other substances chemically modified according to different purposes are substances in which the stimulus-responsive polymer is chemically bonded to the lipid or a molecule of a similar structure as the main constituent component of the membrane of the carrier for cell delivery. The stimulus-responsive polymer can be stably bound to the membrane, and therefore, it is particularly preferred to bind it to the lipid. In the embodiments, it is referred to as a stimulus-responsive polymer-bound lipid, which is a preferred example of a molecule containing a stimulus-responsive polymer.

[0171] Further preferably, the cell delivery carrier membrane is mainly composed of lipids with surface activity, and the stimulus-responsive polymer is a substance chemically bonded to a lipid with surface activity or a molecule with a similar structure thereof, which is the main constituent of the cell delivery carrier membrane. The stimulus-responsive substance that can be used in the carrier of the present invention can be a structure having a straight-chain or branched polymer structure containing one or more monomers selected from temperature stimulus-responsive substances, pH stimulus-responsive substances, and light stimulus-responsive substances. Further, in the present invention, the characteristic of a more effective stimulus-responsive substance is that when used in combination with the vitamin derivatives in Table 2 above, the attenuation rate of the vitamin derivative is suppressed to less than 20% in an accelerated test at 40°C, 80% humidity, and 6 months, and remains stable. The inventors have found that if one or more stimulus-responsive substances are selected from the substance group of Table 5 in paragraph 0057, a cell delivery carrier that can restore stability under these conditions can be manufactured. Furthermore, after the cell delivery carrier of the present invention containing these stimulus-responsive polymers was stored at 40°C and 80% humidity for 6 months, when the state of the carrier was observed with an ordinary optical microscope and a polarizing microscope, the carrier was not destroyed, and as at the beginning of the test, it was observed under the microscope that the fluorescent dye was contained in the carrier, and the presence of maltase orthogonal polarization could be confirmed under the polarizing microscope. Therefore, the substance that suppresses the attenuation rate of the vitamin derivative to less than 10% and keeps the vitamin derivative stable is a stimulus-responsive substance that can be particularly effectively used in the present invention. As an example of these stimulus-responsive substances, the inventors have confirmed stimulus-responsive polymers in which one or more chemical substances selected from the substance group of Table 7 are chemically modified with covalent bonds.

[0172] The lipid part bound to the stimulus-responsive polymer is fused with the hydrocarbon of the lipid or the hydrocarbon part of the lipid that exhibits the surface activity of the membrane component of the cell delivery carrier, and the stimulus-responsive polymer is dispersed in the water solvent part outside the cell delivery carrier, so it has a structure like the stimulus-responsive polymer protruding from the solvent side of the cell delivery carrier membrane to the outside. This state can also be expressed as modifying the cell delivery carrier membrane with a stimulus-responsive polymer by binding lipids to the stimulus-responsive polymer. In this case, the effect of suppressing cell death after intracellular collapse is more excellent, and from the perspective of excellent delivery efficiency into the cell, among the molecules containing stimulus-responsive polymers modified by the lipid, the molecules containing stimulus-responsive polymers in all lipids as membrane constituents are preferably 0.05 to 40 mol%, more preferably 1.0 to 20 mol, and further preferably 2.0 to 8.mol%. In addition, the molecules containing temperature, pH and light stimulus-responsive polymers in the present invention are preferably combined with membrane fusogenic lipids, and can also be combined with 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE).

[0173] At a temperature below the lower critical solution temperature (LCST) of the temperature-responsive polymer in water, a hydration layer is formed on the surface of the cell delivery carrier, reducing the affinity between the cell delivery carrier and the cell membrane, but above the lower critical solution temperature, it aggregates and hydrophobizes, increasing the affinity between the cell delivery carrier and the cell membrane. Further, with hydrophobization, the membrane balance is destroyed, and the membrane is destroyed. In this way, when the lower critical solution temperature in water is low, the temperature-responsive polymer of the present invention can reduce the affinity between the cell delivery carrier and the cell membrane to move freely in the tissue. The time to reach the target cell is estimated and the temperature is increased, thereby enhancing the cell membrane adhesion, and the cell delivery carrier that is endocytosed and taken into the cell disintegrates, helping the substance in the cell delivery carrier to diffuse into the cell. In the case of pH and light stimulus-responsive polymers, similar phenomena can occur not by temperature increase but by pH changes inside and outside the membrane and light stimulation of the device.

[0174] The lower critical solution temperature in water containing the temperature stimulus responsive polymer molecules in the present invention is preferably a temperature close to body temperature and the highest temperature during vehicle transportation in summer when the product is circulated, that is, 70°C (for example, 35.0 to 70.0°C). On the other hand, even if the lower critical solution temperature of the temperature responsive polymer of the present invention is close to body temperature, raising the temperature as much as possible can easily inhibit cell death after delivery to cells. In this way, the lower critical solution temperature of the temperature responsive polymer in water is preferably 37.0 to 42.0°C, more preferably 37.5 to 41.0°C, and further preferably 38.0 to 40.5°C, because the delivery into cells is excellent at this temperature, and it is easy to inhibit cell death after intracellular delivery of nucleic acids. In addition, in the present invention, the lower critical solution temperature of the temperature responsive polymer in water is measured by differential scanning calorimetry (DSC).

[0175] Specific examples of monomers constituting the molecular units of the temperature, pH and light stimuli-responsive polymers contained in the cell delivery carrier of the present invention.

[0176] For example, it can be a polymer composed of homopolymerization of these monomers, a copolymer of two or more of these monomers. In addition, it can be a substance obtained by copolymerization with monomers other than these monomers, graft polymerization or copolymerization between polymers, or a mixture of homopolymers and copolymers of these monomers. In addition, the temperature-responsive polymer can also be cross-linked within a range that does not damage the original properties of the polymer.

[0177] The lower critical solution temperature of the temperature-responsive polymer in water can be adjusted by selecting monomers according to the properties of the monomers constituting the temperature-responsive polymer.

[0178] In particular, copolymers of various stimulus-responsive monomers and other monomers such as dimethylaminopropyl acrylamide (DMAPAA) can be used as molecules of the stimulus-responsive polymer containing temperature, pH and light, because they are excellent in intracellular delivery and are easy to inhibit cell death after intracellular delivery. Regarding the molar number of various stimulus-responsive monomers and other monomers in the polymer, various stimulus-responsive monomers are more preferably 90-99, and other monomers are more preferably 1-10.

[0179] For example, a copolymer of N-isopropyl (meth) acrylamide (NIPAA) and dimethylaminopropyl acrylamide (DMAPAA) can be used as a temperature-responsive polymer because it is excellent in intracellular delivery and is easy to inhibit cell death after intracellular delivery. Regarding the molar number of NIPAA and DMAPAA in the polymer, NIPAA is more preferably 90-99, and DMAPAA is more preferably 1-10.

[0180] The molecular weight of the molecule of the stimuli-responsive polymer containing temperature, pH and light in the present invention is not particularly limited, for example, the weight average molecular weight can be 1000 to 100000, but the weight average molecular weight is more preferably 2000 to 70000, because in this case the delivery into the cell is excellent, and it is easy to inhibit cell death after delivery into the cell. In addition, the weight average molecular weight can be measured by gel filtration chromatography (GPC).

[0181] In order to modify the surface of a cell delivery carrier with a temperature-responsive polymer, for example, when a cell delivery carrier is prepared using a cationic lipid or an anionic lipid and a membrane fusion lipid, the temperature responsive polymer is chemically modified in advance with a membrane fusion lipid or any one of the cationic lipids or anionic lipids, and the temperature responsive polymer modified with the lipid is mixed with the cell delivery carrier during preparation, thereby obtaining a structure in which the surface of the cell delivery carrier is modified with the temperature responsive polymer after the preparation.

[0182] The method for preparing the cell delivery carrier of the present invention can adopt conventional known methods. For example, when the cell delivery carrier of the present invention is prepared by a cationic lipid or anionic lipid and a membrane fusion lipid, the cationic lipid or anionic lipid and the membrane fusion lipid are dissolved in a solvent (e.g., chloroform, etc.), and after removing the solvent, the formed lipid film is hydrated with phosphate buffered saline, etc., and then ultrasonic treatment and extruder treatment are performed to adjust the particle size of the cell delivery carrier, thereby preparing it.

[0183] The particle size of the cell delivery carrier is not particularly limited, and for example, a carrier having an average particle size of 0.05 to 1 μm can be used. In addition, the average particle size of the cell delivery carrier is measured by dynamic light scattering (DLS).

[0184] The cell delivery carrier of the present invention may be a structure in which any one or more of the vitamin derivatives and the stimuli-responsive polymer-containing molecules constitute the emulsified membrane of the cell delivery carrier. Alternatively, the cell delivery carrier of the present invention may also be a structure in which one or more of the vitamin derivatives and the stimuli-responsive polymer-containing molecules are ionically bonded to the surface of the cell delivery carrier.

[0185] The cells delivered by the cell delivery carrier of the present invention are not particularly limited, and examples thereof include keratinocytes, thorny cells, granulocytes, corneocytes, fibroblasts, pigment cells, dendritic cells, Langerhans cells, Merkel cells, vascular endothelial cells, sebaceous gland cells, exocrine gland cells, apocrine gland cells, adipocytes, Merkel disc cells, Martensii corpuscle cells, Ruffini terminal cells, Pacinian corpuscle cells, hair follicle cells, hair papilla cells, hair matrix cells, hair matrix, hair fiber cells, inner root sheath cells, outer root sheath cells, cuboidal epithelial cells, sheath epithelial cells, arrector pili muscle cells, skin stem cells, hair follicle stem cells, pigment stem cells, sweat gland cells, sebaceous gland cells, hair follicle infundibulum cells, lung cells, colon cells, rectal cells, anal cells, bile duct cells, small intestinal cells, stomach cells, Cells, esophageal cells, gallbladder cells, liver cells, pancreatic cells, appendix cells, breast cells, ovarian cells, cervical cells, prostate cells, kidney cells, glioblastoma cells, skin cells, lymphocytes, chorionic tumor cells, head and neck cells, osteosarcoma cells, blood cells, etc., or cancer cells thereof (cervical cancer cells, lung cancer cells, colon cancer cells, rectal cancer cells, anal cancer cells, bile duct cancer cells, small intestinal cancer cells, gastric cancer cells, esophageal cancer cells, gallbladder cancer cells, liver cancer cells, pancreatic cancer cells, appendix cancer cells, breast cancer cells, ovarian cancer cells, prostate cancer cells, kidney cancer cells, cancer cells of the central nervous system, glioblastoma cells, skin cancer cells, pigment cancer cells, lymphoma cells, chorionic carcinoma tumor cells, head and neck cancer cells, osteosarcoma cells, blood cancer cells, etc.). The cells delivered by the cell delivery carrier of the present invention are particularly suitable for delivery to cells present in the skin because of their intracellular delivery efficiency, antioxidant effect, tissue fluidity, skin barrier permeability, and easy inhibition of cell death after delivery.

[0186] In addition to the vitamin derivatives, the cell delivery carrier of the present invention may further contain one or more substances selected from Table 8 of paragraph 0057 as active ingredients. Furthermore, known active ingredients that can be contained in the cell delivery carrier of the present invention may be mixed, and these active ingredients may be active ingredients described in known standards and documents. For example, representative standards and documents include but are not limited to the following. For example, Japanese Pharmacopoeia 17th Edition ISBN 978-4840748315, United States Pharmacopoeia National Formulary 2018, USP41-NF36, ISBN 978-3-7692-7022-8, International Cosmetic Ingredients Dictionary and Handbook (2016) 16th Edition (Personal Care Products Association, Washington, USA) ISBN 1-882621-55-7, Revised List of Quasi-drug Additives, Yakuji Daily, 2017, ISBN: 978-4-8408-1492-8C3047, List of Active Ingredients in So-called Medicinal Cosmetics as Announced by the Director of the Pharmaceutical and Food Bureau, Ministry of Health, Labor and Welfare of Japan, Notice No. 1225001, Standards for Quasi-drug Ingredients: Comprehensive Edition 2006, Yakuji Daily, 2013 ISBN: 978-4-8408-1227-6C3047, Standards for Quasi-drug Ingredients: Comprehensive Edition 2006 Supplement 2, Yakuji Daily, 2018 ISBN: 978-4-8408-1464-5C3047. When these active ingredients are included in the present cell delivery carrier, the concentration of the active ingredient is not particularly limited and can be appropriately changed according to the concentration of the active ingredient's effect and purpose, and can be selected, for example, from the range of 1 ppm to 50% by weight.

[0187] When a vitamin derivative is used in the cell delivery carrier of the present invention, the effect of the vitamin derivative can be exerted, so other inclusion active ingredients do not necessarily need to be present. Alternatively, the concentration of the active ingredient is not particularly limited and can be appropriately changed according to the concentration of the active ingredient and the purpose, for example, it can be selected from the range of 1 ppm to 50% by weight.

[0188] The amount of the cell delivery carrier of the present invention is not particularly limited and can be appropriately changed according to the concentration of the active ingredient and the purpose. However, when added to an external preparation and applied to the skin, the preparation prepared by adding 0.001% to 50% by weight of the cell delivery carrier of the present invention to the preparation can be 1 μg to 10 g / 1 cm relative to the skin surface area. 2 The amount per day is administered in one to ten divided doses per day.

[0189] The administration method of the cell delivery vector of the present invention is not particularly limited and can be appropriately selected according to the type of target cells. For example, external administration, oral administration, injection (intravenous injection, subcutaneous injection, or intramuscular injection, etc.) can be adopted.

[0190] Furthermore, various devices such as iontophoresis, electroporation, sound waves, ultrasound, low frequency, high frequency, heaters, various lasers, various light energy devices, gauze, non-woven fabrics, paper, films, towels, facial masks, carbonic acid generators, steam generators, oxygen generators, etc. can be used for drug administration. Furthermore, microneedles, mesotherapy devices, etc. can also be used.

[0191] The cell delivery carrier of the present invention can be used for any application where the effect can be exerted, but is preferably used for an application selected from pharmaceuticals, quasi-drugs, cosmetics, supplements, veterinary drugs, and sundries.

[0192] Furthermore, the dosage form of the preparation of the cell delivery carrier of the present invention when used for these purposes is not particularly limited, but it can be preferably selected from external preparations, oral preparations, suppositories, oral preparations, poultices, facial masks, sprays, injections, flavoring agents, liquids, ointments, aerosols, powders, compressed preparations, pastes, external sprays, powders, granules, tablets, soft capsules, pills, plate-shaped dosage forms, lozenges, pastes, solid preparations, wetting agents, and adhesives. Alternatively, when these cell delivery carriers are used in cosmetics or quasi-drugs, their efficacy or effects can be selected from the aforementioned Table 9, but are not limited thereto.

[0193] The target animal of the cell delivery vector of the present invention is not particularly limited, and can be applied to any organism including humans, for example, mice, rats, dogs, cats, monkeys, pigs, cattle, sheep, rabbits, fish, edible aquatic animals, useful plants, and useful fungi.

[0194] In addition to known effective ingredients, the components of the cell delivery vector of the present invention may include nucleic acids, fungi, viruses, cells, and the like.

[0195] The target vitamin derivative of the cell delivery carrier of the present invention must promote the activities of both autophagy-related genes and cathepsin synthesis genes.

[0196] The vitamin derivatives that can be used for the cell delivery carrier of the present invention as the simultaneous activation of autophagy-related genes and cathepsin synthesis genes are shown in Table 2. As shown in the examples, it promotes the activity of autophagy-related genes and cathepsin synthesis genes. In the present invention, at least one or more of these vitamin derivatives need to be included in the cell delivery carrier. More preferably, when different types of vitamin derivatives are selected from Table 2 and two or more vitamin derivatives are mixed for use, the adhesion of the cells is enhanced, and the delivery rate of the substance in the carrier can be improved.

[0197] Molecules containing stimulus-responsive polymers that can be used in the present invention are polymers used in chemistry and biology such as drug delivery (DDS), bio-conjugation, tissue engineering, biosensors and bioseparation, and are also called "smart" polymers or environmentally responsive polymers because of their properties that change with external stimuli.

[0198] Molecules containing stimulus-responsive polymers that can be used in the present invention refer to polymers whose microstructures contain stimulus-responsive molecules that undergo reversible or non-chemical changes depending on the surrounding external stimuli (e.g., temperature, pH, ionic strength, magnetic field, electric field, light, sound waves, pressure, solvents, acceleration, chemical species), all of which can be used in the present invention.

[0199] Molecules containing stimulus-responsive polymers are classified according to their physical shapes as follows: (a) free linear polymers in solution, (b) covalently cross-linked reversible gels, (c) surface adsorbed polymers or surface grafted polymers reversibly bound by ionic bonds, hydrogen bonds, etc., any of which can be used in the present invention, but preferably, the molecules containing stimulus-responsive polymers are bound to one of the amphiphilic antioxidant vitamin derivatives or lipids, and further, the bond is preferably any one of a covalent bond, an ionic bond, and a hydrogen bond. The reason for this is that the effects of molecular changes in response to external stimuli can be more rapidly and directly applied to the bound cell delivery carrier.

[0200] As the molecule containing a stimulus-responsive polymer used in the present invention, a polymer containing a molecule that responds to any one or more of the three external stimuli of temperature, pH, and light is suitable.

[0201] In the present invention, the molecule containing the stimulus-responsive polymer may be present in the emulsion composition, but preferably, it is bound to, contained in, or penetrates the outermost membrane of the cell delivery carrier, and preferably part or all of the molecules containing the stimulus-responsive polymer are present on the outermost side of the cell delivery carrier. This is because when the change in the response state is a light response or a pH response, the stimulus is often transmitted from the outside to the inside, so it is important that the molecule with the response of the sensor part is in contact with the outside of the cell delivery carrier. Furthermore, it is most easy to transmit the property changes caused by the change in the shape of the molecule after the stimulus response to the external environment, so this is very important.

[0202] The form in which the molecule containing the stimulus-responsive polymer of the present invention is bound to any of the amphiphilic antioxidant vitamin derivatives or lipids continuously bound to 8 or more carbon atoms other than the amphiphilic antioxidant vitamin derivatives can be any of the forms in which the molecule containing the stimulus-responsive polymer is bound to the amphiphilic antioxidant vitamin derivative and the molecule containing the stimulus-responsive polymer is bound to the lipid, and further, the binding form can be any of an ionic bond, a covalent bond or a hydrogen bond.

[0203] As examples of the forms in which the molecules containing the stimulus responsive polymer of the present invention are bound to lipids, include the cases in which the molecules containing the stimulus responsive polymer are respectively bound to lipids, fatty acids and liquid crystal layers to form surfactants, any of which can be used in the present invention, but the forms in which the molecules containing the stimulus responsive polymer are covalently bonded to fatty acids and the forms in which the molecules containing the stimulus responsive polymer are covalently bonded to liquid crystal layers to form surfactants are the most suitable because they have extremely high stability, simple synthesis, low cost, and can be synthesized in high yield.

[0204] As a specific example of the case where a molecule containing a stimulus-responsive polymer is covalently bonded to a fatty acid, alkyl-polyisopropylacrylamide (Non-patent Document 12) is known. In the case where a molecule containing a stimulus-responsive polymer is covalently bonded to a liposome, dioleoylphosphoethanolamine, mercaptopropionyl (isopropylacrylamide / dimethylaminopropylacrylamide) copolymer (Patent Document 7), etc. are known. Any of these polymers can be used in the present invention.

[0205] In the known examples described above, when the polymer is used alone, the active ingredient cannot be effectively protected from attack by active oxygen and the like. In particular, there is a problem that the active ingredient that is easily oxidized is oxidized and inactivated in the preparation.

[0206] The molecules containing the temperature stimulus responsive polymer of the present invention form a hydrated liquid crystal layer and dissolve in water when the temperature is below the lower critical solution temperature in water, but become hydrophobic when the temperature is above the lower critical solution temperature, and the cell membrane permeability of the liposome increases.

[0207] Therefore, the lower critical solution temperature of the molecule containing the temperature stimulus responsive polymer in the past is preferably close to the body temperature, that is, 37 to 42°C. However, the upper limit of the circulation temperature of most products including medicines, foods and cosmetics, to which the products including the present invention are applied, may be 45°C in summer. Therefore, when the lower critical solution temperature is set to 36 to 42°C, which is the body temperature, the following problems arise: the cell delivery carrier is combined with other hydrophobic components and separated, or when the container is made of plastic, the active ingredient remains in the container due to adhesion. Therefore, the lower critical solution temperature of the present invention is suitable to be above 35°C. Further, when the lower critical solution temperature is set to above 45°C, the human body needs to be. The temperature of the lower critical adaptive part of the present invention is set to above 45°C, but it has been found that by the local use of a steam towel, the frictional heat generated by local friction, the use of a heated gas, and the use of a heating device, etc., local short-term heating is performed, thereby minimizing the thermal damage without residual side effects even at 70°C. Since irreversible thermal damage often occurs above 70°C, the lower critical solution temperature of the present invention is preferably 35°C to below 70°C. More preferably, the temperature is set to 45° C. to 60° C. In addition, in the present invention, the lower critical solution temperature of the temperature-responsive polymer in water is measured by differential scanning calorimetry (DSC).

[0208] As suitable examples of pH stimulus responsive polymers that can be used in the present invention, polyglucosamine with glucosamine as a monomer can be cited, but chitosan with glucosamine as a constituent unit can also be used. Further, a polymer obtained by polymerization using chitosan as a raw material can be used, and low molecular weight chitosan obtained by cutting chitosan using an enzyme or the like, or neutral chitosan obtained by alkali treatment can also be used.

[0209] Non-patent Documents 13, 14, and 15, which are known documents, disclose examples of chitosan-coated liposomes obtained by processing chitosan into liposomes. The chitosan described in these documents can also be used in the present invention.

[0210] When the cell delivery carrier containing the molecule containing the pH stimulus responsive polymer of the present invention is a cell delivery carrier containing chitosan, as its manufacturing process, a cell delivery carrier not containing chitosan of the present invention can be reacted with a chitosan aqueous solution to allow chitosan to be electronically bonded to the surface of the cell delivery carrier. When preparing a chitosan solution, it is usually necessary to dissolve it in an acid, so the pH value must be below 5. Therefore, when it is applied to the human body, due to its acidity, it can cause skin inflammation. Further, under such acidic conditions, there are problems such as the destruction of the cell delivery carrier, separation, and precipitation. Neutralization with an alkali will induce turbidity and separation of the solution, and when a neutralizing salt such as sodium chloride is formed, there is a problem of skin irritation. Therefore, the chitosan itself used in the present invention is preferably a neutral chitosan with a pH of 6 to 8. After dissolving the neutral chitosan in an acid such as lactic acid, citric acid, ascorbic acid, it is preferably contacted with an anion exchange resin, or mixed with chitosan from natural products, thereby adsorbing and removing the acid and adjusting the pH to 6 to 8.

[0211] Regarding the stimulus-responsive polymer that can be used for the carrier of the present invention, if it is a liquid in the range of 15°C to 70°C, and when used in combination with the vitamin derivatives in Table 2 of the above paragraph 0057, the decay rate of the vitamin derivative is suppressed to less than 20% in an accelerated test at 40°C, 80% humidity, and 6 months, and the vitamin derivative is kept stable, it can be used. Among the stimulus-responsive polymers that meet these conditions, it is found that the stimulus-responsive polymer in which one or more chemical substances selected from a specific substance group are chemically modified by covalent bonds is suitable, and the group of the substance can be specified. That is, the inventors have found that if it is a stimulus-responsive polymer in which one or more chemical substances selected from the substance group of Table 7 of paragraph 0057 are chemically modified by covalent bonds, a cell delivery carrier that can restore the stability of these conditions can be made. Furthermore, the inventors have included various active ingredients in the cell delivery carrier of the present invention to study the stability of the carrier. This is because it was found that the stability of the cell delivery carrier of the present invention varies not only with the constituent components of the carrier, but also with the types of components contained in the carrier. In particular, a substance that can stably maintain a liquid crystal layer structure even after an accelerated test under the above-mentioned conditions is optimal as a substance to be contained in the carrier of the present invention. The test results show that if it is a substance selected from Table 8 in paragraph 0057, it can be stably contained even after an accelerated test under the said conditions.

[0212] By applying the cell delivery carriers of the present invention comprising the active ingredients selected from Table 8 to humans, the inventors were able to confirm that the effects of Table 9 in Paragraph 0057 were expressed.

[0213] In addition, regarding these effects, it was found that a temperature stimulus responsive polymer having an effect expression temperature of 45 to 70°C for a cell delivery carrier is included in the cell delivery carrier, and the tissue temperature of the application site of the polymer is artificially increased, thereby improving its cell delivery rate and expressing a higher effect.

[0214] Furthermore, in the present invention, polyols, synthetic antioxidants, ultraviolet absorbers and preservatives used as stabilizers for common emulsion preparations can be used, and these substances are necessary when preparing carriers. Among these substances, in particular, if they are liquid in the range of 15°C to 70°C, and when used in combination with the vitamin derivatives in Table 2, the lipids in Table 3, the lipids with surface active effects in Table 4 and the stimulus-responsive polymers in Table 5, the substances that suppress the attenuation rate of the vitamin derivatives to less than 20% in the accelerated test at 40°C, 80% humidity, and 6 months, and keep the liquid crystal layer structure stable, are the most suitable for the present invention. These substances were screened and confirmed that one or more components selected from the emulsion stabilizers shown in Table 6 correspond to this.

[0215] The best mode for carrying out the present invention is as described Figure 2 As shown, it is a cell delivery carrier, which is composed of a substance that simultaneously activates autophagy-related genes and cathepsin synthesis genes, and one or more substances in the molecule containing a stimulus-responsive polymer, which constitute a part of a membrane molecule mainly composed of lipids. Further, as another best mode for implementing the present invention, a cell delivery carrier can be listed, wherein, as mentioned above Figure 3 Molecules containing stimuli-responsive polymers are shown ionically bonded to lipids.

[0216] Specific uses of the cell delivery carrier of the present invention include: pharmaceuticals, quasi-drugs, cosmetics, supplements, veterinary drugs, and groceries. The preparations that can be used for the cell delivery carrier of the present invention are particularly limited, and if the dosage form is a cell delivery carrier selected from the following, it is more suitable as a circulating dosage form: external preparations, oral preparations, suppositories, oral preparations, health drinks, poultices, facial masks, sprays, injections, flavorings, liquids, ointments, aerosols, powders, compressed preparations, pastes, external sprays, powders, granules, tablets, soft capsules, pills, plate-shaped dosage forms, lozenges, pastes, solid preparations, wetting agents, and adhesives.

[0217] (ATG-CTS activity of vitamin derivatives)

[0218] The following experiment was conducted using a mixture of three different vitamin derivatives with ascorbic acid-2-phosphate in their structure, namely, trisodium ascorbyl phosphate (APS), trisodium ascorbyl palmitate phosphate (APPS), and potassium ascorbyl tocopheryl phosphate (EPC). Normal human epidermal fibroblasts were cultured at 5×10 cells / mL in DMEM (low glucose) containing 5% FBS. 5 The density of cells / well was cultured at 37°C for 24 hours, and then replaced with a medium containing a mixed test sample (100 μM APS, 100 μM APPS, 100 μM EPC were added to make the final total concentration 300 μMn) and cultured at 37°C for 24 hours. Next, each cell was recovered, RNA was protected with RNA protect cell Reagent (QIAGEN), and stored at -80°C until analysis. After quality inspection of total RNA, a comprehensive analysis using 3D-Gene full genotype DNA chip was performed. As a result, according to each factor from autophagy-related genes (ATG) and lysosomal localized proteases, namely cathepsin (CTS), compared with the amount of RNA in the no-addition control, for the average value of the test sample addition group, the increase of RNA biosynthesis in ATG by 1.2 times or more was marked as ◎, the increase of CTS by 1.2 times or more was marked as ◇, and the rest was marked as X, and the results are shown in Table 12 below.

[0219] Results of ATG-CTS activity of vitamin derivatives

[0220] [Table 12]

[0221]

[0222] (Test 2)

[0223] The same experiment and evaluation as above were conducted on the following 84 vitamin derivatives, and ○ was marked for the presence of ◎ and ◇ at least 1 and the total number of which was at least 10, △ was marked for the presence of ◎ and ◇ at least 1 and the total number of which was at least 5, and X was marked for the others. In addition, X includes the case where the sample size did not reach the specified amount for conducting this test. As a result, as shown in paragraph 0131, there were 53 vitamin derivative samples corresponding to ○ and △ that can be used in the present invention, including unknown samples, and 32 X samples. In addition, when the three derivatives having ascorbic acid-2-phosphate in the structure used in the comparative experiment of the present invention were compared, ascorbic acid (AA) and trisodium ascorbyl phosphate (APS) were X, trisodium ascorbyl palmitate phosphate (APPS) was △, and potassium ascorbyl tocopheryl phosphate (EPC) was ○. Therefore, regarding the activity of ATG-CTS, the activity from high to low is EPC>APPS>APS, AA.

[0224] (Results of ATG-CTS activity of 84 vitamin derivatives)

[0225] Potassium ascorbyl tocopheryl phosphate: ○, (ascorbic acid / PCA) magnesium: X, 2,4-diethoxycarbonyl pantothenate ethyl ester: ○, 3-O-ethyl ascorbic acid: ○, 3-O-hexadecyl ascorbic acid: ○, 3-ascorbyl carbonyl dipeptide-17: △, ethyl ascorbic acid: ○, ascorbyl methylsilanol pectin: ○, ascorbic acid (orange / lemon / lime) polypeptide: X, allantoin ascorbate: X, ascorbyl diglyceride tocopherol: ○, ascorbyl diester tocopherol: ○, tetrahexyldecyl ascorbate: ○, ascorbic acid polypeptide: △, methylsilanol ascorbate: △, acetyl pantothenate ethyl: X, allantoin panthenol: X, isostearyl ascorbyl phosphate disodium: ○, ascorbyl isostearate: ○, ascorbic acid Trisodium palmitate phosphate: △, 2-octanoylglyceryl ascorbic acid: ○, 3-octanoylglyceryl ascorbic acid: ○, pyridoxine glycyrrhetinate: X, tocopheryl succinate: ○, succinyl tripeptide-34 ascorbyl phosphate copper: X, succinyl pentapeptide-12 ascorbyl phosphate: X, diethyl ascorbic acid: ○, dioleyl tocopheryl methylsilanol: ○, pyridoxine dioctanoate: ○, diethoxycarbonyl ethyl pantothenate: ○, pyridoxine dipalmitate: ○, ascorbyl stearate: △, diacetyl resveratrol lipoic acid: X, lipoic acid stearate: ○, lipoic acid palmitate: ○, lipoic acid heptadecanoate: ○, methoxy PEG-45 lipoic acid: X, tetrahexyldecyl ascorbate: ○, riboflavin tetrabutyrate: ○, Tocopheryl ethyl succinate ethyl diammonium ethosulfate: X, tocopheryl oxypropyl trisiloxane: ○, tocopheryl glucoside: ○, tocopheryl dimethylglycine: ○, tocopheryl dimethylglycine hydrochloride: ○, tocopheryl phosphate sodium: ○, tocopherol: ○, tranexamic acid tocopheryl hydrochloride: X, pyridoxine trihexyldecanoate: ○, pyridoxine tripalmitate: X, tocopheryl nicotinate: ○, ascorbyl palmitate: X, ascorbyl hyaluronate: X, ascorbyl propyl hyaluronate: ○, bis (hydroxyethyl tocopheryl succinylamide) hydroxypropane: X, thiamine dilauryl sulfate: X, hydroxydecyl ubiquinone: △, hydroxypropyl trimethyl ascorbic acid: X, retinol propionate: O, ascorbyl tocopheryl maleate: ○, maleic acid di Octyl aminoethyl dimethylamine: X, panthenol: X, ubiquinone: X, ubiquinone disodium: X, lauryl iminodipropionate tocopheryl phosphate disodium: △, tocopheryl linoleate: ○, retinol linoleate: ○, ascorbyl phosphate trisodium: X, ascorbyl magnesium phosphate: X, ascorbyl aminopropyl phosphate: X, aminopropyl tocopheryl phosphate: X, tocopheryl phosphate disodium: ○, tocopheryl retinoate: ○, hydroxypinacolone retinoate: X, retinol retinoate: ○, retinol: X, retinyl trimethylsilane: X, ethyl pantobenzoate: X, tocopheryl acetate: ○, retinyl acetate: ○, retinyl palmitate: △, sodium ascorbic acid / cholesteryl phosphate: ○, tocopheryl linoleate / oleate: ○, ascorbic acid: X,Ascorbyl glucoside: △, no added control: X. ,

[0226] (Stability Test)

[0227] Each ascorbic acid derivative of APS, APPS, and EPC was dissolved in pure water to a concentration of 0.02 mol / L, and stored at 50°C for one month. The potency of each substance was measured by high performance liquid chromatography, and the initial potency of each substance was set as 100%. The potency after one month was measured in % weight. The results are shown in the following Table 13. ○ represents a residual of more than 95%, △ represents a residual of less than 95% and more than 80%, and X represents a residual of less than 80%. The names of the substances of the existing vitamin derivative group used as comparative examples and their abbreviations are as follows. Ascorbic acid-2-phosphate sodium: APS, ascorbic acid-2-phospho-6-palmitate trisodium: APPS, tocopherol ascorbyl-2-phosphate potassium: EPC, ascorbic acid: AA.

[0228] Stability test results

[0229] [Table 13]

[0230] Test substance name Survival rate Evaluation results EPC 96% ○ APS 91% △ APPS 78% X AA 56% X

[0231] From the above results, it can be seen that the physical stability is from high to low EPC>APS>APPS>AA. The ATG-CTS activity is from high to low EPC>APPS>APS, AA, so it can be seen that ATG-CTS activity is not related to physical stability.

[0232] (Surface activity test) Each ascorbic acid derivative of APS, APPS, EPC, and AA was dissolved in pure water to a concentration of 0.5% (by weight), and foamed with a sponge under the same conditions. The time until defoaming (defoaming time) was measured, and this time was set as a parameter for comparing the surface activity of each sample. The results are shown in Table 14. The defoaming time of APPS, which has the longest defoaming time, is set as 100%, and each defoaming time is calculated in %, with 90% or more being marked as ○ (best), 80% or more to less than 90% being marked as △ (good), and 80% or less being marked as X (poor). Explanation of abbreviations: Sodium ascorbyl-2-phosphate: APS, trisodium ascorbyl-2-phospho-6-palmitate: APPS, potassium tocopheryl ascorbyl-2-phosphate: EPC, ascorbic acid: AA.

[0233] Surface activity test

[0234] [Table 14]

[0235] Test substance name Survival rate Evaluation results APPS 100% ○ EPC 85% △ APS 3% X AA 1% X

[0236] From the above results, it can be seen that the surface activity obtained from the defoaming time in the aqueous solution is APPS>EPC>=APS>AA from high to low. Regarding ATG-CTS activity, the activity is EPC>APPS>APS, AA from high to low, so it can be seen that ATG-CTS activity is not related to surface activity.

[0237] The following experiments demonstrated that the activity of ATG-CTS correlated with the cellular delivery rate.

[0238] (Comparative experiment with the present invention)

[0239] The total amount of lipids was 20 mg, and the molar ratio of (1,2-dioleoyl-3-trimethylammonium propane as lipid): (total weight of dioleoylphosphatidylethanolamine and DOPEMP (NIPAA / DMAPAA 5%) Cop as liquid crystal layer forming surfactant) = 3:7 was dissolved in chloroform. Further, 1 mg of fluorescent dye, i.e., rhodamine (carboxyrhodamine 110-PEG4-alkyne), was added and dissolved. In addition, the lower critical solution temperature of DOPEMP (NIPAA / DMAPAA 5%) Cop. used in this experiment in water was 40°C. The molar ratio of dioleoylphosphatidylethanolamine and DOPEMP (NIPAA / DMAPAA 5%) Cop added as a layer forming surfactant was 6.5:0.5 based on the total weight.

[0240] The solution was transferred to an eggplant-shaped flask, and the solvent was removed by an evaporator to prepare a lipid film. Three vitamin derivatives with different ATG-CTS activities, namely, 5 mg each of EPC, APPS, APS, and AA, were added to the lipid film, dissolved in 1 ml of PBS to hydrate the lipid film, and then dispersed by vortexing. After that, ultrasonic treatment was performed in an ultrasonic bath for 30 minutes to reduce the size of the liposomes, and then the liposomes were passed through a 200nm filter with an extruder to adjust the size of the liposomes. The average particle size of the embodiments and comparative examples was 111nm±10nm. After that, the liposomes were separated and purified by gel filtration to prepare a cell delivery carrier of the present invention containing an ATG-CTS activating substance, a temperature-responsive polymer, and a hydrocarbon. When the cell delivery carrier was observed using a transmission electron microscope with a staining method, a multilayer vesicle structure (multilayer liquid crystal structure) was confirmed, and it was confirmed that these cell delivery carriers had a lamellar liquid crystal structure.

[0241] Next, normal human epidermal fibroblasts were cultured in a 6-well plate at a concentration of 5×10 5The density of cells / well was cultured at 37°C for 24 hours, and then replaced with the culture medium containing the four cell delivery carriers of the above-prepared examples and comparative examples (rhodamine was added to make the final concentration 1μM), and cultured at 35°C for 1 hour. After that, it was treated at 40°C for 20 minutes, and further cultured at 35°C for 1 hour. After that, it was washed five times with PBS, fixed with 4% paraformaldehyde phosphate buffer for 20 minutes, and then washed twice with PBS. The fluorescence intensity was measured with a fluorescence microplate reader to determine the relative concentration of the fluorescent substance taken into the cells. For the no-addition control, the cells of the cell delivery carrier of the vitamin derivative were cultured in the same way, and the fluorescence intensity was measured.

[0242] As a result, when the fluorescence intensity of the EPC-added group was set to 100%, APPS was 78%, APS was 49%, and AA was 52%. Therefore, the cell absorption rate was EPC>APPS>APS, AA from high to low, and the activity of ATG-CTS was EPC>APPS>APS, AA from high to low, so it can be seen that the cell absorption rate and ATG-CTS activity are related.

[0243] The present inventors have found that the reason why vitamin derivatives can enhance the activity of ATG-CTS is completely unrelated to the stability and surface activity of the vitamin derivatives, and the reason is presumed to be as follows. That is, in the first stage, vitamins are important nutrients for human cells, and the intracellular concentration is higher than the blood concentration. Therefore, it is believed that vitamins adhere to vitamin receptors on the surface of certain cells in the first stage and are actively transported by specific channel proteins in the second stage. Stable vitamin derivatives adhere to vitamin receptors, but cannot be actively transported by specific channel proteins in the second stage.

[0244] That is, the vitamin receptor on the cell surface recognizes a part of the vitamin molecule and only adheres to this part, but in the second stage, the specific channel protein recognizes the entire vitamin molecule and takes it into the protein so that it is actively transported through the gate, so most of the vitamin derivatives adhere to and stay on the cell surface without being actively transported. When this state is maintained for a period of time, it is taken into the cell in a state bound to the receptor through frequent endocytosis (pinocytosis) of taking in extracellular fluid, forming a vesicle (endosome) filled with extracellular fluid.

[0245] The vitamin receptors that bind to the vitamin derivatives in the cell need to be recovered, decomposed, and regenerated into new vitamin receptors. The endosome activates CTS to form lysosomes, and fuses with them to digest the vitamin derivatives in the vesicles, but a portion of the derivatives are directly decomposed and released into the cell. The foreign body is recognized by the autophagy system of some systems, activating the ATG gene to form autophagosomes, activating CTS to form lysosomes, and fusing with them to decompose the vitamin derivatives in the vesicles. In this way, the vitamin derivatives taken into the cell eventually become vitamins that can be used by the cell. Therefore, by adding a vitamin derivative with ATG-CTS activity to the cell delivery carrier for delivering cells of the present invention, the adhesion to the cell delivery carrier can be enhanced, and the intracellular uptake can be promoted.

[0246] The following experiment was conducted to investigate whether the intracellular uptake would change by adding vitamin derivatives with different ATG-CTS activities to a carrier for cell delivery. That is, according to the experiment, ascorbyl palmitate (PA) is X, trisodium ascorbyl isopalmitate phosphate (APPS) is △, and potassium ascorbyl tocopheryl phosphate (EPC) is ○ regarding ATG-CTS activity, and therefore, the intracellular uptake rate was investigated using these three ascorbic acid derivatives to investigate whether the intracellular uptake rate would change.

[0247] (Preparation of Cell Delivery Vectors for Comparative Experiments)

[0248] In order to study the effect of vitamin derivatives with different ATG-CTS activities on the cellular uptake of cell delivery carriers, a cell delivery carrier with the stimulus-responsive polymer removed was prepared, and the following experiment was performed. 6g of glycerol, 1g of sodium cocoyl glutamate and 1g of each of three vitamin derivatives with different ATG-CTS activities (PA, APPS and EPC) were mixed with an electric hand mixer, and a mixture of 0.1g of fluorescent dye, namely rhodamine B, was added to 20g of jojoba oil and stirred for 20 minutes. PBS was added to 100g, stirred with an electric hand mixer for 10 minutes to prevent bubbling, and the three cell delivery carriers of the present invention were obtained. As a non-added control, a cell delivery carrier without added vitamin derivatives was also prepared using the same method.

[0249] Normal human dermal fibroblasts were cultured at 5×10 cells / well in DMEM (low glucose) containing 5% FBS in a 6-well plate. 5The density of cells / well was cultured at 37°C for 24 hours, and then replaced with the culture medium containing the three cell delivery vectors of the present invention prepared above (PA, APPS, and EPC were added to a final concentration of 200 μM respectively), and cultured at 37°C for 1 hour. After that, the cells were washed five times with PBS, fixed with 4% paraformaldehyde phosphate buffer for 20 minutes, and washed twice with PBS. The fluorescence intensity was measured with a fluorescence microplate reader at an excitation wavelength of 555 (nm) and a fluorescence wavelength of 580 (nm) to determine the relative concentration of the fluorescent substance taken into the cells. For the no-addition control, cells without the addition of the cell delivery vector of the vitamin derivative were cultured in the same manner, and the fluorescence intensity was measured.

[0250] As a result, when the fluorescence intensity of EPC was set to 100%, the fluorescence intensity of APPS was 76%, the fluorescence intensity of PA was 58%, and the fluorescence intensity of the cell delivery carrier without adding vitamin derivatives was 45%. The ATG-CTS activities of the three vitamin derivatives were EPC>APPS>PA from high to low, and the cellular uptake rate of the fluorescent substance contained in the cell delivery carrier was EPC>APPS>PA from high to low. The cellular uptake rate of the cell delivery carrier of the present invention of the vitamin derivative was proportional to the magnitude of the ATG-CTS activity.

[0251] (Synthesis of Stimuli Responsive Polymers - Step 1-01)

[0252] The first monomer responsive to (temperature) stimulus, i.e. N-isopropylacrylamide, and the second monomer responsive to (temperature) stimulus, i.e., aminopropylacrylamide and aminopropylacrylamide, are dissolved in dimethylformamide at a molar ratio of 95%:5%. The total amount of monomers is set to 10 g. After dissolution, 0.03 mol times of 3-mercaptopropionic acid of N-isopropylacrylamide is added, and 60 mg of azobisisobutyronitrile is added. After that, nitrogen substitution and ultrasonic degassing are performed in the solvent, and free radical polymerization is performed at 70°C for 6 hours. After the reaction, the temperature of the liquid is returned to room temperature, and then it is dropped into pre-cooled diethyl ether for reprecipitation and purification. After that, the precipitate is recovered by filtration. Reprecipitation and purification are performed twice more to recover the polymer. The polymer is dialyzed with water and then freeze-dried to obtain a (temperature) stimulus responsive polymer, i.e., a mercaptopropionic acid (isopropylacrylamide / dimethylaminopropylacrylamide 5%) copolymer. In addition, the molecular weight of the temperature stimulus responsive polymer is 5500, and the lower critical solution temperature in water is 40°C.

[0253] (Synthesis of Stimuli-Responsive Polymer-Conjugated Lipids)

[0254] The stimulus responsive polymer prepared above, namely, the copolymer of mercaptopropionic acid (isopropyl acrylamide / dimethylaminopropyl acrylamide 5%): N,N'-dicyclohexylcarbodiimide: N-hydroxysuccinimide, was dissolved in chloroform in a molar ratio of 1:2.5:2.5, and reacted at room temperature for 24 hours. After the reaction, dicyclohexyl urea as a by-product was removed by suction filtration, and reprecipitation and purification were performed with diethyl ether, and N-succinimidyl mercaptopropionic acid (isopropyl acrylamide / dimethylaminopropyl acrylamide 5%) copolymer (MPA stimulus responsive polymer) was recovered as a precipitate.

[0255] N-succinimidylmercaptopropionic acid (isopropylacrylamide / dimethylaminopropylacrylamide 5%) copolymer and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine, which is a lipid having an ethanolamine group and a surfactant for forming a liquid crystal layer, were dissolved in dioxane at a molar ratio of 1:1 and reacted at room temperature for 24 hours. By vacuuming the reacted solution with an evaporator to remove the solvent, a temperature stimulus responsive polymer-bound lipid, i.e., dioleoylphosphatidylethanolaminemercaptopropionyl (isopropylacrylamide / dimethylaminopropylacrylamide 5%) copolymer, as shown in the following chemical formula 1 was prepared. The inventors abbreviated the temperature stimulus responsive polymer-bound lipid as DOPEMP (NIPAA / DMAPAA 5%) Cop. Alternatively, when it is written as DOPEMP (NIPAA / DMAPAA) Cop below, it refers to DOPEMP (NIPAA / DMAPAA 5%) Cop. The abbreviation of dioleoylphosphatidylethanolaminemercaptopropionyl(isopropylacrylamide / dimethylaminopropylacrylamide)copolymer is DOPEMP(NIPAA / DMAPAA)Cop.

[0256]

Chemical formula 1

[0257]

[0258] Chemical formula 1 is the chemical formula of dioleoylphosphatidylethanolaminemercaptopropionyl(isopropylacrylamide / dimethylaminopropylacrylamide) copolymer which can be used in the present invention. The abbreviation is denoted as DOPEMP(NIPAA / DMAPAA)Cop below.

[0259] The first monomer of the above embodiment, N-isopropylacrylamide, is replaced with another first monomer described in Table 15 below, so that a lipid-bound temperature stimulus responsive polymer can be prepared in the same manner as described above. In addition, although the use of a second monomer is described in the above method, the second monomer may be a substance different from the first monomer used and also selected from the first monomer group. Furthermore, the second monomer may not be added, and for the formulation ratio in this case, the amount of the second monomer increased or decreased may be the corresponding amount of the first monomer. According to the results of the stability test conducted in the above preparation process and at 40°C and 80% humidity for 6 months, the monomers shown in Table 15 can be used in the present invention as temperature stimulus responsive first monomers with a decomposition rate of less than 10%.

[0260] [Table 15]

[0261] (Polyoxyethylene octylphenyl ether) acrylate, (polyoxyethylene octylphenyl ether) methacrylate, (polyoxyethylene nonylphenyl ether) acrylate, (polyoxyethylene nonylphenyl ether) methacrylate, (polyoxyethylene lauryl ether) acrylate, (polyoxyethylene lauryl ether) methacrylate, 1,2,4,5-tetrakis(N,N-dithiocarbamoylmethyl)benzene, 1,3,5-tris(bromomethyl)benzene, 2-n-propyl-2-oxazoline, 2-N,N-dimethylaminoethyl acrylate, 2-N,N-dimethylaminoethyl methacrylate DMAEMA, 2-amino-2-hydroxymethyl-1,3-propanediol, 2-amino-2-hydroxymethyl-1,3-propanediol Tris, 2-hydroxy-3-phenoxypropyl acrylate, 2-hydroxybutyl acrylate, 2-hydroxybutyl methacrylate, 2-hydroxypropyl acrylate, 2-hydroxypropyl methacrylate, 3,5-tris(N,N-dithiocarbamoylmethyl)benzene, 3-N,N-dimethylaminopropyl acrylamide, N-acryloyl asparagine, N-acryloyl glycinamide, N-acryloyl glutamine, N-acetylacrylamide, N-methacryloyl asparagine, N,N-dimethyl methacrylamide, N,N-dimethyl acrylamide, N,N-methylenebisacrylamide, N,N-ethyl methacrylamide, N,N-ethyl methyl amide, N,N-ethyl methyl amide, ,N-ethylmethacrylamide, N,N-dialkyl-dithiocarbamoylmethyl, N,N-dialkylacrylamide, N,N-diethylacrylamide, N,N-diethylamide, N,N-diethylmethacrylamide, N,N-dithiocarbamic acid, N,N-dithiocarbamic acid, N,N-dimethylacrylamide, N,N-dimethylmethacrylamide, N,N-propylacrylamide, N,N-propylmethacrylamide, N-acryloylpiperidine, N-acryloylmorpholine, N-alkylacrylamide, N-alkylmethacrylamide, N-alkylsubstitutedacrylamide, N-alkylsubstitutedmethacrylamide, N-propylenephthalimide, N- Isopropyl acrylamide, N-isopropylamide, N-isopropylbut-2,3-dienamide, N-isopropylmethacrylamide, N-ethylacrylamide, N-ethylmethacrylamide, N-ethoxyethylacrylamide, N-ethoxyethylamide, N-ethoxyethylmethacrylamide, N-cyclopropylacrylamide, N-cyclopropylamide, N-cyclopropylmethacrylamide, N-tetrahydrofurfurylacrylamide, N-tetrahydrofurfurylmethacrylamide, N-biotin-N'-methacryloyltrimethyleneamide, N-vinylacrylamide, N-vinylalkylacrylamide, N-vinylmethacrylamide, N-propylacrylamide, N-methacryloylpiperidine, N- or N,N-dialkyl substituted methacrylamide, S-butylacrylamide, t-butylacrylamide, acryloyl glycinamide, acryloyl sarcosine amide, acryloyl piperidine carboxamide, acryloyl methyl uracil, acetylacrylamide, isopropyl acrylamide, ethyl isopropyl acrylamide, ethylene glycol, ethylene glycol allyl methyl ether, oxyethylene acrylate, oxyethylene sorbitan laurate, oxyethylene methacrylate, oxyethylene laurylamine, oligoethylene glycol acrylate, diisopropyl acrylamide, diethyl acrylamide, diethylamine Acrylate, diethylamino methacrylate, diethylene glycol allyl methyl ether, dibutyl acrylamide, dipropyl acrylamide, dimethyl acrylamide, dimethylamino acrylamide, dimethylamino acrylamide, dimethylamino acrylate, dimethylaminopropyl acrylamide, dimethylaminopropyl methacrylamide, dimethylamino methacrylamide, dimethylamino methacrylate, sodium N,N-dithiocarbamic acid, propylene glycol, hexa(N,N-dithiocarbamoylmethyl)benzene, hexa(bromomethyl)benzene, methacrylamide,

[0262] Table 16 shows the results of the stability test for 6 months of the (temperature) stimulus-responsive MPA polymers prepared according to the above-mentioned examples and conducted at 40°C and 80% humidity for 6 months, and having a decomposition rate of 10% or less.

[0263] [Table 16]

[0264] MPA (((Polyoxyethylene octyl phenyl ether) acrylate / dimethylaminopropyl acrylamide) copolymer, MPA (((Polyoxyethylene octyl phenyl ether) methacrylate / dimethylaminopropyl acrylamide) copolymer, MPA (((Polyoxyethylene nonyl phenyl ether) acrylate / dimethylaminopropyl acrylamide) copolymer, MPA (((Polyoxyethylene nonyl phenyl ether) methacrylate / dimethylaminopropyl acrylamide) copolymer, MPA (((Polyoxyethylene lauryl ether) acrylate / dimethylaminopropyl acrylamide) copolymer, MPA (((Polyoxyethylene lauryl ether) methacrylate / dimethylaminopropyl acrylamide) copolymer, MPA (1,2,4,5-tetrakis(N,N-dithiocarbamoyl) MPA (1,3,5-tris(bromomethyl)benzene / dimethylaminopropyl acrylamide) copolymer, MPA (2-n-propyl-2-oxazoline / dimethylaminopropyl acrylamide) copolymer, MPA (2-N,N-dimethylaminoethyl acrylate / dimethylaminopropyl acrylamide) copolymer, MPA (2-N,N-dimethylaminoethyl methacrylate DMAEMA / dimethylaminopropyl acrylamide) copolymer, MPA (2-amino-2-hydroxymethyl-1,3-propanediol / dimethylaminopropyl acrylamide) copolymer, MPA (2-amino-2-hydroxymethyl-1-3-propanediol (Tris) / dimethylaminopropyl acrylamide) Copolymer, MPA (2-amino-2-hydroxymethyl-1,3-propanediol / dimethylaminopropyl acrylamide) copolymer, MPA (2-hydroxy-3-phenoxypropyl acrylate / dimethylaminopropyl acrylamide) copolymer, MPA (2-hydroxybutyl acrylate / dimethylaminopropyl acrylamide) copolymer, MPA (2-hydroxybutyl methacrylate / dimethylaminopropyl acrylamide) copolymer, MPA (2-hydroxypropyl acrylate / dimethylaminopropyl acrylamide) copolymer, MPA (2-hydroxypropyl methacrylate / dimethylaminopropyl acrylamide) copolymer, MPA (3,5-tris (N,N-dithiocarbamoylmethyl) benzene / dimethylaminopropyl acrylamide) copolymer, MPA ( 3-N,N-dimethylaminopropyl acrylamide / dimethylaminopropyl acrylamide) copolymer, MPA (N-acryloyl asparagine / dimethylaminopropyl acrylamide) copolymer, MPA (N-acryloyl glycinamide / dimethylaminopropyl acrylamide) copolymer, MPA (N-acryloyl glutamic acid / dimethylaminopropyl acrylamide) copolymer, MPA (N-acetylacrylamide / dimethylaminopropyl acrylamide) copolymer, MPA (N-methacryloyl asparagine / dimethylaminopropyl acrylamide) copolymer, MPA (N,N-dimethylmethacrylamide / dimethylaminopropyl acrylamide) copolymer, MPA (N,N-dimethylacrylamide / dimethylaminopropyl acrylamide) copolymer,MPA (N,N-methylenebisacrylamide / dimethylaminopropyl acrylamide) copolymer, MPA (N,N-ethylmethacrylamide / dimethylaminopropyl acrylamide) copolymer, MPA (N,N-ethylmethylacrylamide) / dimethylaminopropyl acrylamide) copolymer, MPA (N,N-ethylmethylmethacrylamide / dimethylaminopropyl acrylamide) copolymer, MPA (N,N-dialkyl-dithiocarbamoylmethyl)benzene / dimethylaminopropyl acrylamide) copolymer, MPA (N,N-dialkylacrylamide / dimethylaminopropyl acrylamide) copolymer, MPA (N,N-diethylacrylamide / dimethylaminopropyl acrylamide) copolymer, MPA (N,N-diethylamide) / dimethylamine MPA (N,N-diethylmethacrylamide / dimethylaminopropylacrylamide) copolymer, MPA (N,N-dithiocarbamic acid / dimethylaminopropylacrylamide) copolymer, MPA (N,N-dithiocarbamate / dimethylaminopropylacrylamide) copolymer, MPA (N,N-dimethylacrylamide / dimethylaminopropylacrylamide) copolymer, MPA (N,N-dimethylmethacrylamide / dimethylaminopropylacrylamide) copolymer, MPA (N,N-propylacrylamide / dimethylaminopropylacrylamide) copolymer, MPA (N,N-isopropylmethacrylamide / dimethylaminopropylacrylamide) copolymer, MPA (N-acryloylpiperidinium / dimethyl MPA (N-acryloylmorpholine / dimethylaminopropylacrylamide) copolymer, MPA (N-alkylacrylamide / dimethylaminopropylacrylamide) copolymer, MPA (N-dialkylmethacrylamide / dimethylaminopropylacrylamide) copolymer, MPA (N-alkylsubstitutedacrylamide / dimethylaminopropylacrylamide) copolymer, MPA (N-alkylsubstitutedmethacrylamide / dimethylaminopropylacrylamide) copolymer, MPA (N-alkylsubstitutedmethacrylamide / dimethylaminopropylacrylamide) copolymer, MPA (N-propylenephthalimide / dimethylaminopropylacrylamide) copolymer, MPA (N-isopropylacrylamide) / dimethylaminopropylacrylamide) copolymer, MPA (N-isopropylamide / dimethylaminopropylacrylamide) Copolymers, MPA (N-isopropyl butane-2,3-dienamide / dimethylaminopropyl acrylamide) copolymers, MPA (N-isopropyl methacrylamide / dimethylaminopropyl acrylamide) copolymers, MPA (N-ethyl acrylamide / dimethylaminopropyl acrylamide) copolymers, MPA (N-ethyl methacrylamide / dimethylaminopropyl acrylamide) copolymers, MPA (N-ethoxyethyl acrylamide / dimethylaminopropyl acrylamide) copolymers, MPA (N-ethoxyethyl amide / dimethylaminopropyl acrylamide) copolymers, MPA (N-ethoxyethyl methacrylamide / dimethylaminopropyl acrylamide) copolymers, MPA (N-cyclopropyl acrylamide / dimethylaminopropyl acrylamide) copolymers,MPA (N-cyclopropyl amide / dimethylaminopropyl acrylamide) copolymer, MPA (N-cyclopropyl methacrylamide / dimethylaminopropyl acrylamide) copolymer, MPA (N-tetrahydrofurfuryl acrylamide / dimethylaminopropyl acrylamide) copolymer, MPA (N-tetrahydrofurfuryl methacrylamide / dimethylaminopropyl acrylamide) copolymer, MPA (N-biotin-N'-methacryloyl trimethylene amide / dimethylaminopropyl acrylamide) copolymer, MPA (N-vinyl acrylamide / dimethylaminopropyl acrylamide) copolymer, MPA (N-vinyl alkyl acrylamide / dimethylaminopropyl acrylamide) copolymer, MPA (N-vinyl methacrylamide / dimethylaminopropyl acrylamide) copolymer ) copolymer, MPA (N-propyl acrylamide / dimethylaminopropyl acrylamide) copolymer, MPA (N-methacryloyl piperidine / dimethylaminopropyl acrylamide) copolymer, MPA (N-dialkyl methacrylamide / dimethylaminopropyl acrylamide) copolymer, MPA (s-butyl acrylamide / dimethylaminopropyl acrylamide) copolymer, MPA (t-butyl acrylamide / dimethylaminopropyl acrylamide) copolymer, MPA (acryloyl glycinamide / dimethylaminopropyl acrylamide) copolymer, MPA (acryloyl sarcosine amide / dimethylaminopropyl acrylamide) copolymer, MPA (acryloyl piperidine carboxamide / dimethylaminopropyl acrylamide) copolymer, MPA (acryloyl methyl uracil) copolymer MPA (ethylene glycol / dimethylaminopropyl acrylamide) copolymer, MPA (ethylene glycol allyl methyl ether / dimethylaminopropyl acrylamide) copolymer, MPA (oxyethylene acrylate / dimethylaminopropyl acrylamide) copolymer, MPA (oxyethylene sorbitan laurate / dimethylaminopropyl acrylamide) copolymer, MPA (oxyethylene methacrylate / dimethylaminopropyl acrylamide) copolymer, MPA (oxyethylene sorbitan laurate / dimethylaminopropyl acrylamide) copolymer, MPA (oxyethylene methacrylate / dimethylaminopropyl acrylamide) copolymer, MPA (oxyethylene MPA (diethyl acrylamide / dimethylaminopropyl acrylamide) copolymer, MPA (diisopropyl acrylamide / dimethylaminopropyl acrylamide) copolymer, MPA (diethyl acrylamide / dimethylaminopropyl acrylamide) copolymer, MPA (diethylamino acrylate / dimethylaminopropyl acrylamide) copolymer, MPA (diethylamino methacrylate / dimethylaminopropyl acrylamide) copolymer, MPA (diethylene glycol propylene diene methyl ether / dimethylaminopropyl acrylamide) copolymer, MPA (dibutyl acrylamide / dimethylaminopropyl acrylamide) copolymer, MPA (dipropyl acrylamide / dimethylaminopropyl acrylamide) copolymer,MPA (dimethylacrylamide / dimethylaminopropyl acrylamide) copolymer, MPA (dimethylaminoacrylamide / dimethylaminopropyl acrylamide) copolymer, MPA (dimethylaminoacrylate / dimethylaminopropyl acrylamide) copolymer, MPA (dimethylaminopropyl acrylamide / dimethylaminopropyl acrylamide) copolymer, MPA (dimethylaminopropyl methacrylamide / dimethylaminopropyl acrylamide) copolymer, MPA (dimethylaminomethacrylamide / dimethylaminopropyl acrylamide) copolymer, MPA (dimethylamino methyl acrylate / dimethylaminopropyl acrylamide) copolymer), MPA (sodium N,N-dithiocarbamate / dimethylaminopropyl acrylamide) copolymer, MPA (propylene glycol / dimethylaminopropyl acrylamide) copolymer, MPA (hexa(N,N-dithiocarbamoylmethyl)benzene / dimethylaminopropyl acrylamide) copolymer, MPA (hexa(bromomethyl)benzene / dimethylaminopropyl acrylamide) copolymer, MPA (methacrylamide / dimethylaminopropyl acrylamide) copolymer,

[0265] Furthermore, based on the results of the 6-month stability test conducted at 40°C and 80% humidity in the above-mentioned preparation process, the stimuli-responsive polymer-bound lipids that can be used in the present invention and have a decomposition rate of 10% or less are shown in Table 17. Hereinafter, dioleoylphosphatidylethanolamine mercaptopropionyl is abbreviated as "DOPEAMP". Furthermore, dimethylaminopropylacrylamide is also abbreviated as "DMAPAA".

[0266] [Table 17]

[0267] DOPEAMP (polyoxyethylene octyl phenyl ether) acrylate / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (polyoxyethylene octyl phenyl ether) methacrylate / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (polyoxyethylene nonyl phenyl ether) acrylate / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (polyoxyethylene nonyl phenyl ether) methacrylate / dimethylaminopropyl acrylamide) copolymer, DOPEAMP ((polyoxyethylene lauryl ether) acrylate / dimethylaminopropyl acrylamide) copolymer, DOPEAMP ((polyoxyethylene lauryl ether) methacrylate / dimethylaminopropyl acrylamide) copolymer, DOPEAMP ((polyoxyethylene DOPEAMP (1,2,4,5-tetrakis(N,N-dithiocarbamoylmethyl)benzene / dimethylaminopropylacrylamide) copolymer, DOPEAMP (1,3,5-tris(bromomethyl)benzene / dimethylaminopropylacrylamide) copolymer, DOPEAMP (2-n-propyl-2-oxazoline / dimethylaminopropylacrylamide) copolymer, DOPEAMP (2-N,N-dimethylaminoethylacrylate / dimethylaminopropylacrylamide) copolymer, DOPEAMP (2-N,N-dimethylaminoethylmethacrylate DMAEMA / dimethylaminopropylacrylamide) copolymer, DOPEAMP (2 -Amino-2-hydroxymethyl-1,3-propanediol / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (2-amino-2-hydroxymethyl-1,3-propanediol / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (2-amino-2-hydroxymethyl-1,3-propanediol (Tris) / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (2-amino-2-hydroxymethyl-1,3-propanediol / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (2-hydroxy-3-phenoxypropyl acrylamide / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (2-hydroxybutyl acrylate / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (methyl Acrylic acid-2-hydroxybutyl / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (2-hydroxypropyl acrylate / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (2-hydroxypropyl methacrylate / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (3,5-tris(N,N-dithiocarbamoylmethyl)benzene / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (3-N,N-dimethylaminopropyl acrylamide / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (N-acryloyl asparagine / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (N-acryloyl glycinamide / dimethylaminopropyl acrylamide) copolymer,DOPEAMP (N-acryloylglutamic acid / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (N-acetylacrylamide / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (N-methacryloylasparagine / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (N,N-dimethylmethacrylamide / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (N,N-dimethylacrylamide / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (N,N-methylenebisacrylamide / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (N,N-ethylmethacrylamide / dimethylaminopropyl acrylamide) copolymer, D OPEAMP (N,N-ethylmethylacrylamide / dimethylaminopropylacrylamide) copolymer, DOPEAMP (N,N-ethylmethylmethacrylamide / dimethylaminopropylacrylamide) copolymer, DOPEAMP (N,N-dialkyl-dithiocarbamoylmethyl)benzene / dimethylaminopropylacrylamide) copolymer, DOPEAMP (N,N-dialkylacrylamide / dimethylaminopropylacrylamide) copolymer, DOPEAMP (N,N-diethylacrylamide / dimethylaminopropylacrylamide) copolymer, DOPEAMP (N,N-diethylamide / dimethylaminopropylacrylamide) copolymer, DOPEAMP (N,N-diethylmethacrylamide / dimethylaminopropylacrylamide) copolymer amide) copolymer, DOPEAMP (N,N-dithiocarbamic acid / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (N,N-dithiocarbamate / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (N,N-dimethylacrylamide / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (N,N-dimethylmethacrylamide / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (N,N-propylacrylamide / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (N,N-isopropylmethacrylamide / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (N-acryloylpiperidinium / dimethylaminopropyl acrylamide) copolymer amine) copolymer, DOPEAMP (N-acryloylmorpholine / dimethylaminopropylacrylamide) copolymer, DOPEAMP (N-alkylacrylamide / dimethylaminopropylacrylamide) copolymer, DOPEAMP (N-dialkylmethacrylamide / dimethylaminopropylacrylamide) copolymer, DOPEAMP (N-alkylsubstitutedacrylamide / dimethylaminopropylacrylamide) copolymer, DOPEAMP (N-alkylsubstitutedacrylamide / dimethylaminopropylacrylamide) copolymer, DOPEAMP (N-alkylsubstitutedmethacrylamide / dimethylaminopropylacrylamide) copolymer, DOPEAMP (N-alkylsubstitutedmethacrylamide / dimethylaminopropylacrylamide) copolymer, DOPEAMP (N-propylenephthalimide / dimethylaminopropylacrylamide) copolymer,DOPEAMP (N-isopropylacrylamide / dimethylaminopropylacrylamide) copolymer, DOPEAMP (N-isopropylamide / dimethylaminopropylacrylamide) copolymer, DOPEAMP (N-isopropylbut-2,3-dienamide / dimethylaminopropylacrylamide) copolymer, DOPEAMP (N-isopropylmethacrylamide / dimethylaminopropylacrylamide) copolymer, DOPEAMP (N-ethylacrylamide / dimethylaminopropylacrylamide) copolymer, DOPEAMP (N-ethylmethacrylamide / dimethylaminopropylacrylamide) copolymer, DOPEAMP (N-ethoxyethylacrylamide / dimethylaminopropylacrylamide) copolymer, DOPEAMP (N-ethoxyethyl amide / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (N-ethoxyethyl methacrylamide / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (N-cyclopropyl acrylamide / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (N-cyclopropyl amide / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (N-cyclopropyl methacrylamide / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (N-tetrahydrofurfuryl acrylamide / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (N-tetrahydrofurfuryl methacrylamide / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (N-biotin-N ′-methacryloyl trimethylene amide / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (N-vinyl acrylamide / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (N-vinyl alkyl acrylamide / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (N-vinyl methacrylamide / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (N-propyl acrylamide / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (N-methacryloyl piperidine / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (N-dialkyl methacrylamide / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (s-butyl DOPEAMP (acryloyl glycinamide / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (acryloyl sarcosine amide / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (acryloyl methyl uracil / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (acetyl acrylamide / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (isopropyl acrylamide / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (ethyl isopropyl acrylamide / dimethylaminopropyl acrylamide) copolymer,DOPEAMP (ethylene glycol / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (ethylene glycol allyl methyl ether / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (oxyethylene acrylate / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (oxyethylene sorbitan laurate / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (oxyethylene methacrylate / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (oxyethylene lauramine / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (oligoethylene glycol acrylate / dimethylaminopropyl acrylamide) copolymer DOPEAMP (diisopropyl acrylamide / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (diethyl acrylamide / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (diethylaminoacrylate / dimethylaminopropyl acrylate) copolymer, DOPEAMP (diethylaminomethacrylate / dimethylaminopropyl acrylate) copolymer, DOPEAMP (diethylene glycol allyl dienyl methyl ether / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (dibutyl acrylamide / dimethylaminopropyl acrylamide) copolymer, DOPEAM P (dipropyl acrylamide / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (dimethylacrylamide / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (dimethylaminoacrylamide / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (dimethylaminoacrylate / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (dimethylaminopropyl acrylamide / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (dimethylaminopropyl methacrylamide / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (dimethylaminomethacrylamide / dimethyl DOPEAMP (dimethylamino methyl acrylate / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (sodium N,N-dithiocarbamate / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (propylene glycol / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (hexa(N,N-dithiocarbamoylmethyl)benzene / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (hexa(bromomethyl)benzene / dimethylaminopropyl acrylamide) copolymer, DOPEAMP (methacrylamide / dimethylaminopropyl acrylamide) copolymer,

[0268] Based on the results of a 6-month stability test at 40°C and 80% humidity using the lipids having an ethanolamine group shown below instead of the dioleoylphosphatidylethanolamine shown above, lipids having an ethanolamine group and a decomposition rate of less than 10% that can be used as the stimulus-responsive polymer-conjugated lipids of the present invention are shown in Table 18.

[0269] [Table 18]

[0270] 2-Alkyl-N-carboxymethyl-N-hydroxyethylimidazolium betaine ethanolamine, N-acyl aspartate ethanolamine, N-acyl glutamate ethanolamine, N-acyl sarcosine ethanolamine, N-acyl methyl alanine ethanolamine, N-acyl methyl taurine ethanolamine, N-stearoyl dihydrosphingosine ethanolamine, N-stearoyl phytosphingosine ethanolamine, acyl (C12,14) Aspartic acid ethanolamine, acyl N-methyl amino acid ethanolamine, acyl amino acid ethanolamine, acyl lactic acid ethanolamine, acetylethyl carboxymethylthiazolidine carboxylic acid ethanolamine, aminoacetic acid betaine ethanolamine, alkyl (alkenyl) oligomer glycol ethanolamine, alkylphenol polyethylene glycol ethanolamine, alkoxylated triglycerol ether ethanolamine, phytosteryl isostearate ethanolamine, caproyl proline ethanolamine, glycerophosphoethanolamine, glucuronic acid ethanolamine, cocoyl alanine ethanolamine, cocoyl glutamate ethanolamine, cocoyl methyl taurine ethanolamine, succinic acid ethanolamine, surfactant protein ethanolamine, lysine distearoyl glutamate ethanolamine, diphosphatidylglycerol ethanolamine, lysine dimyristoyl glutamate ethanolamine, lysine Dilauroyl glutamate ethanolamine, dilinoleoyl glutamate lysine ethanolamine, dioctyldodecyl stearoyl glutamate ethanolamine, stearoyl glutamate ethanolamine, spore penicillin acid ethanolamine, sphingomyelin ethanolamine, ceramide phosphoethanolamine, ceramide aminoethylphosphonic acid ethanolamine, cerebroside ethanolamine, palm kernel oil fatty acid amide propyl betaine ethanolamine, palm fatty acid glutamate ethanolamine, palmitoyl aspartic acid ethanolamine, bis (Nε-lauroyl-L-lysine) sebacoyl ethanolamine, hydroxystearyl phytosphingosine ethanolamine, polyoxyethylene glyceryl pyroglutamate isostearate ethanolamine, glyceryl monopyroglutamate monooleate ethanolamine, phosphatidylethanolamine, polyoxyethylene stearyl ethanolamine, polyoxyethylene sorbitan hard Fatty ethanolamine, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene methyl glucose stearyl ethanolamine, polyoxyethylene stearyl ethanolamine, polyoxyethylene lauryl ethanolamine, myristoyl glutamate ethanolamine, myristoyl methylaminopropionic acid hexyl decyl ethanolamine, myristoyl methyl taurine ethanolamine, polyoxyethylene sorbitan monooleate ethanolamine, coconut oil alkyl betaine ethanolamine, coconut oil fatty acid N-methyl ethanolamine, coconut fatty acid acyl glycine ethanolamine, coconut fatty acid acyl glutamate ethanolamine, coconut oil fatty acid amide propyl betaine ethanolamine, coconut oil fatty acid glyceride ethanolamine, coconut oil fatty acid glutamate ethanolamine, coconut oil fatty acid sarcosine ethanolamine, coconut oil fatty acid methyl alanine ethanolamine Alcoholamine, Coconut Oil Fatty Acid Methyl Taurine Ethanolamine, Lauramidopropyl Betaine Ethanolamine, Laurylaminodiacetic Acid Ethanolamine, Lauryl Diethylenediaminoglycine Ethanolamine, Lauryl Dimethylaminoacetic Acid Betaine Ethanolamine, Lauryl Aminopropyl Betaine, Lauryl Ether Acetate Ethanolamine, Lauryl Ether Sulfate Ethanolamine, Lauroyl Aspartate Ethanolamine, Dihexyldecyl Lauroyl Glutamate Ethanolamine, Lauroyl Glutamate Triethanolamine, Methyl Alanine Lauroyl Glutamate Ethanolamine, Lauroyl Glucosine Triethanolamine, Lauroyl Methyl Alanine Ethanolamine, Lauroyl Methyl Glycine Ethanolamine, Lauroyl Methyl Taurine Ethanolamine, Lauroyl Monoethanolamide Succinate Ethanolamine, Lysophosphatidylethanolamine,

[0271] (Preparation of pH and light stimulus responsive polymers)

[0272] In the case of pH and light stimulus responsive polymers, the polymer containing N atoms can bind the polymer to the cell delivery carrier example through an ionic bond, so it can be polymerized with the first monomer only without adding 3-mercaptopropionic acid. In this case, the polymer described in the following paragraph 0158 can be prepared. According to the results of a 6-month stability test at 40°C and 80% humidity, the decomposition rate of these polymers is 10% or less.

[0273] Polyglucosamine, (alkyl acrylamide / polyacrylic acid) copolymer, polyethylene alkyl acrylamide, polyalkyl acrylamide, poly(phenylazophenyl) acrylamide, poly[(4-pyridyl azo) phenoxy] hexamethacrylate, N-vinyl alkyl acrylamide, poly[(vinyloxy) ethoxy] azobenzene

[0274] (Preparation of pH and light stimulus responsive MPA polymer)

[0275] Similar to the first preparation example, the following pH and light stimulus responsive polymers can be prepared using pH and light stimulus responsive monomers. In the case of pH and light stimulus responsive polymers, since precise temperature settings are not required, the stimulus responsive polymer described in the following paragraph 0159 can be prepared by polymerizing only the first monomer without performing a polymerization reaction with the second monomer. The formulation ratio in this case can be changed by increasing the amount of the first monomer corresponding to the amount of the reduced second monomer, and the following polymers can be prepared. Hereinafter, mercaptopropionic acid is referred to as "MPA". According to the results of a 6-month stability test conducted at 40°C and 80% humidity, the decomposition rate of these polymers was less than 10%. pH stimulus responsive polymers: MPA (polyglucosamine), MPA (poly(ethoxyvinyl ethyl ether)), MPA (alkyl acrylamide / polyacrylic acid) copolymer, MPA (poly(vinyl alkyl acrylamide)), MPA (poly(vinyloxyethoxy)benzoic acid), MPA (poly(vinyloxyethoxy)hexanoic acid), MPA (poly(vinyloxy)hexanoic acid), MPA (poly(isobutyl vinyl ether)), light stimulus responsive polymers: MPA (poly(alkyl acrylamide)), MPA (poly((4-phenylazophenyl)acrylamide)), MPA (poly([(pyridyl azo) phenoxy] hexamethacrylate)), MPA (poly(vinyl alkyl acrylamide)), MPA (poly((vinyloxy)ethoxy)azobenzene)), MPA (poly((ethoxy)ethoxyvinyl ethyl ether))

[0276] (Preparation of pH and light stimulus responsive polymer-bound lipids)

[0277] The above MPA derivatives were used to modify dioleoylphosphatidylethanolamine, a lipid forming a liquid crystal layer structure, and the stimulus-responsive polymer-binding lipid described in the following paragraph 0160 was similarly prepared. Hereinafter, dioleoylphosphatidylethanolamine mercaptopropionyl is referred to as "DOPEAMP". According to the results of a 6-month stability test conducted at 40°C and 80% humidity, the decomposition rate of these polymers was less than 10%.

[0278] pH stimulus responsive polymers: DOPEAMP (polyglucosamine), DOPEAMP (poly(ethoxyvinyl ethyl ether), DOPEAMP (alkyl acrylamide / polyacrylic acid) copolymer, DOPEAMP (poly(vinyl alkyl acrylamide)), DOPEAMP (poly(vinyloxyethoxy)benzoic acid), DOPEAMP (poly(vinyloxyethoxy)hexanoic acid), DOPEAMP (poly(vinyloxy)hexanoic acid), DOPEAMP (poly(isobutyl vinyl ether)), light stimulus responsive polymers: DOPEAMP (poly(alkyl acrylamide)), DOPEAMP (poly((4-phenylazophenyl)acrylamide)), DOPEAMP (poly([pyridyl azo) phenoxy] hexamethacrylate)), DOPEAMP (poly(vinyl alkyl acrylamide)), DOPEAMP (poly(((vinyloxy)ethoxy)azobenzene)), DOPEAMP (poly((ethoxy)ethoxyvinyl ethyl ether))

[0279] (Preparation of three hybrid cell delivery vehicles composed of a stimuli-responsive polymer-bound lipid, a vitamin derivative having ATG-CTS activity, and a liquid crystal layer-forming surfactant composed of hydrocarbons)

[0280] The total amount of lipids was 20 mg, and the vitamin derivative with high ATG-CTS activity, namely VCIP (ascorbic acid tetrahexyldecanoate): liquid crystal layer forming surfactant, namely dioleoylphosphatidylethanolamine mercaptopropionyl (DOPE): DOPEMP (NIPAA / DMAPAA) Cop) was dissolved in chloroform at a molar ratio of 3:7. In addition, the molar ratio of the liquid crystal layer forming surfactant dioleoylphosphatidylethanolamine (DOPE) of DOPE dissolved in chloroform to the temperature stimulus responsive polymer-bound lipid DOPEMP (NIPAA / DMAPAA) Cop was set to 6.5:0.5. The solution was transferred to an eggplant-shaped flask, and the solvent was removed by an evaporator to prepare a lipid film. 1 ml of pure water was added to the lipid film to hydrate the lipid film, and then dispersed by vortexing. After that, the size of the liposomes was reduced by ultrasonic treatment in an ultrasonic bath for 30 minutes, and the liposomes were then passed through a 200 nm filter using an extruder to adjust the size of the liposomes. The average particle size was 152 nm. Then, the liposomes were separated and purified by gel filtration to prepare the cell delivery carrier of the present invention containing the ATG-CTS activating substance, the temperature-responsive polymer and the hydrocarbon. When the cell delivery carrier was observed by staining using a transmission electron microscope, a multilamellar vesicle structure (multilamellar liquid crystal structure) was confirmed, and it was confirmed that these cell delivery carriers had a lamellar liquid crystal structure.

[0281] (Preparation of a cell delivery carrier composed of a stimuli-responsive polymer-bound lipid, a vitamin derivative having ATG-CTS activity, a liquid crystal layer-forming surfactant composed of hydrocarbons, and a lipid)

[0282] Add lecithin 2%, glycerol 50%, behenyl alcohol 8%, stearyl alcohol 7%, PEG-20 phytosterol 4%, cetyl alcohol 3%, phytosterol 1%, stearyl glyceryl 1%, tri (caprylic acid / capric acid) glyceride 2%, cholesterol 0.3%, ATG-CTS high activity vitamin derivatives, namely GOVC (glyceryl octyl ascorbic acid) 1% and DOPEMP (NIPAA / DMAPAA) Cop 0.2% and squalane 10%, and stir with a self-rotating revolution stirrer. Add pure water to 100% and disperse by vortex. After that, ultrasonic treatment in an ultrasonic bath for 30 minutes to reduce the size of the emulsified particles, and then pass it through a 200nm filter with an extruder to adjust the size of the liposomes. The average particle size is 122nm. After that, the liposomes are separated and purified by gel filtration to prepare the cell delivery carrier of the present invention containing ATG-CTS activating substances, temperature stimulus responsive polymers and hydrocarbons. When the cell delivery carriers were observed by staining using a transmission electron microscope, a multilamellar vesicle structure (multilamellar liquid crystal structure) was confirmed, and it was confirmed that these cell delivery carriers had a lamellar liquid crystal structure.

[0283] (Comparative experiment with the present invention)

[0284] The total amount of lipids was 20 mg, and the molar ratio of (vitamin derivative with high ATG-CTS activity, i.e., ascorbic acid tetrahexyldecanoate, VCIP) : (1,2-dioleoyl-3-trimethylammonium propane as lipid) : (total weight of dioleoylphosphatidylethanolamine and DOPEMP (NIPAA / DMAPAA 5%) Cop as liquid crystal layer forming surfactant) = 1:2:7 was dissolved in chloroform. Further, 1 mg of fluorescent dye, i.e., rhodamine (carboxyrhodamine 110-PEG4-alkyne), was added and dissolved. In addition, the lower critical solution temperature of DOPEMP (NIPAA / DMAPAA 5%) Cop used in this experiment in water was 40°C. Based on the total weight, the molar ratio of dioleoylphosphatidylethanolamine and DOPEMP (NIPAA / DMAPAA 5%) Cop as liquid crystal layer forming surfactant was 6.5:0.5. The solution was transferred to an eggplant-shaped flask, and the solvent was removed by an evaporator to prepare a lipid film. 1 ml of PBS was added to the lipid film to hydrate the lipid film, and then dispersed by vortexing. After that, the size of the liposomes was reduced by ultrasonic treatment in an ultrasonic bath for 30 minutes, and then the liposomes were passed through a 200 nm filter with an extruder to adjust the size of the liposomes. The average particle size of the embodiments and comparative examples was 114 nm ± 1 nm. In addition, only in the embodiments of the present invention, filters of different large sizes were used to prepare liposomes with an average particle size of 252 nm, 312 nm, 578 nm and 812 nm. After that, the liposomes were separated and purified by gel filtration to prepare a cell delivery carrier of the present invention containing an ATG-CTS activating substance, a temperature-responsive polymer and a hydrocarbon. When the cell delivery carrier was observed using a transmission electron microscope with a staining method, a multilayer vesicle structure (multilayer liquid crystal structure) was confirmed, and it was confirmed that these cell delivery carriers had a layer liquid crystal structure.

[0285] (Comparative Example 1)

[0286] Lipofectamine (registered trademark) (RNAiMAX) manufactured by Invitrogen was used as the liposome of Comparative Example 1. Rhodamine was contained at the same final concentration as in the example.

[0287] (Comparative Example 2)

[0288] When preparing liposomes, liposomes were prepared in the same manner as in Example 1, except that DOPEMP (NIPAA / DMAPAA) Cop was not added. Comparative Example 2 was the same as in Example 1, except that the temperature stimulus responsive polymer was not present.

[0289] (Comparative Example 3)

[0290] Liposomes were prepared in the same manner as in Example 1, except that PEG (polyethylene glycol, molecular weight: 2000) was used instead of DOPEMP (NIPAA / DMAPAA) Cop.

[0291] Normal human dermal fibroblasts were cultured at 5×10 cells / well in DMEM (low glucose) containing 5% FBS in a 6-well plate. 5 The density of cells / well was cultured at 37°C for 24 hours, and then replaced with the culture medium containing the four cell delivery carriers of the above-prepared examples and comparative examples (rhodamine was added to a final concentration of 1 μM), and cultured at 35°C for 1 hour. After that, the group of only the examples of the present invention was divided into a group in which the culture temperature was not changed and maintained for 20 minutes and a group treated at 40°C for 20 minutes. Furthermore, both groups were cultured at 35°C for 1 hour. After that, it was washed five times with PBS, fixed with 4% paraformaldehyde phosphate buffer for 20 minutes, and then washed twice with PBS. The fluorescence intensity was measured with a fluorescence microplate reader at an excitation wavelength of 555 (nm) and a fluorescence wavelength of 580 (nm) to determine the relative concentration of the fluorescent substance taken into the cells. For the no-addition control, cells without the addition of the cell delivery carrier of the vitamin derivative were cultured in the same way, and the fluorescence intensity was measured.

[0292] As a result, when the fluorescence intensity of the particle size of 114 nm in the group treated at 40°C for 20 minutes in the example was set to 100%, the fluorescence intensity of Comparative Example 1 was 82%, the fluorescence intensity of Comparative Example 2 was 35%, and the fluorescence intensity of Comparative Example 3 was 22%. From this result, it can be seen that the cell delivery carrier of the present invention has a very high cellular uptake performance.

[0293] When the fluorescence intensity of the particle size of 114 nm in the group treated at 40° C. for 20 minutes of the embodiment is set to 100%, the fluorescence intensity of the particle size of 114 nm in the group kept at 35° C. for 20 minutes of the embodiment is 80%, and it is obvious that the cell absorption rate in the group treated at 40° C. for 20 minutes increases. Further, the fluorescence intensity of the average particle size of the embodiment of the present invention of different sizes is 94% at 252nm, 81% at 382nm, 72% at 578nm, and 51% at 812nm, confirming that the average particle size of 300nm shows high cell absorption.

[0294] (Comparative experiment between liquid crystal lamellar and non-liquid crystal lamellar) A-10: Cell delivery carrier having a lamellar liquid crystal structure. 1 g of GOVC (an amphiphilic vitamin derivative in which 2-glyceryl-3-ascorbyl caprylate, glycerol: caprylic acid: a matrix composed of ascorbyl esters are combined at a weight ratio of 0.223:0.35:0.427), 1 g of DOPEMP (NIPAA / DMAPAA) Cop, 0.05 g of cholesterol, and 0.1 g of PEG-25 phytostanol (INCI name: PEG-25 Phytostanol) were added to 15 g of glycerol, 3.6 g of diglycerol, and 2 g of sodium cocoyl glutamate at 70°C, and stirred for 10 minutes with an electric hand stirrer while naturally cooling, and 5 g of squalane containing 5% by weight of retinol was added, and stirred for 10 minutes with an electric hand stirrer. This stirring operation of adding lipids was repeated four times in total, and a total of 20 g of squalane containing 5% by weight of retinol was added. Pure water to which 8% phenoxyethanol was added was added to 100 g, and stirred with an electric hand stirrer for 10 minutes to prevent foaming, so that it was completely dispersed, and the composition of the lamellar liquid crystal emulsion containing retinol of the present invention was obtained. The cell delivery carrier was treated with a microfluidizer, and further, it was adjusted to a nano-capsule using a filter with a pore size of 400 nm. A cell delivery carrier with an average particle size of 253 nm was obtained. When the cell delivery carrier was observed with staining using a transmission electron microscope, a multilayer vesicle structure (multilayer liquid crystal structure) was confirmed, and it was confirmed that these cell delivery carriers had a layered liquid crystal structure.

[0295] B-10: Control The above A-10 was replaced with a material containing only GOVC as the matrix component as a control. In addition, the glycerol in the matrix component was increased from the 0.22 g added at the beginning, 0.35 g of octanoic acid was added to squalane in advance, 0.6 g of stabilized trisodium ascorbyl phosphate (same molar mass as ascorbic acid) was added to ascorbic acid, and finally pure water was added to make it the same molar mass as A-10.

[0296] Sample C-10: Non-liquid crystal lamellar cell delivery carrier containing amphiphilic antioxidant vitamins (control 2) 15g of glycerol, 3.6g of diglycerol, 2g of sodium cocoyl glutamate, 1g of GOVC and 1g of DOPEMP (NIPAA / DMAPAA) Cop, 0.05g of cholesterol, 0.1g of PEG-25 plant stanol, 25g of squalane containing 5% by weight of retinol, and 52.25g of purified phenoxyethanol containing 8% by weight were mixed. It was crushed and stirred using a high-speed stirrer without going through the formation process of the liquid crystal layer structure, and then ultrasonically treated, and the cell delivery carrier was treated with a microfluidizer to obtain a cell delivery carrier with an average particle size of 300nm. Further, it was adjusted to a nano-capsule using a filter with a pore size of 400nm.

[0297] Sample D-10: Control of non-liquid crystal lamellar cell delivery carrier without amphiphilic antioxidant vitamins 15.22 g of glycerol, 3.6 g of diglycerol, 2 g of sodium cocoyl glutamate, 1 g of GOVC and 1 g of DOPEMP (NIPAA / DMAPAA) Cop, 0.05 g of cholesterol, 0.1 g of PEG-25 phytostanol, 0.35 g of caprylic acid, 25 g of squalane containing 5 wt% retinol, 0.6 g of trisodium ascorbyl phosphate, and 52.25 g of pure water added with 8 wt% phenoxyethanol were mixed. The carrier was pulverized and stirred using a high-speed stirrer without undergoing the formation process of the liquid crystal layer structure, and then subjected to ultrasonic treatment. The carrier was treated with a microfluidizer to obtain a carrier having an average particle size of 300 nm. Further, it was adjusted to a nano-capsule using a filter with a pore size of 400 nm.

[0298] A-10, B-10, C-10 and D-10 were stored at 40°C under light-shielding conditions for 3 months, and the retinol content at the beginning and end of the experiment was measured by HPLC. The analysis conditions were as follows: Chromatographic column: Shim-pack FC-ODS (75 mmL×4.6 mm), solvent: methanol, flow rate: 1.2 mL / min, column temperature: 35°C, detection wavelength: 350 nm.

[0299] As a result, when the retinol content at the beginning of the experiment was set to 100%, the retinol content of A-10 of the present invention was 95.67% at the end of the experiment, while that of B-10, C-10, and D-10 as controls was 73.2%, 32.5%, and 22.7%, respectively. The stability of retinol in A-10 of the present invention is very high. Furthermore, when the active ingredient such as retinol added to the capsule is an easily oxidizable ingredient, an antioxidant is used to prevent the oxidation of the active ingredient. However, there is a problem that the effective period of the antioxidant is short, so the active ingredient is oxidized. The oxidation of the active ingredient is suppressed by adding an amphiphilic substance such as GOVC.

[0300] The cell delivery carrier of the present invention of Example A-10, the cell delivery carriers of B-10, C-10, D-10, and E-10, and a placebo cream not containing any cell delivery carrier were used as negative controls. Creams were prepared according to the following formulations, and their anti-wrinkle effect, anti-acne effect, moisturizing effect, barrier function strengthening effect, inhibitory effect on ultraviolet-induced inflammation, anti-bedsore effect, and free radical inhibitory effect were evaluated.

[0301] The test cream was formulated by adding 10 wt % each of the above-mentioned A-10, B-10, C-10 and D-10 to a cream base material manufactured by ITO (Nishitokyo City, Tokyo) and treating it with an autorotating and revolving stirrer for 5 minutes.

[0302] 100 healthy subjects and subjects with wrinkles, acne, pigmentation, and dry skin were divided into 5 groups (A-10, B-10, C-10, D-10 added group and placebo group) with 20 people in each group and the symptoms of each test group were evenly divided into 5 groups, and the effect of each group was evaluated. For healthy subjects, 0.01 ml of the above-mentioned topical preparation was applied to the cheeks, and for other patients, 0.01 ml of the above-mentioned topical preparation was applied to the affected part twice a day, morning and evening. After application, the application site was covered with a hot steam towel for 5 minutes. Under the same lighting conditions, the color of the lesion site before and 10 days after the start of the smearing test was photographed with a digital camera, and wrinkles, acne, and pigmentation were quantified using the image processing device VISIA through the software built into VISIA. Alternatively, for healthy subjects, the amount of lipid peroxides was measured by impregnating filter paper with sebum, and the amount of peroxides in sebum was measured using a peroxide lipid measurement kit filter paper. Dryness and barrier function were compared by measuring the moisture content of the stratum corneum and the amount of epidermal water evaporation. The degree of improvement of bedsores was compared and quantified with the naked eye according to the standard guidelines for bedsores. As a result, 60 days after the start of the test, the total scores of 20 subjects in each group were calculated, and the percentages of the test group and the control group were calculated, with the total score of the placebo ointment being 100%.

[0303] The result after 60 days of the test is that when the placebo group is set to 100%, the effect of A-1 in the embodiment is: wrinkles 44%, acne 27%, and pigmentation 35%, and a significant improvement effect is seen. Further, the water content of the stratum corneum increases to 141%, the evaporation of epidermal water increases to 132%, and dry skin is improved. The effects of anti-wrinkle effect, anti-acne effect, whitening effect, moisturizing effect, and strengthening barrier function effect have all been confirmed. The results of other test groups are as follows. The effect of B-1 is: wrinkles 69%, acne 64%, pigmentation 72%, stratum corneum water content 119%, and epidermal water evaporation 116%; the effect of C-1 is: wrinkles 85%, acne 81%, pigmentation 91%, stratum corneum water content 105%, and epidermal water evaporation 104%; the effect of D-1 is: wrinkles 91%, acne 89%, pigmentation 95%, stratum corneum water content 106%, and epidermal water evaporation 109%.

[0304] Furthermore, the concentration of lipid peroxides in sebum sampled from the cheek skin of patients in group A-1 was reduced by 36% compared to the negative control, confirming the free radical inhibitory effect. Based on these results, it was confirmed that this product is very effective as a drug, quasi-drug, unapproved drug, and cosmetic.

[0305] (Stability and uptake experiment of temperature stimulus responsive cell delivery carrier) Sample A-1) Temperature responsive liquid crystal lamellar cell delivery carrier containing amphiphilic antioxidant vitamins (the present invention) 1g of phosphatidylcholine derived from egg yolk, 0.8g of dioleoylphosphatidylethanolamine, 3g of DOPEMP (NIPAA / DMAPAA) Cop, 0.05g of cholesterol, 0.1g of PEG-25 phytostanol (INCI name: PEG-25Phytostanol) and 0.1g of GOVC (an amphiphilic vitamin derivative in which 2-glyceryl-3-ascorbyl caprylate, glycerol: caprylic acid: a matrix composed of ascorbic acid ester are combined in a weight ratio of 0.223:0.35:0.427) are dissolved in 200ml of chloroform, and the solvent is then removed by an evaporator to form a lamellar liquid crystal structure film.

[0306] 1 mL of a peptide-bound fluorescent substance solution dissolved in PBS at a concentration of 0.2 mg / mL (a mixed aqueous solution of ovalbumin: fluorescein isothiocyanate = 1:1 (equimolar)) and 1 mL of a solution in which mir-125a siRNA duplex containing a protein that inhibits luciferase activity in cells as a nucleic acid was diluted to a concentration of 200 nM with PBS (hereinafter referred to as siRNA solution). Next, the film was pulverized with a stirrer, then ultrasonically treated, and further adjusted to nanocapsules using a filter with a pore size of 400 nm. The cell delivery carrier was purified using PD-10 column gel filtration.

[0307] Sample B-1 Temperature-responsive liquid crystal lamellar cell delivery carrier containing a matrix constituting amphiphilic antioxidant vitamins (control 1) 1g of phosphatidylcholine from egg yolk, 0.8g of dioleoylphosphatidylethanolamine, 3g of DOPEMP (NIPAA / DMAPAA) Cop, 0.05g of cholesterol, 0.1g of PEG-25 plant stanol and 0.035g of caprylic acid were dissolved in chloroform, and the solvent was removed by an evaporator to form a lamellar liquid crystal structure film. 1ml of peptide-bound fluorescent substance solution (same as sample A-1), 0.043g of ascorbic acid, 0.022g of glycerol and 1ml of siRNA solution were mixed therein. Then, the film was pulverized with a high-speed stirrer, then ultrasonically treated, and further adjusted to nano-capsules with a filter with a pore size of 400nm. The cell delivery carrier was purified using PD-10 column gel filtration.

[0308] Sample C-1) Non-liquid crystal lamellar cell delivery carrier containing amphiphilic antioxidant vitamins (control 2). 1 ml of peptide-bound fluorescent substance solution (same as sample A-1) and 1 ml of siRNA solution were mixed with 1 g of egg yolk-derived phosphatidylcholine, 0.8 g of dioleoylphosphatidylethanolamine, 3 g of DOPEMP (NIPAA / DMAPAA) Cop, 0.05 g of cholesterol, 0.1 g of PEG-25 plant stanol and 0.1 g of GOVC. The mixture was pulverized and stirred using a high-speed stirrer without going through the step of forming a liquid crystal layer structure film, and then subjected to ultrasonic treatment, and further passed through a filter with a pore size of 400 nm.

[0309] Sample D-1) Control of non-liquid crystal lamellar cell delivery carrier without amphiphilic antioxidant vitamins 1 ml of peptide-bound fluorescent substance solution (same as sample A-1) and 1 ml of siRNA solution were mixed with 1 g of egg yolk-derived phosphatidylcholine, 0.8 g of dioleoylphosphatidylethanolamine, 3 g of DOPEMP (NIPAA / DMAPAA) Cop, 0.05 g of cholesterol and 0.1 g of PEG-25 phytostanol. The mixture was pulverized and stirred using a high-speed stirrer without going through the step of forming a liquid crystal layer structure film, and then subjected to ultrasonic treatment, and further passed through a filter with a pore size of 400 nm.

[0310] (Measurement of particle size of cell delivery carrier) Each sample A-1, B-1, C-1, and D-1 was stored at room temperature for one week, and the particle size of the prepared cell delivery carrier was measured using a particle size measuring device (ZETASIZER Nano-ZS). Then, the average particle size of A-1 obtained a sharp single peak of 314nm (range 120 to 450nm), and the average particle size of the control B-1 obtained a sharp single peak of 252nm (range 155-342nm). C-1 and D-1 separated over time, and no stable cell delivery carrier was obtained.

[0311] (Cellular uptake experiment) Using a 6-well plate, take 125 μl of the above-prepared A-1 of the present invention, and the following control B-1, C-1, and D-1 composition solutions, and fix the volume to 1 ml with FBS culture medium. The culture medium of HeLa cells (cervical cancer cells) cultured at a concentration of 5.0×10000 cells / ml was replaced with the above-fixed dispersion solution and incubated at 37°C for 48 hours. After incubation, the culture medium was removed from each, diluted five times with PBS, and Picagene cell lysing agent Lcβ (Toyo Ink) was added at 250 μl / well and incubated for 30 minutes, and then the obtained solution was frozen at -80°C, and the solution was thawed in a bath at 37°C, centrifuged at 12000 rpm for 5 minutes, and 50 μl of Picagene solution was added to 10 μl of the obtained supernatant for luminescence measurement, and the intracellular luciferase activity was measured, so as to obtain the inclusion rate of nucleic acid (siRNA) using the following calculation formula. The siRNA mir-125a used in this experiment inhibits luciferase activity after being taken up by cells, so this means that the smaller the luminescence of luciferase, the more siRNA is taken up by cells, and it promotes protein synthesis and inhibits luciferase activity.

[0312] Nucleic acid (siRNA) inclusion rate = luciferase luminescence: C (counts per second) / protein amount: P (protein abundance).

[0313] In addition, 10 μl of the culture medium of cervical cancer cells in which siRNA was not delivered into the cells was taken, and a BCA (bicinchoninic acid method) detection kit was used to prepare a calibration curve for protein quantification using a BCA standard, and the above C / P value was set to 100% (control), and the RNA inclusion rate of the above embodiment was expressed as a percentage by luciferase activity. As a result, A-1 of the present invention was 19%, B-1 of the following controls was 62%, C-1 was 85%, and D-1 was 81%. A-1 in the present invention showed a decrease in the highest luciferase activity (inclusion rate).

[0314] (Determination of the inclusion rate of water-soluble fluorescent dye) The above-prepared A-1 of the present invention and the following control B-1, C-1, and D-1 composition solutions were incubated at a temperature pressure of 40°C for 1 week, and then the stability of the fluorescence characteristics of each composition was studied. That is, it was diluted 20 times with PBS, and its fluorescence intensity was measured with a fluorescence photometer to determine the fluorescence intensity when the peptide-bound fluorescent substance was included. In addition, after adding 1% Triton10X to completely disintegrate the cell delivery carrier, only the peptide-bound fluorescent substance part was separated by gel filtration, and the fluorescence intensity of this part was used as the fluorescence intensity after heat stress. Then, the value of the fluorescence intensity when included was subtracted from the value of the fluorescence intensity when Triton was added, and the difference was calculated. In addition, in order to make a relative comparison, the inclusion rate of the control was calculated with the calculated value of A-1 as 100%. As a result, the inclusion rate of A-1 of the present invention was 100%, the inclusion rate of the following controls B-1 was 25%, the inclusion rate of C-1 was 2%, and the inclusion rate of D-1 was 3%. It can be confirmed that the inclusion rate of A-1 after heat stress is superior as a liquid crystal lamellar cell delivery carrier containing amphiphilic antioxidant vitamins of the present invention.

[0315] (Comparison of skin permeability using Franz cells) LabCyte EPI-MODEL was used as an epidermal skin model, artificial skin was sandwiched between Franz Cells, and 1 ml of the above-prepared A-1 of the present invention containing a peptide-bound fluorescent substance prepared by incubation at 37°C, and the following control B-1, C-1, and D-1 composition solutions were administered to the donor chamber. After administration, 48 hours later, 10 μl of TritonX was added to the sample sample and peptide-bound fluorescent substance emulsified composition in the 15 μl sampling port to prepare a sample solution. 100 μl of the sample solution was taken and the fluorescence intensity was measured using a fluorescence photometer infiniteM1000, and the skin permeability was calculated according to the following formula. As a result, the skin permeability of A-1 of the present invention was 42%, while the following control B-1 was 19%, C-1 was 5%, and D-1 was 4%. The superiority of the skin permeability of A-1 as a liquid crystal lamellar cell delivery carrier containing amphiphilic antioxidant vitamins of the present invention can be confirmed.

[0316] PermeationRate(%)=(Fr / Fd)x100.

[0317] (Fr: Fluourcenceofsamplefromreceptor, Fd: Fluorescenceofdonor)

[0318] In the preparations using the lamellar liquid crystals, the effective concentration of GOVC in the preparations is only 0.01% or more, and the effects can be exerted at low concentrations, which may be due to the increased skin absorption rate.

[0319] In addition, a preparation in which the concentration of GOVC or OGVC was increased to 1% was prepared, and no skin irritation was shown. This may be because the lamellar liquid crystals weakened the skin irritation of GOVC or OGVC. From these results, it can be seen that the lamellar liquid crystal emulsion of the present invention is very effective as a source of ascorbic acid (ASA) when used as a drug, quasi-drug, unapproved drug and cosmetic, and as an external composition for inhibiting the generation of ASA free radicals.

[0320] (In vitro skin irritation test described in OECD TG-439) In vitro skin irritation test was conducted on cultured cells according to OECD guidelines. OECD GUIDELINES FOR THE TESTING OF CHEMICALS, 439. (2015)

[0321] Using LabCyte EPI-MODEL as a normal skin epidermis model, a skin irritation test was conducted and scored. The results (the lower the score, the greater the toxicity and the lower the safety) were: 5% SLS (positive control) was 3 points, water (negative control) was 100 points, A-1 of the present invention was 125 points, B-1 was 101 points, C-1 was 89 points, and D-1 was 83 points. The viable cell rates of all preparations were above 50%, which denied skin irritation. Among them, A-1 of the present invention had the highest score, suggesting that it is highly safe. As a result of the test, no skin irritation of the test substance was observed in the normal skin model.

[0322] (Preparation of pH-responsive cell delivery carrier) Sample A-2) pH-responsive liquid crystal lamellar cell delivery carrier containing amphiphilic antioxidant vitamins (Present invention) 3 g of egg yolk-derived phosphatidylcholine, 0.8 g of dioleoylphosphatidylethanolamine, 0.15 g of cholesterol, 0.3 g of PEG-25 phytostanol (INCI name: PEG-25 Phytostanol), and 0.1 g of GOVC (an amphiphilic vitamin derivative in which 2-glyceryl-3-ascorbyl caprylate, glycerol: caprylic acid: a matrix composed of ascorbate esters are bound at a weight ratio of 0.223:0.35:0.427) were dissolved in 150 ml of chloroform, and then the chloroform was removed under reduced pressure to prepare a membrane. 100 ml of a mixed solution of 0.5 mM calcein and 9.0% (w / v) sucrose was added thereto, and the lipid membrane was peeled off, crushed in an ultrasonic bath, and then adjusted with a filter having a pore size of 100 nm. The average diameter of the cell delivery carrier particles is 87nm. The lamellar liquid crystal structure was confirmed by electron microscopy. Next, gel filtration was performed using a PD-10 column and used as a chitosan pretreatment solution. Next, it was added dropwise to a solution prepared by dissolving 0.1 (w / v) chitosan solution in 1% (v / v) acetic acid solution, reacted at 40°C for 5 hours, and then cooled. It is used as a pH-responsive cell delivery carrier of the present invention and is hereinafter referred to as pH-GOVC-Chito.

[0323] Sample B-2): pH-responsive liquid crystal lamellar cell delivery carrier containing a matrix constituting amphiphilic antioxidant vitamins (control 1) 3 g of egg yolk-derived phosphatidylcholine, 0.8 g of dioleoylphosphatidylethanolamine, 0.15 g of cholesterol, 0.3 g of PEG-25 phytostanol, and 0.035 g of caprylic acid were dissolved in 150 ml of chloroform, and the chloroform was removed by an evaporator to prepare a film. 100 ml of a mixed solution of 0.043 g of ascorbic acid, 0.022 g of glycerol, and 0.5 mM calcein and 9.0% (w / v) sucrose was added thereto, and the lipid film was peeled off, ultrasonically crushed using an ultrasonic bath, and then adjusted using a filter with a pore size of 100 nm. Next, gel filtration was performed using a PD-10 column, and the resulting mixture was added dropwise to a solution prepared by dissolving a 0.1 (w / v) chitosan solution in a 1% (v / v) acetic acid solution, reacted at 40° C. for 5 hours, and then cooled.

[0324] Sample C-2) Non-liquid crystal lamellar cell delivery carrier containing amphiphilic antioxidant vitamins (control 2) was added with 3 g of egg yolk-derived phosphatidylcholine, 0.8 g of dioleoylphosphatidylethanolamine, 0.15 g of cholesterol, 0.3 g of PEG-25 plant stanol and 0.1 g of GOCV and 100 ml of a mixed solution of 0.5 mM calcein and 9.0% (w / v) sucrose, pulverized with a high-speed stirrer, then subjected to ultrasonic treatment and passed through a filter with a pore size of 100 nm. It was added dropwise to a solution prepared by dissolving 0.1 (w / v) chitosan solution in 1% (v / v) acetic acid solution, reacted at 40° C. for 5 hours, and then cooled.

[0325] Sample D-2 Non-liquid crystal lamellar cell delivery carrier not containing amphiphilic antioxidant vitamins (control 3) was added with 3 g of phosphatidylcholine derived from egg yolk, 0.8 g of dioleoylphosphatidylethanolamine, 0.15 g of cholesterol, 0.3 g of PEG-25 phytostanol, and 100 ml of a mixed solution of 0.5 mM calcein and 9.0% (w / v) sucrose, pulverized with a high-speed stirrer, then subjected to ultrasonic treatment and passed through a filter with a pore size of 100 nm. It was added dropwise to a solution prepared by dissolving 0.1 (w / v) chitosan solution in 1% (v / v) acetic acid solution, reacted at 40° C. for 5 hours, and then cooled.

[0326] Chitosan is positively charged and thus easily bonds to the oxygen atom of phosphoric acid bonded to phospholipids through ionic bonds, thereby obtaining a cell delivery carrier tightly coated with chitosan. The cell delivery carriers obtained here are referred to as 0.1% chitosan-bound cell delivery carrier and 0.5% chitosan-bound cell delivery carrier, respectively.

[0327] (Measurement of particle size) A cell delivery carrier diluted 100 times or more with a 9.0% (w / v) sucrose solution was placed in a micro-cuvette, and the particle size distribution at 25° C. was observed using DLS (dynamic light scattering). The particle size of the prepared cell delivery carrier in the chitosan pretreatment solution of A-2pH-GOVC-Chito was 182 nm, and the particle size of the chitosan-bound cell delivery carrier of A-2pH-GOVC-Chito was 198 nm, confirming that the chitosan treatment increased the particle size.

[0328] (Measurement of surface potential) The prepared cell delivery carrier solution was diluted 20 times, and the surface potential at 37°C was measured using an ELS-Z2 laser particle size analyzer by the electrophoretic light scattering (ELS) method. The Z potential measurement results of the prepared cell delivery carriers showed that the pre-chitosan treatment solution of A-2 was -15mV, and the chitosan-bound cell delivery carrier of A-2 was 15mV, confirming that the surface potential also increased with the binding of chitosan. Chitosan is positively charged, so it is easy to bind to the oxygen atom of phosphoric acid bound to phospholipids through ionic bonds, and a cell delivery carrier tightly coated with chitosan can be obtained.

[0329] (Skin permeability of pH-responsive cell delivery carrier) Using an epidermal skin model (LabCyte EPI-MODEL12) and Franz cells filled with PBS in the receptor, 1 ml of the cell delivery carrier solution of A-2 of the present invention and the following controls B-2, C-2 and D-2 was added to the upper donor part, and cultured at 37°C for 24 hours. Then, 150 μL of samples were collected from the lower receiving part and the upper donor part filled with PBS, 20 μL of 10-fold diluted TritonX-100 was added, and the fluorescence intensity (Ex495nm, Em515nm) was measured using InfiniteM1000. Based on these values, the skin permeability was calculated using the following formula.

[0330] Cumulative % dose applied / cm2 = (Fulu orcence of sample from receptor / Fluorcence of donor) × 100% / 0.64 cm2

[0331] The results after 24 hours showed that the chitosan-bound cell delivery carrier of A-2 of the present invention had the highest skin permeability of 0.6, while the control of B-2 was 0.3, C-2 and D-2 were 0.1. From this result, it can be seen that the skin permeability of the pH-responsive liquid crystal lamellar cell delivery carrier containing amphiphilic antioxidant vitamins of A-2 of the present invention is much higher than that of the pH-responsive liquid crystal lamellar cell delivery carrier containing an antioxidant vitamin matrix of B-2 (control 1), the non-liquid crystal lamellar cell delivery carrier containing amphiphilic antioxidant vitamins of C-2 (control 2), and the non-liquid crystal lamellar cell delivery carrier not containing amphiphilic antioxidant vitamins of D-2 (control 3).

[0332] (Melanin production inhibition test) The following melanin production inhibition test was performed using the pH-responsive cell delivery carriers (A-3, B-3, C-3 and D-3) of A-2, B-2, C-2 and D-2 for pretreatment. HMV-II cells were inoculated at a concentration of 1×10000 cells / ml in a 24-well plate and incubated for 24 hours, and then 200μM IBMX as a melanin production stimulating substance and each pH-responsive cell delivery carrier of A-3, B-3, C-3 and D-3 were added to an APS amount of 100μM. After 2 hours, the cells were washed with PBS, 200μM IBMX was added again, and incubated for 70 hours. Then, the melanin was extracted by dissolving with 200μL of 1mol / L NaOH, and the absorbance at 405nm was measured to quantify the extracted melanin. As a result, the amount of melanin production increased by about 3 times due to the addition of IBMX (the pH-responsive cell delivery carrier was the no-addition group). When the melanin production amount at this time is set to 100%, the A-3 supplemented group of the present invention is 48%, B-3 is 78%, C-3 is 85%, and D-3 is 90%.

[0333] From the results, it can be seen that the melanin production inhibitory effect of the pH-responsive liquid crystal lamellar cell delivery carrier containing amphiphilic antioxidant vitamins A-2 of the present invention is much higher than that of the pH-responsive liquid crystal lamellar cell delivery carrier containing an antioxidant vitamin matrix B-2 (control 1), the non-liquid crystal lamellar cell delivery carrier containing amphiphilic antioxidant vitamins C-2 (control 2), and the non-liquid crystal lamellar cell delivery carrier not containing amphiphilic antioxidant vitamins D-2 (control 3).

[0334] (Cytotoxicity evaluation) HMV-II cells were inoculated at a concentration of 1×10000 cells / ml and 500μL / well on a 6-well plate and incubated for 24 hours, and then 200μM IBMX as a melanin production stimulating substance and each pH-responsive cell delivery vector of A-3, B-3, C-3 and D-3 were added to APS in an amount of 100μM. After 2 hours, the cells were washed with PBS, and 200μM IBMX was added again and incubated for 70 hours. 10μL of CCK-8 kit was added thereto. After incubation for 1 hour, the absorbance at 450nm was measured to compare the cytotoxicity caused by the addition of the samples. As a result, cytotoxicity was confirmed by the addition of IBMX (no addition of pH-responsive cell delivery vector), but no cytotoxicity was observed when each pH-responsive cell delivery vector of A-3, B-3, C-3 and D-3 was added.

[0335] (Intracellular distribution test) HMV-II cells were inoculated in a glass-bottomed culture dish at a concentration of 5×1000 cells / ml per 2 ml and incubated for 24 hours (37°C). A-2 and D-4 of the present invention were added, cultured for 2 hours, then washed twice with PBS and incubated for 70 hours. Fix with 4% paraformaldehyde phosphate buffer for 20 minutes, wash twice with PBS, and observe with a confocal laser microscope. The results showed that the fluorescent dye calcein contained in A-4 was hardly taken up into the cells. In contrast, in A-2 of the present invention, calcein was found to be taken up into the cytoplasm and the nucleus, and in particular, calcein was concentrated in the nucleus in a granular form. The fluorescence intensity of calcein in the nucleus is lower than that in the cytoplasm.

[0336] The above test results imply as follows. When the water-soluble fluorescent dye, i.e., calcein, is used alone, it is not taken into the cell in the control, and is enclosed in liposomes, and thus it is observed that it is taken into the cell. Then, in the uncoated liposomes, it is observed that the enclosed fluorescent substance is granular, therefore, it is believed that the liposome is taken into the cell by endocytosis and retained in the endosome. Further, when enclosed in CS liposomes, it is confirmed that the intracellular localization of rhodamine and calcein is different, and it is observed that the water-soluble fluorescent substance, i.e., calcein, is gathered in the cell center. The affinity of the CS AsNa liposome showing cationicity and the cell surface increases, so the intracellular uptake of the endosome is promoted, and then released from the endosome and gathered in the cell center.

[0337] Therefore, it is believed that the proton sponge effect of chitosan is related to the release from the endosome. The proton sponge effect refers to that when a protonated compound is taken into the endosome under a weakly acidic environment, protonation inhibits the decrease of pH in the endosome, and a large number of protons and chloride ions flow into the endosome, thereby increasing the osmotic pressure inside the endosome, causing swelling and rupture of the endosome. The proton sponge effect refers to the effect of absorbing a large number of protons as the pH decreases. For example, cationic polymers with a large number of amino groups show this effect. This hypothesis was proposed by Behr et al. as a method to help the release of endosomes in the delivery of nucleic acid drugs in particular. There is a proton pump called V-ATPPase in the endosomal membrane, which transports protons to the endosome until the pH in the endosome reaches about 5 to 6. The buffer range of cationic polymers with this proton sponge effect is pH5 to 7, and a large number of protons are absorbed as the pH in the endosome decreases. Thus, the decrease in pH of the endosome is suppressed, and more protons need to flow in to reduce pH. In addition, anions also flow in to maintain the charge balance inside and outside the endosome, and the salt concentration and osmotic pressure increase. In order to eliminate this high osmotic pressure, a large amount of water flows into the endosome, and the membrane cannot bear the volume and collapses, thereby promoting endosomal release. Kobunshi, Vol. 58, P. 137 (2009)

[0338] It is known that polyethyleneimine (PEI) and polyamidoamine dendrimers have a proton sponge effect and are widely used to improve the efficiency of gene transfer.

[0339] A high buffering capacity is required to exhibit the proton sponge effect, but in recent years it has been reported that chitosan has a better buffering capacity than PEI in the endosomal pH range (4.5 to 7).

[0340] In addition, it is known that sodium ascorbate has the effect of inhibiting tyrosinase, a melanin synthase, and inhibits the initial stage of melanin synthesis. Further, it is reported that melanin is transported to dendrites as the synthesis stage proceeds, indicating that the initial stage of melanin synthesis is carried out in the center of the cell. In summary, the chitosan-modified liposomes enclosed with sodium ascorbate released from the endosomes are gathered in the center of the cell, thereby inhibiting the initial stage of melanin synthesis, confirming that the melanin production inhibitory effect is significant.

[0341] (Skin irritation test) An in vitro skin irritation test using cultured cells according to the OECD guidelines was conducted. OECD GUIDELINES FOR THE TESTING OF CHEMICALS, 439. (2015) was used as a guide. Using LabCyte EPI-MODEL as a normal skin epidermis model, a skin irritation test was conducted and scored. The results (the lower the score, the greater the toxicity and the lower the safety) were: 5% SLS (positive control) was 3 points, water (negative control) was 100 points, A-1 of the present invention was 134 points, B-2 was 109 points, C-2 was 95 points, and D-2 was 91 points. The viable cell rates of all preparations were above 50%, which negated skin irritation. Among them, A-1 of the present invention had the highest score, suggesting that it is highly safe. As a result of the test, no skin irritation of the test substance was observed in the normal skin model.

[0342] (Preparation of photoresponsive polymer) A photoresponsive fluorinated polymer was synthesized. 2,2,3,3,4,4,4-heptafluorobutyl methacrylate (FMA) and 1'-[2-(methacryloyloxy)ethyl]-3',3'-dimethyl-6-nitrospiro[2H-1-benzopyran-2,2'-dihydroindole] (SpMA) were dissolved in DMF (dimethylformamide) at a molar ratio of 85:15. In addition, the total amount of FMA and SpMA was 10 g. MPA (3-mercaptopropionic acid) was added to the dissolved solvent to make it 0.028 times the molar amount of FMA, and 58 mg of AIBN (azobisisobutyronitrile) was added. After that, nitrogen substitution and ultrasonic degassing were performed in the solvent, and free radical polymerization was performed at 70°C for 5 hours. The temperature of the liquid after the reaction was returned to room temperature, and then it was dropped into pre-cooled diethyl ether for reprecipitation and purification. Thereafter, the precipitate was recovered by filtration. Reprecipitation purification was performed twice more to recover the polymer represented by Chemical Formula 2. The polymer was dialyzed against water and then freeze-dried to further purify it.

[0343] [Chemical formula 2]

[0344]

[0345] (Preparation of light-stimulus-responsive polymer-bound lipid) In order to actively esterify the polymer represented by formula (1), the temperature-responsive polymer represented by formula (1): DCC (N,N'-dicyclohexylcarbodiimide): NHS (N-hydroxysuccinimide) was dissolved in chloroform at a molar ratio of 1:2.5:2.5, and reacted at room temperature for 24 hours. After the reaction, dicyclohexyl urea as a by-product was removed by suction filtration, and reprecipitation and purification were performed with diethyl ether to recover the succinyl polymer as a precipitate. The succinyl polymer and the membrane fusogenic lipid, DOPE (1,2-dioleoyl-sn-glycero-3-phosphoethanolamine), were dissolved in dioxane at a molar ratio of 1:1 and reacted at room temperature for 24 hours. The light-stimulus-responsive polymer-bound lipid represented by formula (2) was prepared by vacuuming the solution after the reaction with an evaporator to remove the solvent. It is abbreviated as DOPEMP (FMA / SpMA) Copo.

[0346] Sample A-1) Photoresponsive liquid crystal lamellar cell delivery carrier containing vitamin derivatives (present invention) 1 g of egg yolk-derived phosphatidylcholine, 0.8 g of dioleoylphosphatidylethanolamine, 1 g of DOPEMP (FMA / SpMA) Copo, 0.05 g of cholesterol, 0.1 g of PEG-25 phytostanol (INCI name: PEG-25 Phytostanol) and 0.1 g of GOVC (an amphiphilic vitamin derivative in which 2-glyceryl-3-ascorbyl caprylate, glycerol: caprylic acid: a matrix composed of ascorbate ester is combined at a weight ratio of 0.223:0.35:0.427) were dissolved in 200 mL of chloroform, and the solvent was removed by an evaporator to form a lamellar liquid crystal structure film. This was irradiated with ultraviolet rays (352 nm) for 3 minutes and shielded from light. The following operations were performed under a red light source in a dark room.

[0347] 1 ml of a peptide-bound fluorescent substance solution dissolved in PBS at a concentration of 0.2 mg / mL (a mixed aqueous solution of ovalbumin: fluorescein isothiocyanate = 1:1 (equimolar)) and 1 ml of a solution in which mir-125a siRNA duplex, which is a protein that inhibits luciferase activity in cells as a nucleic acid, was diluted to a concentration of 200 nM with PBS (hereinafter referred to as siRNA solution). Next, the film was pulverized with a stirrer, then ultrasonically treated, and further adjusted to nanocapsules using a filter with a pore size of 400 nm. The cell delivery vector was purified using PD-10 column gel filtration and stored in a light-shielded bottle.

[0348] Sample B-1) Temperature-responsive liquid crystal lamellar cell delivery carrier containing vitamins that is not a vitamin derivative (control 1) 1g of phosphatidylcholine from egg yolk, 0.8g of dioleoylphosphatidylethanolamine, 1g of DOPEMP (FMA / SpMA) Copo, 0.05g of cholesterol, 0.1g of PEG-25 plant stanol and 0.035g of caprylic acid were dissolved in chloroform, and the solvent was removed by an evaporator to form a lamellar liquid crystal structure film. It was irradiated with ultraviolet light (352nm) for 3 minutes and shielded from light. The following operations were performed under a red light source in a dark room. 1mL of peptide-bound fluorescent substance solution (same as sample A-1), 0.043g of ascorbic acid, 0.022g of glycerol and 1mL of siRNA solution were mixed therein. Next, the film was crushed with a high-speed stirrer, then ultrasonically treated, and further adjusted to nanocapsules with a filter with a pore size of 400nm. The vector for cell delivery was purified using PD-10 column gel filtration and stored in a light-proof bottle.

[0349] Sample C-1) Non-liquid crystal lamellar cell delivery carrier containing vitamin derivatives (control 2) 1 mL of peptide-bound fluorescent substance solution (same as sample A-1) and 1 mL of siRNA solution were mixed with 1 g of phosphatidylcholine from egg yolk, 0.8 g of dioleoylphosphatidylethanolamine, 1 g of DOPEMP (FMA / SpMA) Copo, 0.05 g of cholesterol, 0.1 g of PEG-25 plant stanol and 0.1 g of GOVC. It was irradiated with ultraviolet light (352 nm) for 3 minutes and shielded from light. The following operations were performed under a red light source in a dark room. It was crushed and stirred using a high-speed stirrer without going through the formation process of the liquid crystal layer structure film, and then ultrasonically treated, and further, passed through a filter with a pore size of 400 nm and stored in a light-shielding bottle.

[0350] Sample D-1) Control of non-liquid crystal lamellar cell delivery carrier without vitamin derivatives 1 mL of peptide-bound fluorescent substance solution (same as sample A-1) and 1 mL of siRNA solution were mixed with 1 g of phosphatidylcholine from egg yolk, 0.8 g of dioleoylphosphatidylethanolamine, 1 g of DOPEMP (FMA / SpMA) Copo, 0.05 g of cholesterol, and 0.1 g of PEG-25 plant stanol. It was irradiated with ultraviolet light (352 nm) for 3 minutes and shielded from light. The following operations were performed under a red light source in a dark room. It was crushed and stirred using a high-speed stirrer without going through the formation process of the liquid crystal layer structure film, and then ultrasonically treated, and further, passed through a filter with a pore size of 400 nm and stored in a light-shielding bottle.

[0351] (Measurement of particle size of cell delivery carrier) Each sample A-3, B-3, C-3, and D-3 was stored at room temperature for one week, and the particle size of the prepared cell delivery carrier was measured using a particle size measuring device (ZETASIZER Nano-ZS). Then, the average particle size of A-1 obtained a sharp single peak of 314nm (range 120 to 450nm), and the average particle size of control B-1 obtained a sharp single peak of 198nm (range 110 to 298nm). C-3 and D-3 separated over time, and no stable cell delivery carrier was obtained. Irradiation with ultraviolet light (352nm) or visible light (530nm) for 3 minutes.

[0352] (Cellular uptake experiment) Using a 6-well plate, 125 μl of the above-prepared A-3 of the present invention, and the following control B-3, C-3, and D-3 composition solutions were taken and fixed to 1 ml with FBS medium. The medium of HeLa cells (cervical cancer cells) cultured at a concentration of 5.0×10000 cells / ml was replaced with the above-fixed dispersion, incubated at 37°C for 6 hours in a dark environment, irradiated with visible light (530 nm) for 30 minutes, and then incubated for 42 hours. After incubation, the culture medium was removed from each, diluted five times with PBS, Picagene cell lysis agent Lcβ (Toyo Ink) was added at 250μl / well and incubated for 30 minutes, and then the obtained solution was frozen at -80°C, and the solution was thawed in a bath at 37°C, centrifuged at 12000rpm for 5 minutes, and 50μl of Picagene solution was added to 10μl of the obtained supernatant for luminescence measurement, and the intracellular luciferase activity was measured, so as to obtain the inclusion rate of nucleic acid (siRNA) using the following calculation formula. The mir-125a of the siRNA used in this experiment inhibits luciferase activity after being taken up by cells, so this means that the smaller the luminescence of luciferase, the more siRNA is taken up by cells, and protein synthesis is promoted, inhibiting luciferase activity.

[0353] Nucleic acid (siRNA) inclusion rate = luciferase luminescence: C (counts per second) / protein amount: P (protein abundance). In addition, 10 μl of the culture medium of cervical cancer cells in which siRNA was not delivered into the cells was taken, and a BCA (bicinchoninic acid method) detection kit was used to prepare a calibration curve with BCA standards for protein quantification. The above C / P value was set to 100% (control), and the RNA inclusion rate of the above example was expressed as a percentage by luciferase activity. As a result, A-1 of the present invention was 36%, the following control B-1 was 72%, C-1 was 88%, and D-1 was 85%. A-1 in the present invention showed a decrease in the highest luciferase activity (inclusion rate).

[0354] (Determination of the inclusion rate of fluorescent dye) The above-prepared A-1 of the present invention and the following control B-1, C-1, and D-1 composition solutions were stored at a temperature and pressure of 40°C and in a light-proof environment for two weeks, and then the stability of the fluorescence characteristics of each composition was studied. That is, it was diluted 20 times with PBS, and its fluorescence intensity was measured with a fluorescence photometer to determine the fluorescence intensity when the peptide-bound fluorescent substance was included. In addition, after adding 1% Triton10X to completely disintegrate the cell delivery carrier, only the part of the peptide-bound fluorescent substance was separated by gel filtration, and the fluorescence intensity of this part was used as the fluorescence intensity after heat stress. Then, the value of the fluorescence intensity when included was subtracted from the value of the fluorescence intensity when Triton was added, and the difference was calculated. In addition, in order to make a relative comparison, the inclusion rate of the control was calculated with the calculated value of A-1 as 100%. As a result, the inclusion rate of A-1 of the present invention was 100%, the inclusion rate of the following controls B-1 was 63%, the inclusion rate of C-1 was 11%, and the inclusion rate of D-1 was 15%. It can be confirmed that the inclusion rate of A-1 after heat stress is superior as a liquid crystal lamellar cell delivery carrier containing amphiphilic antioxidant vitamins of the present invention.

[0355] (Comparison of skin tissue permeability) Using LabCyte EPI-MODEL as an epidermal skin model, the artificial skin was sandwiched between Franz Cells and incubated at 37°C. 1 mL of the above-prepared A-1 of the present invention containing the prepared peptide-bound fluorescent substance, as well as the following control B-1, C-1, and D-1 composition solutions were administered to the donor chamber, incubated at 37°C for 6 hours under light shielding, irradiated with visible light (530 nm) for 30 minutes, and then incubated for 42 hours. Then, 10 μL of 10% TritonX was added to the sample sample at the 150 μL sampling port and the peptide-bound fluorescent substance-containing emulsified composition to prepare a sample solution. 100 μL of the sample solution was taken and the fluorescence intensity was measured using a fluorescence photometer infiniteM1000, and the skin permeability was calculated according to the following formula. As a result, the skin permeability of A-1 of the present invention was 25%, while that of the following controls B-1 was 15%, C-1 was 3%, and D-1 was 2%. This confirms the superiority of the skin permeability of A-1 as a liquid crystal lamellar cell delivery carrier containing amphiphilic antioxidant vitamins of the present invention.

[0356] PermeationRate(%)=(Fr / Fd)x100.

[0357] (Fr: Fluourcenceofsamplefromreceptor, Fd: Fluorescenceofdonor)

[0358] (Skin irritation test) An in vitro skin irritation test was performed on cultured cells according to the OECD guidelines. OECD GUIDELINES FOR THE TESTING OF CHEMICALS, 439. (2015) was used as a guide. Using LabCyteEPI-MODEL as a normal skin epidermis model, a skin irritation test was performed and scored. The results (the lower the score, the greater the toxicity and the lower the safety) were: 5% SLS (positive control) was 3 points, water (negative control) was 100 points, A-1 of the present invention was 111 points, B-1 was 98 points, C-1 was 87 points, and D-1 was 79 points. The viable cell rates of all preparations were above 50%, which denied skin irritation. Among them, A-1 of the present invention had the highest score, suggesting that it is highly safe. As a result of the test, no skin irritation of the test substance was observed in the normal skin model.

[0359] The present composition is an external composition for chemical products, industrial products, civil engineering greening products, fertilizers, coatings, cleaning agents, agricultural and forestry products, gardening materials, granules, powders, sundries, clothing, oral compositions, foods, culture compositions, veterinary drugs, photosensitive materials, water treatment agents, air purifiers, pharmaceuticals, quasi-drugs, unapproved drugs, and cosmetics. Furthermore, the present composition is also effective as an antioxidant for chemical products, industrial products, civil engineering greening products, fertilizers, coatings, cleaning agents, agricultural and forestry products, gardening materials, granules, powders, sundries, clothing, oral compositions, foods, culture compositions, veterinary drugs, photosensitive materials, water treatment agents, and air purifiers, compared with conventional ASA, ASA magnesium phosphate, and conventional A2AT and A3AT.

[0360] The present composition is an embodiment of the following: chemical products, industrial products, civil engineering greening products, fertilizers, coatings, detergents, agricultural and forestry products, gardening materials, granules, powders, groceries, clothing, oral compositions, foods, culture compositions, veterinary drugs, photosensitive materials, water treatment agents, and air purifiers. Furthermore, it can also be an embodiment of a composition for external use of a drug, a quasi-drug, or an unapproved drug.

[0361] (Preparation formula) The preparation of the present invention is prepared according to the following formula. The water-soluble preparation can be used as a liquid cosmetic, a liquid quasi-drug, a liquid drug, a liquid food, a liquid supplement, and a liquid feed additive. More specifically, it can be used as a base for the following forms of external preparations. That is, the external preparations in which the present formulation can be used are in the following forms: shampoo, conditioner, treatment agent, hair mask, hair spray, hair spray, lotion, toner, essence, hair tonic, facial cleanser, makeup remover, lotion, moisturizing lotion, lotion, nourishing lotion, skin moisturizing lotion, moisturizing lotion, massage lotion, cleansing lotion, sunscreen, sunscreen cream, sunscreen milk, cosmetic lotion, cuticle cream, elbow lotion, hand lotion, body lotion, liquid soap, beauty ointment, facial mask, moisturizing essence, whitening essence, anti-ultraviolet essence, basic skin care products, makeup agents, skin perfume, fragrance, perfume, eau de parfum, eau de toilette, cologne, fumigated perfume, deodorant wash, deodorant powder, deodorant spray, deodorant cosmetics, bath agents, and moisturizers.

[0362] (Preparation of the Cell Delivery Carrier of the Present Invention) 2% of lecithin, 50% of glycerol, 8% of behenyl alcohol, 7% of stearyl alcohol, 4% of PEG-20 phytosterol, 3% of cetyl alcohol, 1% of phytosterol, 1% of stearyl glyceryl, 2% of tri(caprylic acid / capric acid)glyceryl, 1% of GOVC (2-glyceryl-3-octyl ascorbic acid), 0.3% of cholesterol, 0.2% of DOPEMP (NIPAA / DMAPAA) Cop, and 10% of squalane were added and stirred with a self-rotating revolution stirrer. Pure water was added thereto to 100%, and dispersed by vortexing. After that, the emulsified particles were ultrasonically treated for 30 minutes in an ultrasonic bath to reduce the size of the emulsified particles, and then passed through a 100 nm filter to adjust the size of the liposomes. The average particle size was 75 nm, and a lamellar liquid crystal structure was observed by electron microscopy. After that, the liposomes were separated and purified by gel filtration to prepare the cell delivery carrier of the present invention. The cell delivery carrier of the present invention with temperature stimulus responsiveness was prepared. Hereinafter referred to as S-GOVC-DDS.

[0363] The total amount of lipids was 20 mg, and vitamin derivatives, namely VCIP (ascorbic acid-2,3,5,6-tetraisopalmitate) and DOTAP (1,2-dioleoyl-3-trimethylammonium propane): liquid crystal layer forming surfactant, namely DOPE: DOPEMP (NIPAA / DMAPAA) Cop, were dissolved in chloroform in a molar ratio of 1:2:7. In addition, the molar ratio of the liquid crystal layer forming surfactant DOPE dissolved in chloroform and the liquid crystal layer forming surfactant, namely DOPEMP (NIPAA / DMAPAA) Cop bound to the temperature-responsive polymer shown in formula (5) was set to 6.5:0.5. The solution was transferred to an eggplant-shaped flask, and the solvent was removed by an evaporator to prepare a lipid film. 1 ml of pure water was added to the lipid film to hydrate the lipid film, and then dispersed by vortexing. Thereafter, the size of the liposomes was reduced by ultrasonic treatment in an ultrasonic bath for 30 minutes, and the liposomes were passed through a 100 nm filter by an extruder to adjust the size of the liposomes. The average particle size was 75 nm, and a lamellar liquid crystal structure was observed by electron microscopy. Afterwards, the liposomes were separated and purified by gel filtration to prepare the cell delivery carrier of the present invention. The cell delivery carrier with temperature stimulus responsiveness of the present invention was prepared. Hereinafter referred to as S-VCIP-DDS.

[0364] The following formulations were prepared using the above-prepared cell delivery carriers containing the temperature stimulus responsive polymer of the present invention, namely S-GOVC and S-VCIP-OVC-DDS, the pH-GOVC-Chito of the present invention containing the pH stimulus responsive polymer shown in the examples, and the DOPEMP (FMA / SpMA)) Copo of the present invention containing the light stimulus responsive polymer shown in the examples. The units of the following formulations are all expressed in weight %. In the following formulations, the mixture obtained by mixing S-GOVC-DDS and S-VCIP-DDS at the same mass of 50%:50% is recorded as S-GOVC-DDS / S-VCIP-DDS. Furthermore, a mixture of S-GOVC-DDS, S-VCIP-DDS, pH-GOVC-Chito and DOPEMP (FMA / SpMA) Copo at the same mass of 25%:25%:25%:25% was recorded as S-GOVC-DDS / S-VCIP-DDS / pH-GOVC-Chito / DOPEMP (FMA / SpMA) Copo.

[0365] (Liquid formulation)

[0366] (1) S-GOVC-DDS / S-VCIP-DDS: 0.5, (2) Glycerin: 6.5, (3) 1,3-Butanediol: 1.0, (4) Phenoxyethanol: 0.5, (5) Fragrance complex: 0.1, (6) Essential oil complex: 0.1, (6) Pure water: the rest (adjust the pH to 7 with (7) citric acid 1.0 and (8) NaOH).

[0367] (Lotion formula)

[0368] (1) Polyoxyethylene (10 E.O.) sorbitan monostearate 1.0: 0.5, (2) Polyoxyethylene (60 E.O.) sorbitan tetraoleate 0.5: 0.5, (3) Glyceryl monostearate: 1.0, (4) F3: 0.1, (5) Behenyl alcohol: 0.5, (6) Squalane: 8.0, (7) Beech bud extract 1: 2.0, (8) Grape extract 2: 2.0, (9) Lithospermum officinale leaf extract 3: 2.0, (1 0) Dipotassium glycyrrhizinate 4: 0.02, (11) S-GOVC-DDS / S-VCIP-DDS: 1.0, (12) Carboxyvinyl polymer: 0.1, (13) Sodium hydroxide: 0.05, (14) Ethanol: 5.0, (15) Pure water: balance, (16) Preservative: appropriate amount, (17) Flavor: appropriate amount (Adjust pH to 7±1 with 1% citric acid and NaOH. The total amount of transition metals in the above emulsion is less than 100 ppm).

[0369] (Ointment formula)

[0370] (1) Stearic acid: 18.0, (2) Cetyl alcohol: 4.0, (3) Triethanolamine: 2.0, (4) F5: 1.0, (5) Urtica dioica extract 1: 0.05, (6) Hawthorn extract 2: 0.05, (7) Bodhi tree extract 3: 0.05, (8) N,N′-diacetylcystine dimethyl ester 4: 0.01, (9) Tranexamic acid 5: 0.2, (10) Purified water: the balance (adjust the pH to 7±1 with 1% citric acid and NaOH. The total amount of transition metals in the above ointment is less than 100 ppm). 1 Maruzen Pharmaceutical 2 Maruzen Pharmaceutical 3 Maruzen Pharmaceutical 4 Merck 5 Merck

[0371] (Gel formula)

[0372] (1) Carboxyvinyl polymer 1: 1.0, (2) triethanolamine: 1.0, (3) 1,3-butanediol: 10.0, (4) F6: 0.5, (5) aloe extract 2: 0.5, (6) allantoin 3: 1.0, (7) S-GOVC-DDS / S-VCIP-DDS: 2.0, (8) 2-hydroxy-4-methoxybenzophenone-5-sodium sulfate 5: 3.0, (9) pure water: the balance (adjust the pH to 7±1 with 1% citric acid and NaOH. The total amount of transition metals in the above gel ointment is less than 100 ppm).

[0373] (Ointment formula)

[0374] (1) Polyoxyethylene (40 E.O.) monostearate: 2.0, (2) Glyceryl monostearate (self-emulsifying type) 1: 5.0, (3) Stearic acid: 5.0, (4) Behenyl alcohol: 0.5, (5) Squalane: 15.0, (6) Cetyl ethylhexanoate: 5.0, (7) 1,3-Butanediol: 5.0, (8) F7: 1.0, (9) Birch extract 2: 0.1, (10) Saxifraga extract 3: 0.2, ( 11) S-GOVC-DDS / S-VCIP-DDS: 1.0, (12) 2-ethylhexyl p-methoxycinnamate 5: 5.0, (13) riboflavin 6: 0.05, (14) cysteine ​​7: 0.1, (15) pure water: balance, (16) preservative: appropriate amount, (17) flavoring: appropriate amount (adjust the pH to 7±1 with 1% citric acid and NaOH. The total amount of transition metals in the above ointment is less than 100 pp).

[0375] (Powder formula)

[0376] (1) Lanolin: 7.0, (2) Liquid paraffin: 5.0, (3) Stearic acid: 2.0, (4) Cetyl alcohol: 1.0, (5) Sunflower oil: 1: 1.0, (6) Glycerin: 5.0, (7) Triethanolamine: 1.0, (8) Carboxymethyl cellulose: 0.7, (9) Pure water: the balance, (10) Mica: 15.0, (11) Talc: 6.0, (12) Titanium oxide: 3.0, (13) Color pigment: 6.0, (14) F5: 0.5, (15) Potentilla officinalis extract 3: 0.5, (16) S-GOVC-DDS / S-VCIP-DDS: 0.2, (17) Glycyrrhetinic acid octadecyl ester 5: 0.1, (18) Preservative: 0.5, (19) Flavor: appropriate amount (adjust pH to 7±1 with 1% citric acid and NaOH. The total amount of transition metals is less than 100 ppm).

[0377] (UV Care Formula)

[0378] (1) Stearic acid: 2.0, (2) Cetyl alcohol: 1.0, (3) Polyoxyethylene sorbitan monooleate (20EO): 0.5, (4) Sorbitan sesquioleate: 0.5, (5) Cetyl 2-ethylhexanoate: 12.0, (6) Shea butter 1: 2.0, (7) Sesame oil 2: 1.0, (8) Scutellaria baicalensis extract 3: 0.1, (9) F3: 0.5, (10) Ergocalciferol 5: 0.1, (11) S-GOVC-DDS / S-VCIP-DDS: 3.0, (12) 2-Ethylhexyl p-methoxycinnamate 7: 8.0, (13) 2-Hydroxy-4-methoxybenzophenone 8: 2.0, (14) 1,3-Butanediol: 10.0, (15) Carboxyvinyl polymer: 0.2, (16) Pure water: balance, (17) Preservative: appropriate amount, (18) Titanium oxide: 3.0, (19) Triethanolamine: 0.5, (20) Fragrance: appropriate amount (Adjust the pH to 7±1 with 1% citric acid and NaOH. The total amount of transition metals in the above sunscreen lotion is less than 100 ppm).

[0379] (Beauty ointment formula)

[0380] (1) Polyvinyl alcohol: 20.0, (2) Ethanol: 20.0, (3) Glycerin: 5.0, (4) Kaolin: 6.0, (5) S-GOVC-DDS / S-VCIP-DDS: 0.5, (6) F2: 0.5, (7) Lily extract 3: 0.05, (8) Resorcinol 4: 0.02, (9) Riboflavin 5: 0.1, (10) Tranexamic acid 6: 0.5, (11) Preservative: 0.2, (12) Flavor: 0.1, (13) Pure water: the balance (adjust the pH to 7±1 with 1% citric acid and NaOH. The total amount of transition metals in the above-mentioned cosmetic ointment is less than 100 ppm).

[0381] (Detergent formula)

[0382] (1) Stearic acid: 10.0, (2) Palmitic acid: 8.0, (3) Myristic acid: 12.0, (4) Lauric acid: 4.0, (5) Oleyl alcohol: 1.5, (6) Refined lanolin: 1.0, (7) Astaxanthin 1: 0.005, (8) Flavor: 0.1, (9) Preservative: 0.2, (10) Glycerin: 18.0, (11) Potassium hydroxide: 6.0, (12) S-GOVC-DDS / S-VCIP-DDS: 0.5, (13) Soapwort extract: 0.5, (14) Dipotassium glycyrrhizate 4: 0.2, (15) L-Ascorbyl palmitate 5: 0.05, (16) Pure water: the balance (adjust the pH to 7±1 with 1% citric acid and NaOH. The total amount of transition metals in the above detergent is less than 100 ppm).

[0383] (Oral Composition)

[0384] 92.7% by mass of animal fat with a melting point of 28±3°C consisting of 50% by mass of chicken fat and 50% by mass of lard, 0.9% by mass of enzyme, 1.0% by mass of vitamin premix with 1% S-GOVC-DDS / S-VCIP-DDS added, 0.9% by mass of powdered probiotics and 4.5% by mass of spices were stirred and dispersed in a 200L stirring mixer manufactured by Meiji Machinery Co., Ltd. for 2 hours to obtain an oral composition of the present invention rich in the vitamin C source of the present invention, which is composed of powder particles with an average particle size of 0.51 mm in the particle size distribution. The oral composition of the present invention is the following embodiments: feed, feed additive, veterinary drug, food, food additive, functional food, oral veterinary drug.

[0385] (tablet)

[0386] The following ingredients were uniformly mixed and tableted according to the following composition ratios in a conventional manner to prepare tablets of 400 mg each: reduced maltose syrup: 17%, agar: 12%, silicon dioxide: 1%, sucrose fatty acid ester: 3%, lyophilized powder of S-GOVC-DDS / S-VCIP-DDS: 1%, powdered cellulose: the balance.

[0387] (Capsules)

[0388] 300 mg of components consisting of 5% freeze-dried powder of S-GOVC-DDS / S-VCIP-DDS and 95% medium-chain fatty acid triglycerides are mixed and filled into 100 mg soft capsule skin (70% gelatin and 25% glycerol) by conventional methods to obtain soft capsules of 440 mg each.

[0389] (Healthy Drinks)

[0390] The following ingredients were mixed and water was added to 10 L according to the conventional method to prepare a healthy drink: S-GOVC-DDS / S-VCIP-DDS: 80 g, royal jelly: 1 g, liquid sugar: 1000 g, DL-sodium tartrate: 1 g, citric acid: 10 g, cyclodextrin: 25 g, potassium chloride: 2 g, magnesium sulfate: 1 g.

[0391] (Liquid formulation)

[0392] (1) S-GOVC-DDS / S-VCIP-DDS / PH-GOVC-CHITO / DOPEMP (FMA / SPMA) COPO: 0.5, (2) glycerol: 6.5, (3) 1,3-butylene glycol: 1.0, (4) phenoxyethanol: 0.5, (5) fragrance complex: 0.1, (6) essential oil complex: 0.1, (6) pure water: the rest (adjust the pH to 7 with (7) citric acid 1.0 and (8) NaOH).

[0393] (Lotion formula)

[0394] (1) Polyoxyethylene (10 E.O.) sorbitol 1.0 monostearate: 0.5, (2) Polyoxyethylene (60 E.O.) sorbitan ester 0.5 tetraoleate: 0.5, (3) Glyceryl monostearate: 1.0, (4) F3: 0.1, (5) Behenyl alcohol: 0.5, (6) Squalane: 8.0, (7) Beech bud extract 1: 2.0, (8) Grape extract 2: 2.0, (9) Lithospermum leaf extract 3: 2.0, (10) Dipotassium glycyrrhizate 4: 0.02, (11) S-GOVC-DDS / S-VCIP-DDS / PH-GOVC-CHITO / DOPEMP(FMA / SPMA)COPO: 1.0, (12) carboxyvinyl polymer: 0.1, (13) sodium hydroxide: 0.05, (14) ethanol: 5.0, (15) pure water: balance, (16) preservative: appropriate amount, (17) flavor: appropriate amount (adjust the pH to 7±1 with 1% citric acid and NaOH. The total amount of transition metals in the above emulsion is less than 100 ppm).

[0395] (Ointment formula)

[0396] (1) Stearic acid: 18.0, (2) Cetyl alcohol: 4.0, (3) Triethanolamine: 2.0, (4) F5: 1.0, (5) Urtica dioica extract 1: 0.05, (6) Hawthorn extract 2: 0.05, (7) Bodhi tree extract 3: 0.05, (8) N,N′-diacetylcystine dimethyl ester 4: 0.01, (9) Tranexamic acid 5: 0.2, (10) Purified water: the balance (adjust the pH to 7±1 with 1% citric acid and NaOH. The total amount of transition metals in the above ointment is less than 100 ppm). 1 Maruzen Pharmaceutical 2 Maruzen Pharmaceutical 3 Maruzen Pharmaceutical 4 Merck 5 Merck

[0397] (Gel formula)

[0398] (1) Carboxyvinyl polymer 1: 1.0, (2) triethanolamine: 1.0, (3) 1,3-butanediol: 10.0, (4) F6: 0.5, (5) aloe extract 2: 0.5, (6) allantoin 3: 1.0, (7) S-GOVC-DDS / S-VCIP-DDS / PH-GOVC-CHITO / DOPEMP (FMA / SPMA) COPO: 2.0, (8) 2-hydroxy-4-methoxybenzophenone-5-sodium sulfate 5: 3.0, (9) pure water: balance (adjust pH to 7±1 with 1% citric acid and NaOH. The total amount of transition metals in the above gel ointment is less than 100 ppm).

[0399] (Ointment formula)

[0400] (1) Polyoxyethylene (40 E.O.) monostearate: 2.0, (2) Glyceryl monostearate (self-emulsifying type) 1: 5.0, (3) Stearic acid: 5.0, (4) Behenyl alcohol: 0.5, (5) Squalane: 15.0, (6) Cetyl ethylhexanoate: 5.0, (7) 1,3-Butanediol: 5.0, (8) F7: 1.0, (9) Birch extract 2: 0.1, (10) Saxifraga extract 3: 0.2, (11) S-GOVC-DDS / S-VC IP-DDS / PH-GOVC-CHITO / DOPEMP (FMA / SPMA) COPO: 1.0, (12) 2-ethylhexyl p-methoxycinnamate 5: 5.0, (13) riboflavin 6: 0.05, (14) cysteine ​​7: 0.1, (15) pure water: balance, (16) preservative: appropriate amount, (17) flavoring: appropriate amount (adjust the pH to 7±1 with 1% citric acid and NaOH. The total amount of transition metals in the above ointment is less than 100 pp).

[0401] (Wet powder formula)

[0402] (1) Lanolin: 7.0, (2) Liquid paraffin: 5.0, (3) Stearic acid: 2.0, (4) Cetyl alcohol: 1.0, (5) Sunflower oil 1: 1.0, (6) Glycerin: 5.0, (7) Triethanolamine: 1.0, (8) Carboxymethyl cellulose: 0.7, (9) Pure water: Balance, (10) Mica: 15.0, (11) Talc: 6.0, (12) Titanium oxide: 3.0, (13) Coloring pigment: 6.0, (14) F5: 0.5 , (15) Potentilla officinalis extract 3: 0.5, (16) S-GOVC-DDS / S-VCIP-DDS / PH-GOVC-CHITO / DOPEMP (FMA / SPMA) COPO: 0.2, (17) Glycyrrhetinic acid octadecyl ester 5: 0.1, (18) Preservatives: 0.5, (19) Flavor: appropriate amount (adjust pH to 7±1 with 1% citric acid and NaOH. The total amount of transition metals is less than 100 ppm).

[0403] (Sunscreen formula)

[0404] (1) Stearic acid: 2.0, (2) Cetyl alcohol: 1.0, (3) Polyoxyethylene sorbitan monooleate (20EO): 0.5, (4) Sorbitan sesquioleate: 0.5, (5) Cetyl 2-ethylhexanoate: 12.0, (6) Shea butter 1: 2.0, (7) Sesame oil 2: 1.0, (8) Scutellaria baicalensis extract 3: 0.1, (9) F3: 0.5, (10) Scutellaria baicalensis extract 5: 0.1, (11) S-GOVC-DDS / S-VCIP-DDS / PH-GOVC-CHITO / DOPEMP( FMA / SPMA) COPO: 3.0, (12) 2-ethylhexyl p-methoxycinnamate 7: 8.0, (13) 2-hydroxy-4-methoxybenzophenone 8: 2.0, (14) 1,3-butanediol: 10.0, (15) carboxyvinyl polymer: 0.2, (16) pure water: balance, (17) preservative: appropriate amount, (18) titanium oxide: 3.0, (19) triethanolamine: 0.5, (20) fragrance: appropriate amount (adjust the pH to 7±1 with 1% citric acid and NaOH. The total amount of transition metals in the above sunscreen lotion is less than 100 ppm).

[0405] (Beauty ointment formula)

[0406] (1) Polyvinyl alcohol: 20.0, (2) Ethanol: 20.0, (3) Glycerin: 5.0, (4) Kaolin: 6.0, (5) S-GOVC-DDS / S-VCIP-DDS / PH-GOVC-CHITO / DOPEMP (FMA / SPMA) COPO: 0.5, (6) F2: 0.5, (7) Lily extract 3: 0.05, (8) Resorcinol 4: 0.02, (9) Riboflavin 5: 0.1, (10) Tranexamic acid 6: 0.5, (11) Preservative: 0.2, (12) Flavor: 0.1, (13) Pure water: the balance (the pH is adjusted to 7±1 with 1% citric acid and NaOH. The total amount of transition metals in the above-mentioned cosmetic ointment is 100 ppm or less).

[0407] (Detergent formula)

[0408] (1) Stearic acid: 10.0, (2) Palmitic acid: 8.0, (3) Myristic acid: 12.0, (4) Lauric acid: 4.0, (5) Oleyl alcohol: 1.5, (6) Refined lanolin: 1.0, (7) Astaxanthin 1: 0.005, (8) Flavor: 0.1, (9) Preservative: 0.2, (10) Glycerin: 18.0, (11) Potassium hydroxide: 6.0, (12) S-GOVC-DDS / S-VCI P-DDS / PH-GOVC-CHITO / DOPEMP (FMA / SPMA) COPO: 0.5, (13) Soapwort extract 3: 0.5, (14) Dipotassium glycyrrhizinate 4: 0.2, (15) L-ascorbyl palmitate 5: 0.05, (16) Pure water: the balance (adjust the pH to 7±1 with 1% citric acid and NaOH. The total amount of transition metals in the above detergents is less than 100 ppm).

[0409] (Oral Composition)

[0410] 92.7% of animal fat with a melting point of 28±3°C consisting of 50% chicken fat and 50% lard, 0.9% enzyme, 1.0% vitamin premix with 1% S-GOVC-DDS / S-VCIP-DDS / PH-GOVC-CHITO / DOPEMP (FMA / SPMA) COPO added, 0.9% powdered probiotics and 4.5% flavorings were stirred and dispersed in a 200L stirring mixer manufactured by Meiji Machinery Co., Ltd. for 2 hours to obtain an oral composition of the present invention rich in the vitamin C source of the present invention, the oral composition consisting of powder particles with an average particle size of 0.51 mm in the particle size distribution. The oral composition of the present invention is the following embodiments: feed, feed additive, veterinary drug, food, food additive, functional food and oral veterinary drug.

[0411] (tablet)

[0412] The following ingredients were uniformly mixed and tableted according to the following composition ratios in a conventional manner to prepare tablets of 400 mg each: reduced maltose syrup: 17%, agar: 12%, silicon dioxide: 1%, sucrose fatty acid ester: 3%, lyophilized powder of S-GOVC-DDS / S-VCIP-DDS / PH-GOVC-CHITO / DOPEMP (FMA / SPMA) COPO: 1%, powdered cellulose: the balance

[0413] (Capsules)

[0414] 300 mg of a component consisting of 5% lyophilized powder of S-GOVC-DDS / S-VCIP-DDS / PH-GOVC-CHITO / DOPEMP (FMA / SPMA) COPO and 95% medium-chain fatty acid triglycerides were mixed and filled into a 100 mg soft capsule skin (70% gelatin and 25%) by conventional methods to obtain 440 mg soft capsules per capsule.

[0415] (Healthy Drinks)

[0416] The following ingredients were mixed and water was added to 10 L in a conventional manner to prepare a healthy drink: S-GOVC-DDS / S-VCIP-DDS / PH-GOVC-CHITO / DOPEMP (FMA / SPMA) COPO: 80 g, royal jelly: 1 g, liquid sugar: 1000 g, DL-sodium tartrate: 1 g, citric acid: 10 g, cyclodextrin: 25 g, potassium chloride: 2 g, magnesium sulfate: 1 g.

[0417] (Stability Test)

[0418] All the above-mentioned preparations of the present invention were subjected to a stability test at 40°C for 6 months. In the evaluation of the stability test, the color change, occurrence of precipitation, and generation of odor of the preparations were evaluated by the following scores, and the average score was calculated and compared. 10 men and women aged 20 to 50 were evaluated separately, and the average score was calculated. (Score) Color change: No change: 0 points, Change observed: 2 points, Drastic change observed: 3 points. Occurrence of precipitation: No occurrence 0 points, Precipitation observed: 2 points, Severe precipitation observed: 3 points. Odor generation: No occurrence 0 points, Occurrence observed: 2 points, Severe odor generation observed: 3 points. As a result, in the above-mentioned formulations of the present invention, no changes over time were observed in the color change, occurrence of precipitation, and generation of odor, and the score was 0 points, which proves the superior stability of the formulations of the present invention.

[0419] (Adjustment of the Cell Delivery Carrier of the Present Invention)

[0420] Each liquid crystal layer-forming lipid described in Table 4 was added 0.005 g and lecithin was added to make it 2 g at the end, and polyols, synthetic antioxidants, ultraviolet absorbers, preservatives and active ingredients of the present invention in Table 8 were added 0.005 g and glycerol was added to make it 50 g at the end, and further, 8 g behenyl alcohol, 7 g stearyl alcohol, 4 g PEG-20 phytosterol, 3 g cetyl alcohol, 1 g phytosterol, 1 g stearic acid glyceryl, 2 g tri (caprylic acid / capric acid) glyceride, 1 g GOVC (2-glyceryl-3-octyl ascorbic acid), 0.3 g cholesterol, 0.2 g DOPEMP (NIPAA / DMAPAA) Cop and each lipid described in Table 3 were added 0.005 g, and squalane was added to make it 30 g at the end, and stirred with a self-rotating revolution stirrer. Pure water was added thereto to 100 g, and dispersed by vortex. After that, the emulsified particles were ultrasonically treated in an ultrasonic bath for 30 minutes to reduce the size of the emulsified particles, and then passed through a 100 nm filter to adjust the size of the liposomes. The average particle size was 79 nm, and a lamellar liquid crystal structure was observed by electron microscopy. After that, the liposomes were separated and purified by gel filtration to prepare the cell delivery carrier of the present invention. The cell delivery carrier of the present invention with temperature stimulus responsiveness was prepared. Next, the cell delivery carrier was used to prepare a liquid. Its formula is as follows. That is, (1) the above-mentioned cell delivery carrier: 0.5, (2) glycerol: 6.5, (3) 1,3-butanediol: 1.0, (4) phenoxyethanol: 0.5, (5) fragrance complex: 0.1, (6) essential oil complex: 0.1, (6) pure water: the remainder (adjust the pH to 7 with (7) citric acid 1.0 and (8) NaOH).

[0421] The above-mentioned various formulation examples can be used as pharmaceuticals, quasi-drugs, cosmetics, supplements, veterinary drugs and sundries, and further, as dosage forms, can be used as external preparations, oral preparations, suppositories, oral preparations, health drinks, poultices, facial masks, sprays, injections, flavorings, liquids, ointments, aerosols, powders, compressed preparations, pastes, external sprays, powders, granules, tablets, soft capsules, pills, plate-shaped dosage forms, lozenges, pastes, solid preparations, wetting agents, and adhesives. Furthermore, it can be confirmed that these preparations have the effects of the above-mentioned Table 9 as cosmetics and quasi-drugs.

[0422] (Carriers for cell delivery in response to different temperatures)

[0423] The effects of two temperature-responsive liquid crystal lamellar cell delivery carriers containing amphiphilic antioxidant vitamins were compared using a body temperature-variable temperature-responsive cell delivery carrier of DOPEMP (NIPAA / DMAPAA) Cop with a lower critical solution temperature of 37 to 42°C (hereinafter referred to as the body temperature-variable type) and a high temperature-variable temperature-responsive cell delivery carrier of DOPEMP (NIPAA / DMAPAA) Cop with a lower critical solution temperature of 45-60°C (hereinafter referred to as the high temperature-variable type).

[0424] The preparation method of the carrier is the same, that is, 1 g of phosphatidylcholine derived from egg yolk, 0.8 g of dioleoylphosphatidylethanolamine, 3 g of DOPEMP (NIPAA / DMAPAA) Cop, 0.05 g of cholesterol, 0.1 g of PEG-25 phytostanol (INCI name: PEG-25Phytostanol) and 0.1 g of GOVC (an amphiphilic vitamin derivative in which 2-glyceryl-3-ascorbyl caprylate, glycerol: caprylic acid: a matrix composed of ascorbic acid ester is combined in a weight ratio of 0.223:0.35:0.427) are dissolved in 200 mL of chloroform, and the solvent is removed by an evaporator to form a layered liquid crystal structure film. 1 mL of a peptide-bound fluorescent substance solution dissolved in PBS at a concentration of 0.2 mg / mL (a mixed aqueous solution of ovalbumin: fluorescein isothiocyanate = 1:1 (equimolar)) and 1 mL of a solution in which mir-125a siRNA duplex, which is a protein that inhibits luciferase activity in cells and is biosynthesized as a nucleic acid in cells, was diluted to a concentration of 200 nM with PBS (hereinafter referred to as siRNA solution). Next, the film was pulverized with a stirrer, then ultrasonically treated, and further adjusted to nano-capsules using a filter with a pore size of 400 nm. The cell delivery carrier was purified using PD-10 column gel filtration. (Comparison of skin tissue permeability) Using LabCyteEPI-MODEL as an epidermal skin model, the artificial skin was sandwiched between Franz Cells and incubated at 37°C. 1 mL of the above-prepared composition solution containing 1% by weight of the body temperature change type and high temperature change type carriers of the present invention containing the prepared fluorescent substance was administered to the donor chamber, shielded from light, and incubated for 0.5 hours at 37°C for the body temperature model and at 45°C for the steam towel model, irradiated with visible light (530 nm) for 30 minutes, and then incubated for 42 hours. Then, 10 μL of 10% TritonX was added to the sample sample of the 150 μL sampling port and the peptide-bound fluorescent substance-containing emulsified composition to prepare a standard sample solution. 100 μL of the sample solution was taken and the fluorescence intensity was measured using a fluorescence photometer infiniteM1000, and the skin permeability was calculated according to the following formula. As a result, the fluorescence intensity of the body temperature-variable type incubated at 37°C was 8%, and that of the high temperature-variable type was 4%. At the body temperature model temperature of 37°C, the body temperature-variable type showed a fluorescence intensity twice that of the high temperature-variable type. On the other hand, the fluorescence intensity of the body temperature-variable type incubated at 45°C was 3%, and that of the high temperature-variable type was 9%. At the steam towel model temperature of 45°C, the high temperature-variable type showed a fluorescence intensity three times that of the body temperature-variable type. As a result, it was confirmed that in a high temperature environment such as using a steam towel, infrared, high frequency, low frequency, etc., the high temperature-variable type carrier at 45°C or above showed a higher drug transport ability than the human body-variable type carrier.

[0425] (Stability test of different vitamin derivatives)

[0426] The stability test of the cell delivery carrier of the present invention in different vitamin derivatives was conducted. The carrier was prepared as follows: 1 g of egg yolk-derived phosphatidylcholine, 0.8 g of dioleoylphosphatidylethanolamine, 3 g of DOPEMP (NIPAA / DMAPAA) Cop, 0.05 g of cholesterol, 0.1 g of PEG-25 phytostanol (INCI name: PEG-25Phytostanol) and 0.1 g of different vitamin derivatives were dissolved in 200 mL of chloroform, and then the solvent was removed by an evaporator to form a lamellar liquid crystal structure film. 1 mL of a peptide-bound fluorescent substance solution (a mixed aqueous solution of ovalbumin: fluorescein isothiocyanate = 1:1 (equimolar)) dissolved in PBS at a concentration of 0.2 mg / mL was mixed with 1 mL of a solution diluted with PBS (hereinafter referred to as a fluorescent solution). Next, the film was pulverized with a stirrer and then subjected to ultrasonic treatment. Further, it was adjusted to a nano-capsule with a filter having an aperture of 100 nm. The state of the capsule was observed with an ordinary optical microscope and a polarizing microscope to confirm that the carrier contained a fluorescent dye under the microscope and that maltase orthogonal polarization was present under the polarizing microscope. After it was stored for 6 months at 40°C and 80% humidity, the state of the carrier was observed with an ordinary optical microscope and a polarizing microscope. At this time, as vitamin derivatives that can be effectively used in the present invention, only vitamin derivatives that can be confirmed that the carrier is not destroyed, that the fluorescent dye is contained in the carrier under the microscope, and that the orthogonal polarization of maltase can be confirmed under the polarizing microscope are set as the ○ group. Vitamin derivatives that cannot be confirmed by either of the above are set as the X group.

[0427] (○ group of vitamin derivatives)

[0428] Table 2. Vitamin derivatives described.

[0429] (Vitamin derivatives of group X)

[0430] Disodium ascorbyl sulfate, dipotassium ascorbyl sulfate, sodium ascorbyl-2-phosphate, magnesium ascorbyl-2-phosphate, sodium ascorbyl-2-phospho-6-palmitate, ascorbyl stearate, disodium isostearyl ascorbyl phosphate, ascorbyl isostearate, ascorbyl palmitate, ascorbyl dipalmitate, trisodium ascorbyl isopalmitate phosphate, tocopheryl dimethylglycine, tocopheryl dimethylglycine hydrochloride

[0431] (Lipid stability test)

[0432] The stability test of the cell delivery carrier of the present invention in different lipids was conducted. The carrier was prepared as follows: 1 g of egg yolk-derived phosphatidylcholine, 0.8 g of dioleoylphosphatidylethanolamine, 3 g of DOPEMP (NIPAA / DMAPAA) Cop, 0.05 g of cholesterol, 0.1 g of PEG-25 phytostanol (INCI name: PEG-25 Phytostanol), 0.5 g of lipid and 0.1 g of GOVC (vitamin derivative, i.e., 2-glyceryl-3-ascorbyl caprylate) were dissolved in 200 mL of chloroform, and then the solvent was removed by an evaporator to form a lamellar liquid crystal structure film. 1 mL of a peptide-bound fluorescent substance solution (ovalbumin: fluorescein isothiocyanate = 1:1 (equimolar) mixed aqueous solution) dissolved in PBS at a concentration of 0.2 mg / mL was mixed with 1 mL of a solution diluted with PBS (hereinafter referred to as a fluorescent solution). Next, the film was pulverized with a stirrer and then subjected to ultrasonic treatment. Further, it was adjusted to a nano-capsule with a filter having a pore size of 100 nm. The state of the capsule was observed with an ordinary optical microscope and a polarizing microscope to confirm that the carrier contained a fluorescent dye under the microscope and that maltase orthogonal polarization was present under the polarizing microscope. After it was stored for 6 months at 40°C and 80% humidity, the state of the carrier was observed with an ordinary optical microscope and a polarizing microscope. At this time, as lipids that can be effectively used in the present invention, only lipids that can be confirmed that the carrier is not destroyed, that the carrier contains a fluorescent dye under the microscope, and that maltase orthogonal polarization is present under the polarizing microscope, and that the attenuation rate of the vitamin derivative is suppressed to less than 10%, and that the vitamin derivative can be kept stable are recorded in Table 3, and lipids that cannot be confirmed in the above two cases are excluded as lipids with safety problems.

[0433] (Stability test of lipids with surfactant effect)

[0434] The stability test of the cell delivery carrier of the present invention in lipids with different surface active effects was conducted. The carrier was prepared as follows: 1 g of egg yolk-derived phosphatidylcholine, 0.8 g of dioleoylphosphatidylethanolamine, 3 g of DOPEMP (NIPAA / DMAPAA) Cop, 0.05 g of cholesterol, 0.5 g of lipid with surface active effect, and 0.1 g of GOVC (vitamin derivative, i.e., 2-glyceryl-3-ascorbyl caprylate) were dissolved in 200 mL of chloroform, and then the solvent was removed by an evaporator to form a lamellar liquid crystal structure film. 1 mL of a peptide-bound fluorescent substance solution (a mixed aqueous solution of ovalbumin: fluorescein isothiocyanate = 1:1 (equimolar)) dissolved in PBS at a concentration of 0.2 mg / mL was mixed with 1 mL of a solution diluted with PBS (hereinafter referred to as a fluorescent solution). Next, the film was pulverized with a stirrer and then subjected to ultrasonic treatment. Further, it was adjusted to a nano-capsule with a filter having a pore size of 100 nm. The state of the capsule was observed with an ordinary optical microscope and a polarizing microscope to confirm that the carrier contained a fluorescent dye under the microscope and that maltase orthogonal polarization was present under the polarizing microscope. After it was stored at 40°C and 80% humidity for 6 months, the state of the carrier was observed with an ordinary optical microscope and a polarizing microscope. At this time, as a lipid with surface activity that can be effectively used in the present invention, it can be confirmed that the carrier is not destroyed, and the carrier contains a fluorescent dye under the microscope, and maltase orthogonal polarization is present under the polarizing microscope, as at the beginning of the test, and the attenuation rate of the vitamin derivative is suppressed to less than 10, and the lipids that can keep the vitamin derivative stable are recorded in Table 4, and lipids that cannot be confirmed in the above two cases are excluded as lipids with safety problems.

[0435] (Stability test of stimuli-responsive substances)

[0436] The stability test of the cell delivery carrier of the present invention in different stimulus response substances was conducted. The preparation method of the carrier is as follows: 1g of phosphatidylcholine derived from egg yolk, 0.8g of dioleoylphosphatidylethanolamine, 3g of different stimulus response substances, 0.05g of cholesterol and 0.1g of GOVC (vitamin derivative, i.e., 2-glyceryl-3-ascorbyl caprylate) are dissolved in 200mL of chloroform, and then the solvent is removed by an evaporator to form a layered liquid crystal structure film. 1mL of a peptide-bound fluorescent substance solution dissolved in PBS at a concentration of 0.2mg / mL (a mixed aqueous solution of ovalbumin: fluorescein isothiocyanate = 1:1 (equimolar)) and 1mL of a solution diluted with PBS (hereinafter referred to as a fluorescent solution) are mixed therein. Next, the film was crushed with a stirrer and then subjected to ultrasonic treatment. Further, it was adjusted to a nano-capsule with a filter having an aperture of 100 nm. The state of the capsule was observed with an ordinary optical microscope and a polarizing microscope to confirm that the carrier contained a fluorescent dye under the microscope and that maltase orthogonal polarization was present under the polarizing microscope. After it was stored for 6 months at 40°C and 80% humidity, the state of the carrier was observed with an ordinary optical microscope and a polarizing microscope. At this time, as a stimulus response substance that can be effectively used in the present invention, it can be confirmed that the carrier is not destroyed, and the carrier contains a fluorescent dye under the microscope, and maltase orthogonal polarization is present under the polarizing microscope, as at the beginning of the test, and the attenuation rate of the vitamin derivative is suppressed to less than 20%, and the substances that can keep the vitamin derivative stable are recorded in Table 5, and the substances that cannot be confirmed in the above two cases are excluded as substances with safety problems.

[0437] (Stability test of emulsion stabilizer)

[0438] The stability test of the cell delivery carrier of the present invention in an emulsion stabilizer selected from polyols, synthetic antioxidants, ultraviolet absorbers, and preservatives was conducted. The carrier was prepared as follows: 1 g of egg yolk-derived phosphatidylcholine, 0.8 g of dioleoylphosphatidylethanolamine, 3 g of DOPEMP (NIPAA / DMAPAA) Cop, 0.05 g of cholesterol, and 0.1 g of GOVC (vitamin derivative, i.e., 2-glyceryl-3-ascorbyl caprylate) were dissolved in 200 mL of chloroform, and then the solvent was removed by an evaporator to form a lamellar liquid crystal structure film. 0.5 g of an emulsion stabilizer selected from polyols, synthetic antioxidants, ultraviolet absorbers, and preservatives, 1 mL of a peptide-bound fluorescent substance solution (a mixed aqueous solution of ovalbumin:fluorescein isothiocyanate = 1:1 (equimolar)) dissolved in PBS was mixed therein, and 1 mL of a solution diluted with PBS (hereinafter referred to as a fluorescent solution) was diluted thereinto. Next, the film was pulverized with a stirrer and then subjected to ultrasonic treatment. Further, it was adjusted to nano-capsules with a filter having a pore size of 100 nm. The state of the capsules was observed with an ordinary optical microscope and a polarizing microscope, and it was confirmed that the carrier contained a fluorescent dye under the microscope and that maltase orthogonal polarization existed under the polarizing microscope. After it was stored for 6 months under an environment of 40°C and 80% humidity, the state of the carrier was observed with an ordinary optical microscope and a polarizing microscope. At this time, as an emulsion stabilizer that can be effectively used in the present invention, it can be confirmed that the carrier is not destroyed, and the carrier contains a fluorescent dye under the microscope as at the beginning of the test, and maltase orthogonal polarization exists under the polarizing microscope, and the attenuation rate of the vitamin derivative is suppressed to less than 10%. The emulsion stabilizers that can keep the vitamin derivative stable are recorded in Table 6, and the emulsion stabilizers that cannot be confirmed in the above two cases are excluded as emulsion stabilizers with problems in safety.

[0439] (Stability test of different modified chain substances in stimulus-responsive polymers)

[0440] The stability test of the cell delivery carrier of the present invention in different modified chain substances in the stimulus-responsive polymer was conducted. The preparation method of the carrier is as follows: 1g of phosphatidylcholine derived from egg yolk, 0.8g of dioleoylphosphatidylethanolamine, 3g of DOPEMP (NIPAA / DMAPAA / modified chain substance), 0.05g of cholesterol and 0.1g of GOVC (vitamin derivative, i.e., 2-glyceryl-3-ascorbyl caprylate) are dissolved in 200mL of chloroform, and then the solvent is removed by an evaporator to form a lamellar liquid crystal structure film. 1mL of a peptide-bound fluorescent substance solution dissolved in PBS at a concentration of 0.2mg / mL (a mixed aqueous solution of ovalbumin:fluorescein isothiocyanate = 1:1 (equimolar)) and 1mL of a solution diluted with PBS (hereinafter referred to as a fluorescent solution) are mixed therein. Next, the film was crushed with a stirrer and then subjected to ultrasonic treatment. Further, it was adjusted to a nano-capsule with a filter having an aperture of 100 nm. The state of the capsule was observed with an ordinary optical microscope and a polarizing microscope to confirm that the carrier contained a fluorescent dye under the microscope and that maltase orthogonal polarization existed under the polarizing microscope. After it was stored at 40°C and 80% humidity for 6 months, the state of the carrier was observed with an ordinary optical microscope and a polarizing microscope. At this time, as a modified chain substance that can be effectively used in the present invention, it can be confirmed that the carrier is not destroyed, and the carrier contains a fluorescent dye under the microscope, and maltase orthogonal polarization exists under the polarizing microscope, as at the beginning of the test, and the attenuation rate of the vitamin derivative is suppressed to less than 10%. The substances that can keep the vitamin derivative stable are recorded in Table 7, and the substances that cannot be confirmed in the above two cases are excluded as substances with safety problems.

[0441] (Including stability test of active ingredients)

[0442] The stability test of the cell delivery carrier of the present invention in different active ingredients was conducted. The carrier was prepared as follows: 1 g of egg yolk-derived phosphatidylcholine, 0.8 g of dioleoylphosphatidylethanolamine, 3 g of DOPEMP (NIPAA / DMAPAA) Cop, 0.05 g of cholesterol, and 0.1 g of GOVC (vitamin derivative, i.e., 2-glyceryl-3-ascorbyl octanoate) were dissolved in 200 mL of chloroform, and then the solvent was removed by an evaporator to form a lamellar liquid crystal structure film. 0.5 g of different active ingredients and 1 mL of a peptide-bound fluorescent substance solution (a mixed aqueous solution of ovalbumin: fluorescein isothiocyanate = 1:1 (equimolar)) dissolved in PBS were mixed in 1 mL of a solution diluted with PBS (hereinafter referred to as a fluorescent solution). Next, the film was pulverized with a stirrer and then subjected to ultrasonic treatment. Further, it was adjusted to a nano-capsule with a filter having an aperture of 100 nm. The state of the capsule was observed with an ordinary optical microscope and a polarizing microscope to confirm that the carrier contained a fluorescent dye under the microscope and that maltase orthogonal polarization existed under the polarizing microscope. After it was stored for 6 months under an environment of 40°C and 80% humidity, the state of the carrier was observed with an ordinary optical microscope and a polarizing microscope. At this time, as the effective ingredients effectively used in the present invention, it can be confirmed that the carrier is not destroyed, and the carrier contains a fluorescent dye under the microscope, and maltase orthogonal polarization exists under the polarizing microscope, as at the beginning of the test, and the attenuation rate of the vitamin derivative is suppressed to less than 10%, and the effective ingredients that can keep the vitamin derivative stable are recorded in Table 8, and the effective ingredients that cannot be confirmed in both of the above two cases are excluded as the effective ingredients with safety problems.

[0443] (Including stability test of active ingredients)

[0444] Dermatologists and plastic surgeons were asked to conduct effectiveness tests on the cell delivery carriers of the present invention prepared as described above and containing different active ingredients, and multiple effectiveness was confirmed. The specific effects are shown in Table 9.

[0445] Industrial Applicability

[0446] The use of the cell delivery carrier of the present invention can be applied to all biological cells, such as animal cells, plant cells, yeast, bacteria, fungi, slime molds, mycoplasmas, amoeba, etc., and can be used for all useful products selected from drugs, quasi-drugs, cosmetics, supplements, veterinary drugs, fertilizers, pesticides, culture fluids, groceries, etc., and can improve the efficiency of cell delivery. As a specific preparation, it can be applied to the following preparations: external preparations, oral preparations, suppositories, oral preparations, health drinks, mud compresses, facial masks, sprays, injections, flavorings, liquids, ointments, aerosols, powders, compressed preparations, pastes, external sprays, powders, granules, tablets, soft capsules, pills, plate-shaped dosage forms, lozenges, and pastes. BRIEF DESCRIPTION OF THE DRAWINGS

[0447] Figure 1 : is a diagram showing the effect of the cell delivery carrier of the present invention. Figure 1 In the figure, (5) represents the cell membrane, the upper side of (5) is outside the cell, and the lower side of (5) is inside the cell. (1) is a molecule containing a stimulus-responsive polymer that is bound to the cell delivery vector of the present invention. The active ingredient is represented by (2) and is contained in the cell delivery vector. There is a long tail structure in (1), which represents a stimulus-responsive polymer, which is bound to the membrane of the cell delivery vector through a lipid (ellipse) with surface activity that is bound to it. (3) is a substance that simultaneously activates autophagy-related genes and protease synthesis genes, for example, a vitamin derivative, which has amphipathic properties and is therefore also connected to the membrane of the cell delivery vector. A is a cell delivery vector that is bound to a vitamin receptor (represented by a square and a circle with a notch at the top) that passes through the cell membrane, namely (5). In this way, the vitamin derivative (3) binds to the vitamin receptor on the surface of the cell membrane, but its molecular shape is different from that of the original vitamin, so it cannot be transported through the vitamin transport channel, and a part of the cell membrane is sunken into a bag B), and is taken up from the cell membrane surface into the cell C) through endocytosis. C) The cell delivery carrier enclosed in the endosome, due to external stimuli such as temperature and light 4), the stimulus response polymer on the cell surface shrinks and becomes hydrophobic, thereby breaking the parallelism of the membrane, easily destroying the membrane of the cell delivery carrier, and releasing the active ingredients into the endosome. On the other hand, 6) is a lysosome with digestive enzymes (small quadrilaterals). D) The lysosome fuses with the endosome and moves the digestive enzymes to the endosome, decomposing (digesting) the molecules in the endosome in E). As a result, stable vitamin derivatives can be converted into vitamins that can be used by cells. F) Finally, the endosome is destroyed, and the active ingredients (black ▲), vitamins (ovals) and undigested vitamin derivatives (7) are released into the cell. The undigested vitamin derivatives further activate the autophagy system, are digested by the autophagosome, and are finally converted into vitamins for cell use.

[0448] Figure 2This is a typical structural example 1 of the lipid bilayer membrane (single-layer liquid crystal structure) of the cell delivery carrier of the present invention. The cell delivery carrier of the present invention can also be a lipid monolayer membrane. In this case, the membrane structure at the top (outermost layer) in the figure can be used. The lipids of the molecules constituting the outermost membrane are combined with the lipids of the inner membrane molecules to form a bilayer membrane structure (single-layer liquid crystal structure). The molecules constituting the outer membrane are composed of molecules (1) containing stimulus-responsive polymers, substances (2) (such as vitamin derivatives) that simultaneously activate autophagy-related genes and protease synthesis genes, and lipids (3). These three elements (1), (2) and (3) constitute the membrane molecules of the cell delivery carrier of the present invention. (1) is a stimulus-responsive polymer composed of a long tail structure and lipids (rectangular) bound thereto, and the lipids are partially embedded in the membrane molecules of the cell delivery carrier. (2) is an amphiphilic substance, such as a vitamin derivative, whose lipids (hexagonal) are embedded in the membrane molecules of the cell delivery carrier. (3) shows two typical molecules constituting the membrane of the cell delivery carrier, which are composed of lipids (hexagons) and amphiphilic substances (rectangles and circles combined) constituting the emulsified membrane. The circular part represents water-soluble molecules, and the cell delivery carrier of the present invention can be dispersed and suspended in water-soluble solvents and extracellular fluids. The membrane molecules on the inside are mainly composed of (2) and (3). In the present invention, these double-layer membranes (single-layer liquid crystal structure) can be further connected on the inside to form a multi-layer membrane structure (multi-layer liquid crystal structure).

[0449] Figure 3 This is a typical structural example 2 of the lipid bilayer membrane of the cell delivery carrier of the present invention. The cell delivery carrier of the present invention may also be a lipid monolayer membrane. In this case, the membrane structure at the top (outermost) in the figure can be used. The lipids of the molecules constituting the outermost membrane can be combined with the lipids of the inner membrane molecules to form a bilayer membrane structure (monolayer liquid crystal structure). Among the molecules constituting the outermost membrane, the molecule (1) containing the stimulus-responsive polymer is ionically bound (dashed line) to the water-soluble molecular part (circle) of the lipid (2).

[0450] The lipids in (2) have a structure in which a water-soluble molecular part (circle) and a fat-soluble molecular part (hexagon) are combined, but molecules (hexagons) composed only of fat-soluble molecules may also exist in the membrane. (3) is a substance that simultaneously activates autophagy-related genes and protease synthesis genes, such as amphiphilic vitamin derivatives. (3) also has a structure in which a water-soluble molecular part (teardrop-shaped part) and a fat-soluble molecular part (hexagon) are combined, and the fat-soluble part is fused with the lipids of the membrane. In the present invention, these double-layer membranes (single-layer liquid crystal structure) can be further connected on the inside to form a multi-layer membrane structure (multi-layer liquid crystal structure).

Claims

1. A cell delivery carrier, which is composed of a mixture of the following three groups: a substance that simultaneously activates autophagy-related genes and cathepsin synthesis genes, a molecule containing a stimulus-responsive polymer, and a lipid, wherein: The mixture is selected from one or more substances in three groups respectively, the cell delivery carrier has any one of a single-layer liquid crystal structure and a multi-layer liquid crystal structure, and the substance that simultaneously activates autophagy-related genes and tissue protease synthesis genes is octanoyl 2-glyceryl ascorbic acid.

2. The cell delivery carrier according to claim 1, wherein Some or all of the lipids are lamellar liquid crystal surfactants.

3. The cell delivery carrier according to claim 1, wherein The autophagy-related gene is selected from the group consisting of the following genes: ULK1, ULK2, ATG2A, ATG2B, ATG3, ATG4A, ATG4B, ATG4C, ATG4D, ATG5, BECN1, ATG7, GABARAP, GABARAPL1, GABARAPL2, MAP1LC3A, MAP1LC3B, MAP1LC3B2, MAP1LC3C, ATG9A, ATG9B, ATG10, ATG12, ATG13, ATG14, ATG16L1, ATG16L2, RB1CC1, WIPI1, WIPI2, SNX30, SNX4, ATG101, AMBRA1; The cathepsin synthesis gene is selected from the group consisting of the following genes: CTSA, CTSB, CTSC, CTSD, CTSD, CTSE, CTSF, CTSG, CTSH, CTSK, CTSL, CTSLP6, CTSO, CTSS, CTSV, CTSW, CTSZ; Furthermore, the autophagy-related gene and the cathepsin synthesis gene are genes registered in the Human Genome Nomenclature Committee of the Human Genome Organization.

4. The cell delivery carrier according to claim 1, wherein The molecules containing stimulus-responsive polymers include any one or more of the following three stimulus-responsive molecules: temperature stimulus-responsive molecules, pH stimulus-responsive molecules, and light stimulus-responsive molecules.

5. The cell delivery carrier according to claim 1, wherein The molecule containing the stimulus-responsive polymer has a structure of a straight-chain or branched polymer structure containing one or more monomers of a temperature stimulus-responsive substance, a pH stimulus-responsive substance, and a light stimulus-responsive substance, wherein: The temperature stimulus response substance is selected from the group consisting of the following compounds: (polyoxyethylene octylphenyl ether) acrylate, (polyoxyethylene octylphenyl ether) methacrylate, (polyoxyethylene nonylphenyl ether) acrylate, (polyoxyethylene nonylphenyl ether) methacrylate, (polyoxyethylene lauryl ether) acrylate, (polyoxyethylene lauryl ether) methacrylate, 1,2,4,5-tetrakis(N,N-dithioaminomethyl)benzene, 1,3,5-tris(bromomethyl)benzene, 2-n-propyl-2-oxazoline, 2-N,N-dimethylaminoethyl acrylate, 2-N,N-dimethylaminoethyl methacrylate DMAEMA, 2-amino-2-hydroxymethyl-1,3-propanediol, 2-amino-2-hydroxymethyl-1,3-propanediol hydrochloride, 2-hydroxy- 3-phenoxypropyl, 2-hydroxybutyl acrylate, 2-hydroxybutyl methacrylate, 2-hydroxypropyl acrylate, 2-hydroxypropyl methacrylate, 3-N,N-dimethylaminopropyl acrylamide, N-acryloyl asparagine, N-acryloyl glycinamide, N-acryloyl glutamine, N-methacryloyl asparagine, N,N-dimethyl methacrylamide, N,N-dimethyl acrylamide, N,N-methylene bisacrylamide, N,N-ethyl methacrylamide, N,N-ethyl methyl amide, N,N-dialkyl-dithiocarbamoyl methyl, N,N-diethyl acrylamide, N,N-diethyl amide, N,N-diethyl methacrylamide, N,N-diethyl ammonium dithiocarbamate (sodium N,N-dithiocarbamate), N,N-propyl acrylamide, N,N-propyl methacrylamide, N-acryloylpiperidine, N-acryloylmorpholine, N-allylphthalimide, N-isopropylamide, N-isopropylbut-2,3-dienamide, N-isopropylmethacrylamide, N-ethylacrylamide, N-ethylmethacrylamide, N-ethoxyethylacrylamide, N-ethoxyethylamide, N-ethoxyethylmethacrylamide, N-cyclopropylacrylamide, N-cyclopropylamide, N-cyclopropylmethacrylamide, N-tetrahydrofurfurylacrylamide, N-tetrahydrofurfurylmethacrylamide, N-biotin-N′-methacryloyltrimethyleneamide, N-vinylacrylamide, N-vinylmethacrylamide, N-propylacrylamide, N-methacryloylpiperidine, s-butylacrylamide, t-butylacrylamide, acryloylglycinamide, acryloylsarcosineamide, acryloylpiperidinecarboxamide, acryloylmethyluracil pyridine, acetylacrylamide, ethylisopropylacrylamide, ethylene glycol / propylene glycol copolymer, ethylene glycol allyl methyl ether, oxyethylene sorbitan laurate, oxyethylene laurylamine, acrylates with oligoethylene glycol in the side chain, diisopropylacrylamide, diethylacrylamide, diethylaminoacrylate, diethylaminomethacrylate, diethylene glycol allyl methyl ether, dibutylacrylamide, dipropylacrylamide, dimethylacrylamide, dimethylaminoacrylamide, dimethylaminoacrylate, dimethylaminopropylacrylamide, dimethylaminopropylmethacrylamide, dimethylaminomethacrylamide, dimethylaminomethacrylamide, sodium N,N-dithiocarbamic acid, hexa(N,N-dithiocarbamoylmethyl)benzene, hexa(bromomethyl)benzene, methacrylamide / N-acetylacrylamide copolymer, and its sodium, magnesium, potassium, aluminum, zinc, calcium, triethanolamine salts; The pH stimulus responsive substance is selected from the group consisting of the following compounds: glucosamine, chitosan, 2-ethoxyethyl vinyl ether, 4-(2-vinyloxyethoxy)benzoic acid, 6-(2-vinyloxyethoxy)hexanoic acid, 6-(vinyloxy)hexanoic acid, isobutyl vinyl ether and its alkali metal salts, and salts of sodium, magnesium, potassium, aluminum, zinc, calcium, and triethanolamine; The light stimulus responsive substance is selected from the group consisting of the following compounds: n-(4-phenylazophenyl)acrylamide, 6-[4-(4-pyridylazo)phenoxy]hexamethylacrylate, 4-[2-(vinyloxy)ethoxy]azobenzene, 2-(2-ethoxy)ethoxyethyl vinyl ether, and salts of sodium, magnesium, potassium, aluminum, zinc, calcium, and triethanolamine.